StartDate,EndDate,Status,IPAddress,Progress,Duration (in seconds),Finished,RecordedDate,ResponseId,RecipientLastName,RecipientFirstName,RecipientEmail,ExternalReference,LocationLatitude,LocationLongitude,DistributionChannel,Q1,Q2,Q3,Q4,Q4_4_TEXT,Q5,Q6,Q7,Q1,Q2,Q3,Q3_6_TEXT,Q4,Q5,Q6,Q7,Q7_7_TEXT,Q8,Q9,Q10,Q11,Q12,Q13,Q13_7_TEXT,Q14
Start Date,End Date,Response Type,IP Address,Progress,Duration (in seconds),Finished,Recorded Date,Response ID,Recipient Last Name,Recipient First Name,Recipient Email,External Data Reference,Location Latitude,Location Longitude,Distribution Channel,"Which of the following answers most accurately describes
your hospital?","How many patients are admitted to your Intensive Care Unit
per year? (Please include level 2 admissions):","How many staffed Intensive Care beds (level 2 and level 3)
does your Department have?",Please state the case mix of your ICU/HDU: - Selected Choice,Please state the case mix of your ICU/HDU: - Specialist ICU (please name specialty): - Text,Please state your level of training:,How many years of experience do you have in Critical Care?,Please state your complimentary specialty:,"At which heart rate would you intervene in patients with
fast AF and stable blood pressure?","Which is your primary treatment goal in new onset fast atrial
fibrillation in critically ill patients without a known cardiac history, in
whom blood pressure remains stable?","Which is the most commonly used anti-arrhythmic drug for new
onset fast atrial fibrillation in your ICU? - Selected Choice","Which is the most commonly used anti-arrhythmic drug for new
onset fast atrial fibrillation in your ICU? - Other anti-arrhythmics (e. g. Verapamil, sotalol): please specify: - Text","In a patient with chest sepsis (no cardiac history, blood
pressure 100/60 mmHg, receiving 15 ml/min (0.25 mcg/kg/min) noradrenaline), who
develops fast new onset AF with a heart rate of 140-160 bpm, your primary treatment
strategy consists of:","In critically ill patients with new onset fast AF, which
Serum Potassium level would you aim for?","In critically ill patients with new onset fast AF, which
Serum Magnesium level would you aim for?","Which of the following represent the main reason(s) for your
choice of anti-arrhythmics? Please tick all that apply. - Selected Choice","Which of the following represent the main reason(s) for your
choice of anti-arrhythmics? Please tick all that apply. - Other, please specify: - Text","When would you normally anti-coagulate critically ill patients
with new-onset atrial fibrillation, if no contra-indications for
anti-coagulation are known?","Please tick all answers that reflect your views on stroke
risk assessment in critically ill patients with new-onset atrial fibrillation?","In critically ill patients with new-onset fast atrial
fibrillation which of the following do you consider appropriate for
anticoagulation provided that no contra-indications are known? Please tick all answers that reflect your views.","In critically ill patients with new-onset fast atrial
fibrillation: (Please tick all that apply)","Would you consider taking part in a clinical trial
investigating treatment of new onset fast AF in the critically ill?","In the setting of a research study on general ICU patients,
which anti-arrhythmic treatment would you primarily want to study as treatment
for critically ill patients with new-onset fast AF? - Selected Choice","In the setting of a research study on general ICU patients,
which anti-arrhythmic treatment would you primarily want to study as treatment
for critically ill patients with new-onset fast AF? - Other anti-arrhythmics (e. g. verapamil, sotalol): Please specify: - Text","In the setting of a research study investigating the
effectiveness of anti-arrhythmics in critically ill patients with new-onset
fast AF, would you accept a placebo arm, i. e. do you think it is acceptable to
not treat new onset fast AF with anti-arrythmics as long as blood
pressure and, if measured, cardiac output are maintained?"
"{""ImportId"":""startDate""}","{""ImportId"":""endDate""}","{""ImportId"":""status""}","{""ImportId"":""ipAddress""}","{""ImportId"":""progress""}","{""ImportId"":""duration""}","{""ImportId"":""finished""}","{""ImportId"":""recordedDate""}","{""ImportId"":""_recordId""}","{""ImportId"":""recipientLastName""}","{""ImportId"":""recipientFirstName""}","{""ImportId"":""recipientEmail""}","{""ImportId"":""externalDataReference""}","{""ImportId"":""locationLatitude""}","{""ImportId"":""locationLongitude""}","{""ImportId"":""distributionChannel""}","{""ImportId"":""QID5""}","{""ImportId"":""QID6""}","{""ImportId"":""QID7_TEXT""}","{""ImportId"":""QID8""}","{""ImportId"":""QID8_4_TEXT""}","{""ImportId"":""QID9""}","{""ImportId"":""QID10""}","{""ImportId"":""QID11""}","{""ImportId"":""QID13""}","{""ImportId"":""QID14""}","{""ImportId"":""QID15""}","{""ImportId"":""QID15_6_TEXT""}","{""ImportId"":""QID16""}","{""ImportId"":""QID17""}","{""ImportId"":""QID18""}","{""ImportId"":""QID19""}","{""ImportId"":""QID19_7_TEXT""}","{""ImportId"":""QID20""}","{""ImportId"":""QID21""}","{""ImportId"":""QID22""}","{""ImportId"":""QID23""}","{""ImportId"":""QID24""}","{""ImportId"":""QID25""}","{""ImportId"":""QID25_7_TEXT""}","{""ImportId"":""QID26""}"
31/10/2016 15:39,31/10/2016 15:43,IP Address,89.197.125.47,100,215,TRUE,31/10/2016 15:43,R_2YwZZH19t6SKOAl,,,,,51.51420593,-0.093093872,anonymous,Teaching Hospital,500-1000,3,Predominantly medical,,Trainee,1-3 years,Anaesthesia,120-139/beats per min,Rate control,Flecainide,,Supplement electrolytes to a high normal level and DC cardioversion,>4 mmol/l,1.0-1.2 mmol/l,Cost,,New onset AF within 72 hours,"I regularly calculate a risk score (e. g. CHAD2, CHA2DS2-VASc) to assess the need for anti-coagulation","Subcutaneous Low Molecular Weight heparin in therapeutic dose,Use of novel oral anti-coagulants (NOACs)",I regularly perform or request transoesophageal echocardiography,No,ß-blocker,,Yes
31/10/2016 15:57,31/10/2016 16:01,IP Address,185.58.164.44,100,257,TRUE,31/10/2016 16:01,R_2pKT2acCPJ9abuF,,,,,55.83329773,-4.25,anonymous,District General Hospital,<500,4,Mixed ICU,,Consultant,More than 10 years,Anaesthesia,"Independent of their heart rate I treat all patients who have developed new onset fast AF, even if the blood pressure remains stable",Rhythm control,Amiodarone,,Supplement electrolytes to a high normal level and anti-arrhythmics,>4.5 mmol/l,1.0-1.2 mmol/l,ICU drug policy,,New onset AF within 24 hours,I do not use stroke risk scores routinely in critically ill patients with new onset AF to assess the need for anticoagulation,Subcutaneous Low Molecular Weight heparin in therapeutic dose,I regularly perform or request transthoracic echocardiography,Yes,"Amiodarone,DC cardioversion,ß-blocker,Digoxin",,No
31/10/2016 15:57,31/10/2016 16:02,IP Address,185.58.164.44,100,269,TRUE,31/10/2016 16:02,R_8wPDGRgBPcOPG6x,,,,,55.83329773,-4.25,anonymous,Teaching Hospital,1000-2000,20,Mixed ICU,,Consultant,More than 10 years,Anaesthesia,120-139/beats per min,Rate control,Amiodarone,,Supplement electrolytes to a high normal level and anti-arrhythmics,>4.5 mmol/l,I do not aim for a specific serum magnesium level,"Availability from hospital pharmacy,Pharmacokinetic advantages,Pharmacodynamic properties,Adverse effect profile",,New onset AF within 72 hours,"I regularly calculate a risk score (e. g. CHAD2, CHA2DS2-VASc) to assess the need for anti-coagulation,Modified risk scores should be developed for critically ill patients with new-onset atrial fibrillation","Intravenous High Molecular Weight heparin in therapeutic dose,Subcutaneous Low Molecular Weight heparin in therapeutic dose",I regularly perform or request transthoracic echocardiography,Yes,Amiodarone,,No
31/10/2016 15:59,31/10/2016 16:02,IP Address,62.252.201.238,100,165,TRUE,31/10/2016 16:02,R_23TZPRuxXxILuJG,,,,,51.43330383,-1,anonymous,District General Hospital,1000-2000,17,Mixed ICU,,Consultant,5-10 years,Anaesthesia,140-159/beats per min,Rate control,Amiodarone,,Supplement electrolytes to a high normal level and anti-arrhythmics,>4.5 mmol/l,>1.2 mmol/l,"ICU drug policy,Pharmacokinetic advantages,Pharmacodynamic properties,Adverse effect profile",,I do not regularly anti-coagulate critically ill patients with new-onset fast AF,I do not use stroke risk scores routinely in critically ill patients with new onset AF to assess the need for anticoagulation,I do not regularly anti-coagulate critically ill patients with new onset fast AF,I do not routinely perform Echocardiography to guide treatment,Yes,"Amiodarone,ß-blocker",,Yes
31/10/2016 15:59,31/10/2016 16:02,IP Address,212.250.5.220,100,199,TRUE,31/10/2016 16:02,R_3GfUnQrQSYsWvBr,,,,,51.75,-1.25,anonymous,Tertiary Referral Centre or University Hospital,1000-2000,22,Mixed ICU,,Trainee,1-3 years,Anaesthesia,140-159/beats per min,Rate control,Amiodarone,,Supplement electrolytes (magnesium and/or potassium) to a high normal level,>4.5 mmol/l,1.0-1.2 mmol/l,"Pharmacokinetic advantages,Adverse effect profile",,New onset AF within 72 hours,"I regularly calculate a risk score (e. g. CHAD2, CHA2DS2-VASc) to assess the need for anti-coagulation",Subcutaneous Low Molecular Weight heparin in therapeutic dose,I only regularly perform Echocardiography in patients with cardiac history,Yes,"Amiodarone,ß-blocker",,Yes
31/10/2016 15:58,31/10/2016 16:03,IP Address,82.132.215.164,100,256,TRUE,31/10/2016 16:03,R_3szwv3hGGFD5rW2,,,,,51.49639893,-0.122406006,anonymous,District General Hospital,500-1000,16,Predominantly medical,,Consultant,More than 10 years,Anaesthesia,140-159/beats per min,Rate control,Amiodarone,,Supplement electrolytes to a high normal level and anti-arrhythmics,>4.5 mmol/l,1.0-1.2 mmol/l,ICU drug policy,,I do not regularly anti-coagulate critically ill patients with new-onset fast AF,Modified risk scores should be developed for critically ill patients with new-onset atrial fibrillation,I do not regularly anti-coagulate critically ill patients with new onset fast AF,I only regularly perform Echocardiography in patients with cardiac history,Yes,"Amiodarone,ß-blocker,Digoxin",,Yes
31/10/2016 15:58,31/10/2016 16:03,IP Address,212.250.5.222,100,288,TRUE,31/10/2016 16:03,R_6s5Y6GiM0F9LiBr,,,,,51.75,-1.25,anonymous,Tertiary Referral Centre or University Hospital,>2000,25,Mixed ICU,,Consultant,More than 10 years,Anaesthesia,120-139/beats per min,Rate control,Amiodarone,,Supplement electrolytes to a high normal level and anti-arrhythmics,>4.5 mmol/l,1.0-1.2 mmol/l,"Pharmacokinetic advantages,Pharmacodynamic properties,Adverse effect profile",,I do not regularly anti-coagulate critically ill patients with new-onset fast AF,"I do not use stroke risk scores routinely in critically ill patients with new onset AF to assess the need for anticoagulation,Stroke risk scores inaccurately reflect the risk of embolic events in critically ill patients with new-onset atrial fibrillation due to prothrombotic changes associated with critical illness,Stroke risk scores favour anti-coagulation despite a higher risk of bleeding in critical illness,Modified risk scores should be developed for critically ill patients with new-onset atrial fibrillation",Subcutaneous Low Molecular Weight heparin in therapeutic dose,I regularly perform or request transthoracic echocardiography,Yes,"Amiodarone,ß-blocker,Digoxin",,Yes
31/10/2016 16:01,31/10/2016 16:04,IP Address,81.132.236.22,100,159,TRUE,31/10/2016 16:04,R_3p2YrZef5Vnoedp,,,,,53.45509338,-2.26449585,anonymous,District General Hospital,I do not know,14,Mixed ICU,,Trainee,1-3 years,Anaesthesia,120-139/beats per min,Rate control,Amiodarone,,Supplement electrolytes (magnesium and/or potassium) to a high normal level,>4.5 mmol/l,1.0-1.2 mmol/l,"Pharmacodynamic properties,Adverse effect profile",,Before DC cardioversion,I do not use stroke risk scores routinely in critically ill patients with new onset AF to assess the need for anticoagulation,"Intravenous High Molecular Weight heparin in therapeutic dose,Subcutaneous Low Molecular Weight heparin in therapeutic dose",I regularly perform or request transthoracic echocardiography,Yes,"Amiodarone,ß-blocker",,Yes
31/10/2016 15:59,31/10/2016 16:04,IP Address,185.58.164.44,100,296,TRUE,31/10/2016 16:04,R_5c1kHMvdxBsqWqd,,,,,55.83329773,-4.25,anonymous,Tertiary Referral Centre or University Hospital,I do not know,60,Mixed ICU,,Trainee,3-5 years,Anaesthesia,"Independent of their heart rate I treat all patients who have developed new onset fast AF, even if the blood pressure remains stable",Rhythm control,Amiodarone,,Supplement electrolytes to a high normal level and anti-arrhythmics,>4.5 mmol/l,I do not aim for a specific serum magnesium level,"Pharmacokinetic advantages,Pharmacodynamic properties",,I do not regularly anti-coagulate critically ill patients with new-onset fast AF,Stroke risk scores inaccurately reflect the risk of embolic events in critically ill patients with new-onset atrial fibrillation due to prothrombotic changes associated with critical illness,I do not regularly anti-coagulate critically ill patients with new onset fast AF,I do not routinely perform Echocardiography to guide treatment,Yes,"Amiodarone,Other anti-arrhythmics (e. g. verapamil, sotalol): Please specify:",Magnesium,No
31/10/2016 15:57,31/10/2016 16:04,IP Address,193.61.118.252,100,419,TRUE,31/10/2016 16:04,R_a4eolKU0aNbSLSx,,,,,51.47439575,-0.215194702,anonymous,Tertiary Referral Centre or University Hospital,1000-2000,33,Specialist ICU (please name specialty):,Cardiothoracic,Consultant,More than 10 years,Anaesthesia,"Independent of their heart rate I treat all patients who have developed new onset fast AF, even if the blood pressure remains stable",Rhythm control,Amiodarone,,Supplement electrolytes to a high normal level and anti-arrhythmics,>4.5 mmol/l,>1.2 mmol/l,Pharmacodynamic properties,,New onset AF within 48 hours,I do not use stroke risk scores routinely in critically ill patients with new onset AF to assess the need for anticoagulation,Intravenous High Molecular Weight heparin in therapeutic dose,I do not routinely perform Echocardiography to guide treatment,Yes,"Amiodarone,DC cardioversion",,No
31/10/2016 16:00,31/10/2016 16:04,IP Address,109.176.101.162,100,240,TRUE,31/10/2016 16:04,R_8Aq8Bgmv3ZeQbD7,,,,,51.02110291,-3.104705811,anonymous,District General Hospital,1000-2000,12,Mixed ICU,,Consultant,More than 10 years,Anaesthesia,120-139/beats per min,Rate control,Amiodarone,,Supplement electrolytes to a high normal level and anti-arrhythmics,>4.5 mmol/l,1.0-1.2 mmol/l,"Availability from hospital pharmacy,ICU drug policy,Cost,Pharmacokinetic advantages",,I do not regularly anti-coagulate critically ill patients with new-onset fast AF,"I do not use stroke risk scores routinely in critically ill patients with new onset AF to assess the need for anticoagulation,Stroke risk scores inaccurately reflect the risk of embolic events in critically ill patients with new-onset atrial fibrillation due to prothrombotic changes associated with critical illness,Modified risk scores should be developed for critically ill patients with new-onset atrial fibrillation",I do not regularly anti-coagulate critically ill patients with new onset fast AF,I do not routinely perform Echocardiography to guide treatment,Yes,Amiodarone,,No
31/10/2016 15:59,31/10/2016 16:04,IP Address,62.25.77.200,100,335,TRUE,31/10/2016 16:04,R_2A0W7SZsp5NXEic,,,,,51.6000061,-0.216705322,anonymous,District General Hospital,1000-2000,16,Mixed ICU,,Consultant,1-3 years,Anaesthesia,140-159/beats per min,Rate control,Amiodarone,,DC cardioversion when anti-arrhythmics and electrolyte replacement fail to achieve rate and/or rhythm control,>4.5 mmol/l,1.0-1.2 mmol/l,Adverse effect profile,,New onset AF within 48 hours,Modified risk scores should be developed for critically ill patients with new-onset atrial fibrillation,"Intravenous High Molecular Weight heparin in therapeutic dose,Subcutaneous Low Molecular Weight heparin in therapeutic dose",I regularly perform or request transthoracic echocardiography,Yes,"Amiodarone,ß-blocker,Flecainide",,Yes
31/10/2016 16:01,31/10/2016 16:05,IP Address,94.118.247.132,100,239,TRUE,31/10/2016 16:05,R_3eailcpbdh0wgfs,,,,,53.80000305,-1.583297729,anonymous,District General Hospital,<500,12,Mixed ICU,,Consultant,More than 10 years,Anaesthesia,120-139/beats per min,Rhythm control,"Other anti-arrhythmics (e. g. Verapamil, sotalol): please specify:",Cardioversion,DC cardioversion when anti-arrhythmics and electrolyte replacement fail to achieve rate and/or rhythm control,>4.5 mmol/l,1.0-1.2 mmol/l,Pharmacodynamic properties,,New onset AF within 48 hours,"I regularly calculate a risk score (e. g. CHAD2, CHA2DS2-VASc) to assess the need for anti-coagulation",Subcutaneous Low Molecular Weight heparin in therapeutic dose,I do not routinely perform Echocardiography to guide treatment,Yes,"Amiodarone,ß-blocker",,No
31/10/2016 16:00,31/10/2016 16:05,IP Address,2.29.169.117,100,329,TRUE,31/10/2016 16:05,R_2YYEdp1YNYl6ejd,,,,,52.41670227,-1.783294678,anonymous,District General Hospital,500-1000,19,Mixed ICU,,Consultant,5-10 years,Anaesthesia,120-139/beats per min,Rate control,Amiodarone,,Supplement electrolytes to a high normal level and anti-arrhythmics,>4.5 mmol/l,>1.2 mmol/l,"ICU drug policy,Adverse effect profile",,I do not regularly anti-coagulate critically ill patients with new-onset fast AF,"I do not use stroke risk scores routinely in critically ill patients with new onset AF to assess the need for anticoagulation,Stroke risk scores inaccurately reflect the risk of embolic events in critically ill patients with new-onset atrial fibrillation due to prothrombotic changes associated with critical illness,Stroke risk scores favour anti-coagulation despite a higher risk of bleeding in critical illness",I do not regularly anti-coagulate critically ill patients with new onset fast AF,I only regularly perform Echocardiography in patients with cardiac history,Yes,"Amiodarone,ß-blocker,Diltiazem",,Yes
31/10/2016 16:03,31/10/2016 16:07,IP Address,86.188.255.34,100,210,TRUE,31/10/2016 16:07,R_VJuZsrfr6AQtBbX,,,,,52.93330383,-1.5,anonymous,District General Hospital,1000-2000,15,Mixed ICU,,Consultant,More than 10 years,Anaesthesia,140-159/beats per min,Rhythm control,Amiodarone,,Supplement electrolytes (magnesium and/or potassium) to a high normal level,>4.5 mmol/l,1.0-1.2 mmol/l,Pharmacodynamic properties,,Before DC cardioversion,I do not use stroke risk scores routinely in critically ill patients with new onset AF to assess the need for anticoagulation,I do not regularly anti-coagulate critically ill patients with new onset fast AF,I regularly perform or request transthoracic echocardiography,Yes,Amiodarone,,Yes
31/10/2016 16:03,31/10/2016 16:07,IP Address,2.25.115.14,100,253,TRUE,31/10/2016 16:07,R_3oHrsQqKtyoP9zf,,,,,57.14370728,-2.098098755,anonymous,Tertiary Referral Centre or University Hospital,500-1000,12,Mixed ICU,,Trainee,5-10 years,Anaesthesia,"Independent of their heart rate I treat all patients who have developed new onset fast AF, even if the blood pressure remains stable",Rhythm control,Amiodarone,,Supplement electrolytes (magnesium and/or potassium) to a high normal level,>4.5 mmol/l,I do not aim for a specific serum magnesium level,"Availability from hospital pharmacy,Other, please specify:",Unit familiarity,I do not regularly anti-coagulate critically ill patients with new-onset fast AF,I do not use stroke risk scores routinely in critically ill patients with new onset AF to assess the need for anticoagulation,I do not regularly anti-coagulate critically ill patients with new onset fast AF,"I regularly perform or request transthoracic echocardiography,I regularly perform or request transoesophageal echocardiography",Yes,"Amiodarone,DC cardioversion,ß-blocker,Flecainide,Diltiazem,Digoxin",,No
31/10/2016 16:03,31/10/2016 16:08,IP Address,88.150.155.151,100,356,TRUE,31/10/2016 16:08,R_10I8dmjAw3kTm39,,,,,51.49639893,-0.122406006,anonymous,Tertiary Referral Centre or University Hospital,500-1000,11,Predominantly surgical,,Consultant,5-10 years,Anaesthesia,"Independent of their heart rate I treat all patients who have developed new onset fast AF, even if the blood pressure remains stable",Rhythm control,ß-blocker,,Supplement electrolytes (magnesium and/or potassium) to a high normal level,>4.5 mmol/l,>1.2 mmol/l,Adverse effect profile,,New onset AF within 72 hours,I do not use stroke risk scores routinely in critically ill patients with new onset AF to assess the need for anticoagulation,Subcutaneous Low Molecular Weight heparin in therapeutic dose,I only regularly perform Echocardiography in patients with cardiac history,No,Amiodarone,,Yes
31/10/2016 16:03,31/10/2016 16:09,IP Address,130.88.242.136,100,362,TRUE,31/10/2016 16:09,R_26fmjcEecz9PcdI,,,,,53.5,-2.216705322,anonymous,Tertiary Referral Centre or University Hospital,<500,19,Mixed ICU,,Consultant,5-10 years,Intensive Care Medicine only,120-139/beats per min,Rhythm control,ß-blocker,,Supplement electrolytes to a high normal level and anti-arrhythmics,>4.5 mmol/l,I do not aim for a specific serum magnesium level,Pharmacodynamic properties,,I do not regularly anti-coagulate critically ill patients with new-onset fast AF,I do not use stroke risk scores routinely in critically ill patients with new onset AF to assess the need for anticoagulation,Subcutaneous Low Molecular Weight heparin in therapeutic dose,I do not routinely perform Echocardiography to guide treatment,Yes,"Amiodarone,ß-blocker",,Yes
31/10/2016 16:05,31/10/2016 16:09,IP Address,185.69.144.94,100,242,TRUE,31/10/2016 16:09,R_2xzQFCdWxKufMHN,,,,,51.49639893,-0.122406006,anonymous,Tertiary Referral Centre or University Hospital,1000-2000,50,Mixed ICU,,Trainee,3-5 years,Intensive Care Medicine only,120-139/beats per min,Rhythm control,Amiodarone,,Supplement electrolytes (magnesium and/or potassium) to a high normal level,>4.5 mmol/l,>1.2 mmol/l,ICU drug policy,,New onset AF within 72 hours,"Stroke risk scores inaccurately reflect the risk of embolic events in critically ill patients with new-onset atrial fibrillation due to prothrombotic changes associated with critical illness,Stroke risk scores favour anti-coagulation despite a higher risk of bleeding in critical illness,Modified risk scores should be developed for critically ill patients with new-onset atrial fibrillation","Intravenous High Molecular Weight heparin in therapeutic dose,Subcutaneous Low Molecular Weight heparin in therapeutic dose",I regularly perform or request transthoracic echocardiography,Yes,ß-blocker,,Yes
31/10/2016 16:05,31/10/2016 16:12,IP Address,85.115.54.202,100,452,TRUE,31/10/2016 16:12,R_2S0pQOvbOcleomm,,,,,51.49639893,-0.122406006,anonymous,Tertiary Referral Centre or University Hospital,1000-2000,50,Specialist ICU (please name specialty):,cardiothoraic,Consultant,More than 10 years,Anaesthesia,"Independent of their heart rate I treat all patients who have developed new onset fast AF, even if the blood pressure remains stable",Rhythm control,Amiodarone,,DC cardioversion when anti-arrhythmics and electrolyte replacement fail to achieve rate and/or rhythm control,>4.5 mmol/l,>1.2 mmol/l,Pharmacodynamic properties,,New onset AF within 48 hours,"Stroke risk scores inaccurately reflect the risk of embolic events in critically ill patients with new-onset atrial fibrillation due to prothrombotic changes associated with critical illness,Stroke risk scores favour anti-coagulation despite a higher risk of bleeding in critical illness,Modified risk scores should be developed for critically ill patients with new-onset atrial fibrillation","Intravenous High Molecular Weight heparin in therapeutic dose,Subcutaneous Low Molecular Weight heparin in therapeutic dose","I regularly perform or request transthoracic echocardiography,I regularly perform or request transoesophageal echocardiography",Yes,"Amiodarone,DC cardioversion",,Yes
31/10/2016 15:58,31/10/2016 16:13,IP Address,82.40.249.66,100,871,TRUE,31/10/2016 16:13,R_1gcskEtCfTVm97g,,,,,51.46670532,-0.350006104,anonymous,District General Hospital,I do not know,12,Mixed ICU,,Consultant,5-10 years,Anaesthesia,"Independent of their heart rate I treat all patients who have developed new onset fast AF, even if the blood pressure remains stable",Rate control,Amiodarone,,Supplement electrolytes (magnesium and/or potassium) to a high normal level,>4.5 mmol/l,1.0-1.2 mmol/l,"Availability from hospital pharmacy,ICU drug policy,Cost,Pharmacokinetic advantages,Pharmacodynamic properties,Adverse effect profile",,I do not regularly anti-coagulate critically ill patients with new-onset fast AF,I do not use stroke risk scores routinely in critically ill patients with new onset AF to assess the need for anticoagulation,I do not regularly anti-coagulate critically ill patients with new onset fast AF,I regularly perform or request transthoracic echocardiography,Yes,"Amiodarone,DC cardioversion,ß-blocker,Digoxin",,Yes
31/10/2016 16:10,31/10/2016 16:14,IP Address,86.1.14.92,100,240,TRUE,31/10/2016 16:14,R_WDrBBRGSLyr3EQ1,,,,,53.44999695,-2.316696167,anonymous,Tertiary Referral Centre or University Hospital,1000-2000,18,Specialist ICU (please name specialty):,Neuro,Trainee,3-5 years,Acute medicine,"Independent of their heart rate I treat all patients who have developed new onset fast AF, even if the blood pressure remains stable",I have no primary treatment goal in these patients,ß-blocker,,DC cardioversion when anti-arrhythmics and electrolyte replacement fail to achieve rate and/or rhythm control,>4.5 mmol/l,1.0-1.2 mmol/l,"Availability from hospital pharmacy,ICU drug policy,Pharmacokinetic advantages,Pharmacodynamic properties,Adverse effect profile",,New onset AF within 24 hours,Stroke risk scores inaccurately reflect the risk of embolic events in critically ill patients with new-onset atrial fibrillation due to prothrombotic changes associated with critical illness,"Subcutaneous Low Molecular Weight heparin in therapeutic dose,I do not regularly anti-coagulate critically ill patients with new onset fast AF",I regularly perform or request transthoracic echocardiography,Yes,"Amiodarone,DC cardioversion,ß-blocker,Digoxin",,Yes
31/10/2016 16:06,31/10/2016 16:15,IP Address,82.132.232.19,100,516,TRUE,31/10/2016 16:15,R_6SaxqIrzFHAanQd,,,,,51.51420593,-0.093093872,anonymous,District General Hospital,500-1000,9,Mixed ICU,,Consultant,More than 10 years,Anaesthesia,100-119/beats per min,Rate control,Amiodarone,,Supplement electrolytes to a high normal level and anti-arrhythmics,>5 mmol/l,>1.2 mmol/l,Adverse effect profile,,I do not regularly anti-coagulate critically ill patients with new-onset fast AF,"I do not use stroke risk scores routinely in critically ill patients with new onset AF to assess the need for anticoagulation,Stroke risk scores inaccurately reflect the risk of embolic events in critically ill patients with new-onset atrial fibrillation due to prothrombotic changes associated with critical illness,Modified risk scores should be developed for critically ill patients with new-onset atrial fibrillation","Intravenous High Molecular Weight heparin in therapeutic dose,Subcutaneous Low Molecular Weight heparin in therapeutic dose",I regularly perform or request transthoracic echocardiography,Yes,Amiodarone,,No
31/10/2016 16:13,31/10/2016 16:18,IP Address,86.177.95.149,100,273,TRUE,31/10/2016 16:18,R_6EwxoFsQNSrOypr,,,,,53.77760315,-2.707504272,anonymous,Tertiary Referral Centre or University Hospital,>2000,32 + 8,Specialist ICU (please name specialty):,Neuro general ,Consultant,More than 10 years,Anaesthesia,"Independent of their heart rate I treat all patients who have developed new onset fast AF, even if the blood pressure remains stable",Rate control,Amiodarone,,Supplement electrolytes to a high normal level and DC cardioversion,>4.5 mmol/l,I do not aim for a specific serum magnesium level,"ICU drug policy,Cost",,I do not regularly anti-coagulate critically ill patients with new-onset fast AF,Modified risk scores should be developed for critically ill patients with new-onset atrial fibrillation,I do not regularly anti-coagulate critically ill patients with new onset fast AF,I regularly perform or request transthoracic echocardiography,Yes,"Amiodarone,DC cardioversion,ß-blocker",,Yes
31/10/2016 16:12,31/10/2016 16:18,IP Address,82.35.173.204,100,365,TRUE,31/10/2016 16:18,R_1CIzgio6Rba14gt,,,,,51.39920044,-0.255599976,anonymous,District General Hospital,<500,11,Mixed ICU,,Consultant,More than 10 years,Anaesthesia,100-119/beats per min,Rhythm control,Amiodarone,,Supplement electrolytes to a high normal level and anti-arrhythmics,>4.5 mmol/l,>1.2 mmol/l,"ICU drug policy,Other, please specify:",appears to work ,New onset AF within 48 hours,"Stroke risk scores inaccurately reflect the risk of embolic events in critically ill patients with new-onset atrial fibrillation due to prothrombotic changes associated with critical illness,Stroke risk scores favour anti-coagulation despite a higher risk of bleeding in critical illness,Modified risk scores should be developed for critically ill patients with new-onset atrial fibrillation","Intravenous High Molecular Weight heparin in therapeutic dose,Subcutaneous Low Molecular Weight heparin in therapeutic dose",I regularly perform or request transthoracic echocardiography,Yes,Amiodarone,,No
31/10/2016 16:09,31/10/2016 16:19,IP Address,62.254.7.163,100,561,TRUE,31/10/2016 16:19,R_1jOfO98BsEQtfqR,,,,,52.96670532,-1.166702271,anonymous,Tertiary Referral Centre or University Hospital,>2000,49,Mixed ICU,,Consultant,More than 10 years,Anaesthesia,140-159/beats per min,Rate control,Amiodarone,,Supplement electrolytes to a high normal level and anti-arrhythmics,>4.5 mmol/l,1.0-1.2 mmol/l,"Adverse effect profile,Other, please specify:",efficacy,I do not regularly anti-coagulate critically ill patients with new-onset fast AF,I do not use stroke risk scores routinely in critically ill patients with new onset AF to assess the need for anticoagulation,I do not regularly anti-coagulate critically ill patients with new onset fast AF,I do not routinely perform Echocardiography to guide treatment,Yes,"Amiodarone,ß-blocker",,Yes
31/10/2016 16:15,31/10/2016 16:20,IP Address,82.132.238.78,100,290,TRUE,31/10/2016 16:20,R_3oOfnaBALqWCb7a,,,,,51.49639893,-0.122406006,anonymous,District General Hospital,500-1000,18,Mixed ICU,,Consultant,More than 10 years,Anaesthesia,"Independent of their heart rate I treat all patients who have developed new onset fast AF, even if the blood pressure remains stable",Rhythm control,Amiodarone,,Supplement electrolytes to a high normal level and anti-arrhythmics,>4.5 mmol/l,1.0-1.2 mmol/l,ICU drug policy,,I do not regularly anti-coagulate critically ill patients with new-onset fast AF,I do not use stroke risk scores routinely in critically ill patients with new onset AF to assess the need for anticoagulation,I do not regularly anti-coagulate critically ill patients with new onset fast AF,I regularly perform or request transthoracic echocardiography,Yes,Amiodarone,,Yes
31/10/2016 16:10,31/10/2016 16:20,IP Address,81.154.205.60,100,616,TRUE,31/10/2016 16:20,R_1dhvUTPe4bTPp3N,,,,,50.86669922,-0.016693115,anonymous,Tertiary Referral Centre or University Hospital,1000-2000,60,Specialist ICU (please name specialty):,neuro cardiac haemoncology,Consultant,More than 10 years,Anaesthesia,120-139/beats per min,Rhythm control,Amiodarone,,DC cardioversion when anti-arrhythmics and electrolyte replacement fail to achieve rate and/or rhythm control,>4.5 mmol/l,>1.2 mmol/l,"Other, please specify:","You asked what was the commonest agent, not what I would choose!",I do not regularly anti-coagulate critically ill patients with new-onset fast AF,I do not use stroke risk scores routinely in critically ill patients with new onset AF to assess the need for anticoagulation,I do not regularly anti-coagulate critically ill patients with new onset fast AF,I do not routinely perform Echocardiography to guide treatment,Yes,ß-blocker,,Yes
31/10/2016 16:16,31/10/2016 16:21,IP Address,82.18.31.169,100,293,TRUE,31/10/2016 16:21,R_273g416p3rGdkwH,,,,,52.41070557,-1.819503784,anonymous,District General Hospital,1000-2000,25,Mixed ICU,,Trainee,3-5 years,Anaesthesia,100-119/beats per min,Rate control,Digoxin,,Supplement electrolytes (magnesium and/or potassium) to a high normal level,>4.5 mmol/l,1.0-1.2 mmol/l,Adverse effect profile,,New onset AF within 48 hours,"I regularly calculate a risk score (e. g. CHAD2, CHA2DS2-VASc) to assess the need for anti-coagulation","Subcutaneous Low Molecular Weight heparin in therapeutic dose,I do not regularly anti-coagulate critically ill patients with new onset fast AF",I only regularly perform Echocardiography in patients with cardiac history,Yes,"Amiodarone,DC cardioversion,ß-blocker,Digoxin",,Yes
31/10/2016 16:15,31/10/2016 16:21,IP Address,109.152.106.10,100,370,TRUE,31/10/2016 16:21,R_3JC8MruyXuLWQkN,,,,,51.64889526,-3.970901489,anonymous,Teaching Hospital,500-1000,28,Mixed ICU,,SAS,More than 10 years,Intensive Care Medicine only,"Independent of their heart rate I treat all patients who have developed new onset fast AF, even if the blood pressure remains stable",Rate control,Amiodarone,,Supplement electrolytes (magnesium and/or potassium) to a high normal level,>4 mmol/l,1.0-1.2 mmol/l,ICU drug policy,,I do not regularly anti-coagulate critically ill patients with new-onset fast AF,I do not use stroke risk scores routinely in critically ill patients with new onset AF to assess the need for anticoagulation,I do not regularly anti-coagulate critically ill patients with new onset fast AF,I do not routinely perform Echocardiography to guide treatment,Yes,"Amiodarone,DC cardioversion,ß-blocker",,Yes
31/10/2016 16:17,31/10/2016 16:23,IP Address,194.176.105.133,100,348,TRUE,31/10/2016 16:23,R_1PTcuvfhQQDHBPA,,,,,51.44340515,-0.14680481,anonymous,Tertiary Referral Centre or University Hospital,1000-2000,20,Mixed ICU,,Consultant,More than 10 years,Anaesthesia,"Independent of their heart rate I treat all patients who have developed new onset fast AF, even if the blood pressure remains stable",I have no primary treatment goal in these patients,Amiodarone,,Supplement electrolytes to a high normal level and anti-arrhythmics,>4.5 mmol/l,>1.2 mmol/l,Pharmacodynamic properties,,New onset AF within 72 hours,I do not use stroke risk scores routinely in critically ill patients with new onset AF to assess the need for anticoagulation,"Intravenous High Molecular Weight heparin in therapeutic dose,Subcutaneous Low Molecular Weight heparin in therapeutic dose,Use of warfarin",I only regularly perform Echocardiography in patients with cardiac history,Yes,Flecainide,,Yes
31/10/2016 16:21,31/10/2016 16:23,IP Address,185.69.145.181,100,168,TRUE,31/10/2016 16:23,R_1Owqc2nAaqAt81Q,,,,,51.49639893,-0.122406006,anonymous,District General Hospital,500-1000,13,Mixed ICU,,Consultant,3-5 years,Anaesthesia,120-139/beats per min,Rhythm control,ß-blocker,,Supplement electrolytes (magnesium and/or potassium) to a high normal level,>4.5 mmol/l,1.0-1.2 mmol/l,Pharmacokinetic advantages,,I do not regularly anti-coagulate critically ill patients with new-onset fast AF,"I do not use stroke risk scores routinely in critically ill patients with new onset AF to assess the need for anticoagulation,Modified risk scores should be developed for critically ill patients with new-onset atrial fibrillation",I do not regularly anti-coagulate critically ill patients with new onset fast AF,I regularly perform or request transthoracic echocardiography,Yes,ß-blocker,,No
31/10/2016 16:12,31/10/2016 16:24,IP Address,146.198.186.23,100,741,TRUE,31/10/2016 16:24,R_bBn9P2aVlDgA2iJ,,,,,51.55000305,-0.216705322,anonymous,Tertiary Referral Centre or University Hospital,>2000,31,Specialist ICU (please name specialty):,Cardiothoracics,Consultant,5-10 years,Anaesthesia,"Independent of their heart rate I treat all patients who have developed new onset fast AF, even if the blood pressure remains stable",Rhythm control,Amiodarone,,DC cardioversion when anti-arrhythmics and electrolyte replacement fail to achieve rate and/or rhythm control,>4.5 mmol/l,>1.2 mmol/l,Pharmacokinetic advantages,,New onset AF within 72 hours,"I regularly calculate a risk score (e. g. CHAD2, CHA2DS2-VASc) to assess the need for anti-coagulation","Intravenous High Molecular Weight heparin in therapeutic dose,Use of novel oral anti-coagulants (NOACs),Use of warfarin","I regularly perform or request transthoracic echocardiography,I regularly perform or request transoesophageal echocardiography",Yes,"Amiodarone,DC cardioversion",,No
31/10/2016 16:19,31/10/2016 16:24,IP Address,188.29.164.200,100,343,TRUE,31/10/2016 16:24,R_0IdNdBNyXjmzomF,,,,,51.51420593,-0.093093872,anonymous,Tertiary Referral Centre or University Hospital,1000-2000,24,Mixed ICU,,Trainee,1-3 years,Intensive Care Medicine only,120-139/beats per min,Rate control,ß-blocker,,Supplement electrolytes (magnesium and/or potassium) to a high normal level,>4.5 mmol/l,>1.2 mmol/l,"Pharmacokinetic advantages,Pharmacodynamic properties,Adverse effect profile",,I do not regularly anti-coagulate critically ill patients with new-onset fast AF,"I do not use stroke risk scores routinely in critically ill patients with new onset AF to assess the need for anticoagulation,Stroke risk scores inaccurately reflect the risk of embolic events in critically ill patients with new-onset atrial fibrillation due to prothrombotic changes associated with critical illness",Subcutaneous Low Molecular Weight heparin in therapeutic dose,I regularly perform or request transthoracic echocardiography,Yes,"DC cardioversion,ß-blocker",,Yes
31/10/2016 16:21,31/10/2016 16:25,IP Address,109.176.101.162,100,204,TRUE,31/10/2016 16:25,R_bjh2PYCHnAShSJL,,,,,51.02110291,-3.104705811,anonymous,District General Hospital,1000-2000,12,Mixed ICU,,Consultant,More than 10 years,Anaesthesia,>160/beats per min,Rate control,ß-blocker,,DC cardioversion when anti-arrhythmics and electrolyte replacement fail to achieve rate and/or rhythm control,>4 mmol/l,0.75-1 mmol/l,Adverse effect profile,,I do not regularly anti-coagulate critically ill patients with new-onset fast AF,I do not use stroke risk scores routinely in critically ill patients with new onset AF to assess the need for anticoagulation,"Subcutaneous Low Molecular Weight heparin in therapeutic dose,I do not regularly anti-coagulate critically ill patients with new onset fast AF",I do not routinely perform Echocardiography to guide treatment,Yes,Digoxin,,Yes
31/10/2016 16:20,31/10/2016 16:25,IP Address,94.118.240.232,100,297,TRUE,31/10/2016 16:25,R_30kFueXua3UREEA,,,,,53.80000305,-1.583297729,anonymous,Tertiary Referral Centre or University Hospital,1000-2000,25,Predominantly surgical,,Consultant,3-5 years,Intensive Care Medicine only,120-139/beats per min,Rate control,Amiodarone,,Supplement electrolytes to a high normal level and anti-arrhythmics,>4.5 mmol/l,1.0-1.2 mmol/l,"Pharmacokinetic advantages,Pharmacodynamic properties",,I do not regularly anti-coagulate critically ill patients with new-onset fast AF,I do not use stroke risk scores routinely in critically ill patients with new onset AF to assess the need for anticoagulation,I do not regularly anti-coagulate critically ill patients with new onset fast AF,I do not routinely perform Echocardiography to guide treatment,Yes,"Amiodarone,ß-blocker",,Yes
31/10/2016 16:21,31/10/2016 16:26,IP Address,213.205.252.138,100,322,TRUE,31/10/2016 16:26,R_26kwAICxv7Dfvkz,,,,,52.6000061,-2,anonymous,District General Hospital,500-1000,Equivalent 7 level 3 beds,Mixed ICU,,Trainee,3-5 years,Anaesthesia,120-139/beats per min,Rate control,ß-blocker,,Supplement electrolytes to a high normal level and anti-arrhythmics,>4.5 mmol/l,1.0-1.2 mmol/l,Adverse effect profile,,I do not regularly anti-coagulate critically ill patients with new-onset fast AF,I do not use stroke risk scores routinely in critically ill patients with new onset AF to assess the need for anticoagulation,I do not regularly anti-coagulate critically ill patients with new onset fast AF,I only regularly perform Echocardiography in patients with cardiac history,Yes,ß-blocker,,No
31/10/2016 16:21,31/10/2016 16:26,IP Address,82.132.233.183,100,300,TRUE,31/10/2016 16:26,R_QlUmPU4UnxXbSuZ,,,,,51.49639893,-0.122406006,anonymous,District General Hospital,<500,11,Mixed ICU,,SAS,3-5 years,Anaesthesia,120-139/beats per min,Rate control,Amiodarone,,Supplement electrolytes to a high normal level and anti-arrhythmics,>4 mmol/l,1.0-1.2 mmol/l,Pharmacodynamic properties,,I do not regularly anti-coagulate critically ill patients with new-onset fast AF,Stroke risk scores inaccurately reflect the risk of embolic events in critically ill patients with new-onset atrial fibrillation due to prothrombotic changes associated with critical illness,I do not regularly anti-coagulate critically ill patients with new onset fast AF,I regularly perform or request transthoracic echocardiography,Yes,DC cardioversion,,Yes
31/10/2016 16:21,31/10/2016 16:26,IP Address,82.19.176.142,100,321,TRUE,31/10/2016 16:26,R_1CxXCaL0m13jJgX,,,,,53.55000305,-2.116699219,anonymous,District General Hospital,>2000,24,Mixed ICU,,Consultant,More than 10 years,Anaesthesia,120-139/beats per min,Rate control,ß-blocker,,Supplement electrolytes to a high normal level and anti-arrhythmics,>4.5 mmol/l,1.0-1.2 mmol/l,"Availability from hospital pharmacy,ICU drug policy,Cost,Pharmacokinetic advantages,Pharmacodynamic properties,Adverse effect profile",,I do not regularly anti-coagulate critically ill patients with new-onset fast AF,"I do not use stroke risk scores routinely in critically ill patients with new onset AF to assess the need for anticoagulation,Stroke risk scores inaccurately reflect the risk of embolic events in critically ill patients with new-onset atrial fibrillation due to prothrombotic changes associated with critical illness,Modified risk scores should be developed for critically ill patients with new-onset atrial fibrillation",I do not regularly anti-coagulate critically ill patients with new onset fast AF,I do not routinely perform Echocardiography to guide treatment,No,"Amiodarone,ß-blocker,Digoxin",,Yes
31/10/2016 16:22,31/10/2016 16:28,IP Address,194.176.105.144,100,360,TRUE,31/10/2016 16:28,R_cXZraoYMD7t13Zb,,,,,51.51420593,-0.093093872,anonymous,District General Hospital,500-1000,10,Mixed ICU,,Consultant,More than 10 years,Anaesthesia,120-139/beats per min,Rate control,Amiodarone,,Supplement electrolytes to a high normal level and anti-arrhythmics,>4 mmol/l,1.0-1.2 mmol/l,ICU drug policy,,New onset AF within 48 hours,I do not use stroke risk scores routinely in critically ill patients with new onset AF to assess the need for anticoagulation,"Intravenous High Molecular Weight heparin in therapeutic dose,Subcutaneous Low Molecular Weight heparin in therapeutic dose",I regularly perform or request transthoracic echocardiography,Yes,Amiodarone,,Yes
31/10/2016 16:22,31/10/2016 16:29,IP Address,217.41.0.27,100,395,TRUE,31/10/2016 16:29,R_3htDrs1xpLEkQeC,,,,,51.49639893,-0.122406006,anonymous,Tertiary Referral Centre or University Hospital,>2000,15-22,Mixed ICU,,SAS,5-10 years,Intensive Care Medicine only,120-139/beats per min,Rate control,Amiodarone,,DC cardioversion when anti-arrhythmics and electrolyte replacement fail to achieve rate and/or rhythm control,>4.5 mmol/l,I do not aim for a specific serum magnesium level,"ICU drug policy,Adverse effect profile",,I do not regularly anti-coagulate critically ill patients with new-onset fast AF,"I regularly calculate a risk score (e. g. CHAD2, CHA2DS2-VASc) to assess the need for anti-coagulation,Stroke risk scores inaccurately reflect the risk of embolic events in critically ill patients with new-onset atrial fibrillation due to prothrombotic changes associated with critical illness,Stroke risk scores favour anti-coagulation despite a higher risk of bleeding in critical illness","Intravenous High Molecular Weight heparin in therapeutic dose,Subcutaneous Low Molecular Weight heparin in therapeutic dose,Use of novel oral anti-coagulants (NOACs),Use of warfarin",I regularly perform or request transthoracic echocardiography,Yes,ß-blocker,,No
31/10/2016 16:26,31/10/2016 16:30,IP Address,194.176.105.171,100,219,TRUE,31/10/2016 16:30,R_4NpiFOYnZQjbxZz,,,,,51.51420593,-0.093093872,anonymous,Tertiary Referral Centre or University Hospital,I do not know,32,Mixed ICU,,Trainee,3-5 years,Intensive Care Medicine only,120-139/beats per min,Rate control,Amiodarone,,Supplement electrolytes to a high normal level and anti-arrhythmics,>4.5 mmol/l,1.0-1.2 mmol/l,"ICU drug policy,Pharmacokinetic advantages,Pharmacodynamic properties",,I do not regularly anti-coagulate critically ill patients with new-onset fast AF,Stroke risk scores inaccurately reflect the risk of embolic events in critically ill patients with new-onset atrial fibrillation due to prothrombotic changes associated with critical illness,Intravenous High Molecular Weight heparin in therapeutic dose,I regularly perform or request transthoracic echocardiography,Yes,Amiodarone,,No
31/10/2016 16:26,31/10/2016 16:30,IP Address,81.110.70.64,100,278,TRUE,31/10/2016 16:30,R_24qhXTKy72ezTuJ,,,,,52.92849731,-1.104293823,anonymous,Tertiary Referral Centre or University Hospital,>2000,41,Predominantly surgical,,Consultant,More than 10 years,Anaesthesia,"Independent of their heart rate I treat all patients who have developed new onset fast AF, even if the blood pressure remains stable",Rhythm control,Amiodarone,,Anti-arrhythmics only,>4 mmol/l,0.75-1 mmol/l,"ICU drug policy,Pharmacokinetic advantages,Pharmacodynamic properties",,I do not regularly anti-coagulate critically ill patients with new-onset fast AF,"I do not use stroke risk scores routinely in critically ill patients with new onset AF to assess the need for anticoagulation,Modified risk scores should be developed for critically ill patients with new-onset atrial fibrillation",I do not regularly anti-coagulate critically ill patients with new onset fast AF,I do not routinely perform Echocardiography to guide treatment,No,"ß-blocker,Flecainide",,No
31/10/2016 16:26,31/10/2016 16:31,IP Address,195.99.36.70,100,273,TRUE,31/10/2016 16:31,R_DjzGo1kMoRSJZVT,,,,,51.41670227,-0.100006104,anonymous,District General Hospital,500-1000,15,Mixed ICU,,Trainee,1-3 years,Anaesthesia,120-139/beats per min,Rate control,Amiodarone,,Supplement electrolytes to a high normal level and DC cardioversion,>4.5 mmol/l,>1.2 mmol/l,"ICU drug policy,Pharmacokinetic advantages,Pharmacodynamic properties,Adverse effect profile",,New onset AF within 24 hours,"Stroke risk scores inaccurately reflect the risk of embolic events in critically ill patients with new-onset atrial fibrillation due to prothrombotic changes associated with critical illness,Stroke risk scores favour anti-coagulation despite a higher risk of bleeding in critical illness,Modified risk scores should be developed for critically ill patients with new-onset atrial fibrillation",Subcutaneous Low Molecular Weight heparin in therapeutic dose,I regularly perform or request transthoracic echocardiography,Yes,Amiodarone,,No
31/10/2016 16:25,31/10/2016 16:31,IP Address,92.40.249.67,100,339,TRUE,31/10/2016 16:31,R_2VEghCmhlrUvA84,,,,,51.49639893,-0.122406006,anonymous,District General Hospital,500-1000,20,Mixed ICU,,Consultant,More than 10 years,Anaesthesia,120-139/beats per min,Rhythm control,Amiodarone,,Supplement electrolytes to a high normal level and DC cardioversion,>4.5 mmol/l,1.0-1.2 mmol/l,"ICU drug policy,Adverse effect profile",,I do not regularly anti-coagulate critically ill patients with new-onset fast AF,"I do not use stroke risk scores routinely in critically ill patients with new onset AF to assess the need for anticoagulation,Stroke risk scores inaccurately reflect the risk of embolic events in critically ill patients with new-onset atrial fibrillation due to prothrombotic changes associated with critical illness,Modified risk scores should be developed for critically ill patients with new-onset atrial fibrillation",I do not regularly anti-coagulate critically ill patients with new onset fast AF,I do not routinely perform Echocardiography to guide treatment,Yes,"Amiodarone,DC cardioversion,Other anti-arrhythmics (e. g. verapamil, sotalol): Please specify:",Verapamil,No
31/10/2016 16:05,31/10/2016 16:32,IP Address,86.164.60.73,100,1623,TRUE,31/10/2016 16:32,R_1mER7xWm5akqW6k,,,,,50.78329468,-1.983306885,anonymous,Teaching Hospital,1000-2000,34,Mixed ICU,,Consultant,More than 10 years,Anaesthesia,"Independent of their heart rate I treat all patients who have developed new onset fast AF, even if the blood pressure remains stable",Rate control,Digoxin,,Supplement electrolytes to a high normal level and anti-arrhythmics,>4.5 mmol/l,1.0-1.2 mmol/l,Pharmacodynamic properties,,I do not regularly anti-coagulate critically ill patients with new-onset fast AF,I do not use stroke risk scores routinely in critically ill patients with new onset AF to assess the need for anticoagulation,I do not regularly anti-coagulate critically ill patients with new onset fast AF,I do not routinely perform Echocardiography to guide treatment,No,"Amiodarone,DC cardioversion,ß-blocker,Digoxin",,No
31/10/2016 16:30,31/10/2016 16:33,IP Address,86.23.42.128,100,212,TRUE,31/10/2016 16:33,R_3NFbSUg4gD0UETX,,,,,51.56669617,-0.333297729,anonymous,Teaching Hospital,>2000,59,Mixed ICU,,Trainee,5-10 years,Acute medicine,"Independent of their heart rate I treat all patients who have developed new onset fast AF, even if the blood pressure remains stable",Rate control,Amiodarone,,Supplement electrolytes (magnesium and/or potassium) to a high normal level,>4.5 mmol/l,>1.2 mmol/l,"Pharmacokinetic advantages,Pharmacodynamic properties,Adverse effect profile",,I do not regularly anti-coagulate critically ill patients with new-onset fast AF,Stroke risk scores inaccurately reflect the risk of embolic events in critically ill patients with new-onset atrial fibrillation due to prothrombotic changes associated with critical illness,I do not regularly anti-coagulate critically ill patients with new onset fast AF,I regularly perform or request transthoracic echocardiography,Yes,ß-blocker,,Yes
31/10/2016 16:28,31/10/2016 16:33,IP Address,194.176.105.138,100,313,TRUE,31/10/2016 16:33,R_6ziUv4SClXVqLpr,,,,,51.51420593,-0.093093872,anonymous,District General Hospital,500-1000,7,Mixed ICU,,Consultant,More than 10 years,Anaesthesia,100-119/beats per min,Rate control,Amiodarone,,Supplement electrolytes (magnesium and/or potassium) to a high normal level,>4.5 mmol/l,1.0-1.2 mmol/l,ICU drug policy,,I do not regularly anti-coagulate critically ill patients with new-onset fast AF,I do not use stroke risk scores routinely in critically ill patients with new onset AF to assess the need for anticoagulation,"Subcutaneous Low Molecular Weight heparin in therapeutic dose,Use of warfarin,I do not regularly anti-coagulate critically ill patients with new onset fast AF",I only regularly perform Echocardiography in patients with cardiac history,Yes,Amiodarone,,Yes
31/10/2016 16:30,31/10/2016 16:34,IP Address,31.108.154.67,100,218,TRUE,31/10/2016 16:34,R_1i5pQYrlxVqAu8d,,,,,54.44030762,-1.396606445,anonymous,Tertiary Referral Centre or University Hospital,1000-2000,18,Mixed ICU,,Trainee,3-5 years,Anaesthesia,"Independent of their heart rate I treat all patients who have developed new onset fast AF, even if the blood pressure remains stable",I have no primary treatment goal in these patients,Amiodarone,,DC cardioversion when anti-arrhythmics and electrolyte replacement fail to achieve rate and/or rhythm control,>4.5 mmol/l,1.0-1.2 mmol/l,"Availability from hospital pharmacy,Pharmacodynamic properties",,I do not regularly anti-coagulate critically ill patients with new-onset fast AF,Modified risk scores should be developed for critically ill patients with new-onset atrial fibrillation,I do not regularly anti-coagulate critically ill patients with new onset fast AF,I do not routinely perform Echocardiography to guide treatment,Yes,"Amiodarone,DC cardioversion,ß-blocker",,Yes
31/10/2016 16:26,31/10/2016 16:35,IP Address,194.176.105.168,100,510,TRUE,31/10/2016 16:35,R_10C5pnLTs67G5Vd,,,,,51.44999695,-0.416702271,anonymous,District General Hospital,<500,10,Mixed ICU,,Consultant,More than 10 years,Anaesthesia,"Independent of their heart rate I treat all patients who have developed new onset fast AF, even if the blood pressure remains stable",I have no primary treatment goal in these patients,Amiodarone,,Supplement electrolytes to a high normal level and anti-arrhythmics,>4.5 mmol/l,0.75-1 mmol/l,Pharmacodynamic properties,,I do not regularly anti-coagulate critically ill patients with new-onset fast AF,"I do not use stroke risk scores routinely in critically ill patients with new onset AF to assess the need for anticoagulation,Stroke risk scores inaccurately reflect the risk of embolic events in critically ill patients with new-onset atrial fibrillation due to prothrombotic changes associated with critical illness,Modified risk scores should be developed for critically ill patients with new-onset atrial fibrillation",Intravenous High Molecular Weight heparin in therapeutic dose,I regularly perform or request transthoracic echocardiography,Yes,"Amiodarone,ß-blocker",,No
31/10/2016 16:09,31/10/2016 16:35,IP Address,86.134.222.9,100,1560,TRUE,31/10/2016 16:35,R_10OVMXzX6Mk58GF,,,,,51.44340515,-0.14680481,anonymous,Tertiary Referral Centre or University Hospital,500-1000,18,Mixed ICU,,Consultant,More than 10 years,Anaesthesia,120-139/beats per min,Rhythm control,Amiodarone,,Supplement electrolytes to a high normal level and anti-arrhythmics,>4.5 mmol/l,1.0-1.2 mmol/l,"Other, please specify:",Efficacy and years of seeing it work,I do not regularly anti-coagulate critically ill patients with new-onset fast AF,I do not use stroke risk scores routinely in critically ill patients with new onset AF to assess the need for anticoagulation,Intravenous High Molecular Weight heparin in therapeutic dose,I do not routinely perform Echocardiography to guide treatment,No,"Other anti-arrhythmics (e. g. verapamil, sotalol): Please specify:",None - though I might be persuaded if you suggested a question to answer,No
31/10/2016 16:33,31/10/2016 16:37,IP Address,101.177.82.231,100,238,TRUE,31/10/2016 16:37,R_3ltquQFScmzmMZC,,,,,-31.98100281,115.8695984,anonymous,Tertiary Referral Centre or University Hospital,500-1000,10,Specialist ICU (please name specialty):,Paediatric,Consultant,5-10 years,Anaesthesia,120-139/beats per min,Rate control,Amiodarone,,Supplement electrolytes to a high normal level and anti-arrhythmics,>4 mmol/l,1.0-1.2 mmol/l,"ICU drug policy,Adverse effect profile",,I do not regularly anti-coagulate critically ill patients with new-onset fast AF,"I do not use stroke risk scores routinely in critically ill patients with new onset AF to assess the need for anticoagulation,Stroke risk scores favour anti-coagulation despite a higher risk of bleeding in critical illness,Modified risk scores should be developed for critically ill patients with new-onset atrial fibrillation","Intravenous High Molecular Weight heparin in therapeutic dose,Subcutaneous Low Molecular Weight heparin in therapeutic dose",I regularly perform or request transthoracic echocardiography,Yes,ß-blocker,,Yes
31/10/2016 16:34,31/10/2016 16:39,IP Address,194.176.105.168,100,262,TRUE,31/10/2016 16:39,R_6m7skDvD2nqFkDn,,,,,51.44999695,-0.416702271,anonymous,Teaching Hospital,I do not know,25,Mixed ICU,,Trainee,<1 year,Anaesthesia,120-139/beats per min,Rate control,Amiodarone,,Supplement electrolytes to a high normal level and anti-arrhythmics,>4 mmol/l,1.0-1.2 mmol/l,"Pharmacodynamic properties,Adverse effect profile",,I do not regularly anti-coagulate critically ill patients with new-onset fast AF,I do not use stroke risk scores routinely in critically ill patients with new onset AF to assess the need for anticoagulation,Subcutaneous Low Molecular Weight heparin in therapeutic dose,I do not routinely perform Echocardiography to guide treatment,Yes,ß-blocker,,Yes
31/10/2016 16:31,31/10/2016 16:39,IP Address,86.133.87.37,100,455,TRUE,31/10/2016 16:39,R_3MybHjgJveOeURY,,,,,51.68319702,-3.775497437,anonymous,Teaching Hospital,500-1000,23,Mixed ICU,,Consultant,3-5 years,Anaesthesia,"Independent of their heart rate I treat all patients who have developed new onset fast AF, even if the blood pressure remains stable",Rhythm control,Amiodarone,,Supplement electrolytes (magnesium and/or potassium) to a high normal level,>4.5 mmol/l,1.0-1.2 mmol/l,Pharmacodynamic properties,,I do not regularly anti-coagulate critically ill patients with new-onset fast AF,"I do not use stroke risk scores routinely in critically ill patients with new onset AF to assess the need for anticoagulation,Modified risk scores should be developed for critically ill patients with new-onset atrial fibrillation","Intravenous High Molecular Weight heparin in therapeutic dose,I do not regularly anti-coagulate critically ill patients with new onset fast AF",I do not routinely perform Echocardiography to guide treatment,Yes,"Amiodarone,Digoxin",,No
31/10/2016 16:34,31/10/2016 16:40,IP Address,94.192.181.119,100,342,TRUE,31/10/2016 16:40,R_32RqbX4d18Myy42,,,,,51.51420593,-0.093093872,anonymous,District General Hospital,I do not know,22,Predominantly medical,,Trainee,1-3 years,Anaesthesia,"Independent of their heart rate I treat all patients who have developed new onset fast AF, even if the blood pressure remains stable",Rhythm control,Amiodarone,,Supplement electrolytes to a high normal level and anti-arrhythmics,>4.5 mmol/l,>1.2 mmol/l,Pharmacodynamic properties,,New onset AF within 48 hours,"I do not use stroke risk scores routinely in critically ill patients with new onset AF to assess the need for anticoagulation,Stroke risk scores inaccurately reflect the risk of embolic events in critically ill patients with new-onset atrial fibrillation due to prothrombotic changes associated with critical illness,Modified risk scores should be developed for critically ill patients with new-onset atrial fibrillation","Intravenous High Molecular Weight heparin in therapeutic dose,Subcutaneous Low Molecular Weight heparin in therapeutic dose",I regularly perform or request transthoracic echocardiography,Yes,"Amiodarone,Digoxin",,No
31/10/2016 16:36,31/10/2016 16:40,IP Address,90.195.216.232,100,230,TRUE,31/10/2016 16:40,R_3G9w9i3wM4RBYql,,,,,52.41670227,-1.550003052,anonymous,Tertiary Referral Centre or University Hospital,I do not know,22-25,Mixed ICU,,Trainee,<1 year,Intensive Care Medicine only,120-139/beats per min,Rhythm control,Amiodarone,,I only intervene if blood pressure drops or inotrope requirements increase,>4 mmol/l,I do not aim for a specific serum magnesium level,"Other, please specify:",Depends on the patient and their illness ,I do not regularly anti-coagulate critically ill patients with new-onset fast AF,"I do not use stroke risk scores routinely in critically ill patients with new onset AF to assess the need for anticoagulation,Modified risk scores should be developed for critically ill patients with new-onset atrial fibrillation",I do not regularly anti-coagulate critically ill patients with new onset fast AF,I do not routinely perform Echocardiography to guide treatment,Yes,"Amiodarone,ß-blocker",,Yes
31/10/2016 16:36,31/10/2016 16:40,IP Address,213.205.252.185,100,208,TRUE,31/10/2016 16:40,R_1gFHsSXFaW3cUHL,,,,,52.6000061,-2,anonymous,Teaching Hospital,1000-2000,30,Mixed ICU,,Trainee,5-10 years,Intensive Care Medicine only,"Independent of their heart rate I treat all patients who have developed new onset fast AF, even if the blood pressure remains stable",Rhythm control,"Other anti-arrhythmics (e. g. Verapamil, sotalol): please specify:",magnesium,Supplement electrolytes (magnesium and/or potassium) to a high normal level,>4 mmol/l,1.0-1.2 mmol/l,"ICU drug policy,Adverse effect profile",,I do not regularly anti-coagulate critically ill patients with new-onset fast AF,"I do not use stroke risk scores routinely in critically ill patients with new onset AF to assess the need for anticoagulation,Stroke risk scores inaccurately reflect the risk of embolic events in critically ill patients with new-onset atrial fibrillation due to prothrombotic changes associated with critical illness,Stroke risk scores favour anti-coagulation despite a higher risk of bleeding in critical illness",Subcutaneous Low Molecular Weight heparin in therapeutic dose,I do not routinely perform Echocardiography to guide treatment,Yes,"Amiodarone,Digoxin",,Yes
31/10/2016 16:36,31/10/2016 16:41,IP Address,82.1.8.4,100,276,TRUE,31/10/2016 16:41,R_d76DejBFzWdotFj,,,,,53.76669312,-2.716705322,anonymous,Tertiary Referral Centre or University Hospital,1000-2000,24,Mixed ICU,,Consultant,5-10 years,Anaesthesia,120-139/beats per min,Rate control,Amiodarone,,Supplement electrolytes (magnesium and/or potassium) to a high normal level,>4.5 mmol/l,>1.2 mmol/l,Pharmacokinetic advantages,,New onset AF within 24 hours,I do not use stroke risk scores routinely in critically ill patients with new onset AF to assess the need for anticoagulation,Subcutaneous Low Molecular Weight heparin in therapeutic dose,I do not routinely perform Echocardiography to guide treatment,Yes,"Amiodarone,DC cardioversion,ß-blocker,Digoxin",,No
31/10/2016 16:36,31/10/2016 16:41,IP Address,194.176.105.168,100,326,TRUE,31/10/2016 16:41,R_9TesDlBhpYR8eZT,,,,,51.44999695,-0.416702271,anonymous,Tertiary Referral Centre or University Hospital,>2000,85,Mixed ICU,,Consultant,More than 10 years,Anaesthesia,100-119/beats per min,Rhythm control,Amiodarone,,Supplement electrolytes (magnesium and/or potassium) to a high normal level,>4.5 mmol/l,>1.2 mmol/l,"Pharmacokinetic advantages,Pharmacodynamic properties,Adverse effect profile",,New onset AF within 24 hours,Modified risk scores should be developed for critically ill patients with new-onset atrial fibrillation,"Subcutaneous Low Molecular Weight heparin in therapeutic dose,Use of novel oral anti-coagulants (NOACs)",I only regularly perform Echocardiography in patients with cardiac history,Yes,"Amiodarone,DC cardioversion,ß-blocker",,No
31/10/2016 16:35,31/10/2016 16:42,IP Address,163.160.107.179,100,424,TRUE,31/10/2016 16:42,R_5pv0kyPRl921Mwp,,,,,53.80000305,-1.583297729,anonymous,Tertiary Referral Centre or University Hospital,1000-2000,34,Mixed ICU,,Consultant,More than 10 years,Anaesthesia,"Independent of their heart rate I treat all patients who have developed new onset fast AF, even if the blood pressure remains stable",Rhythm control,Amiodarone,,DC cardioversion when anti-arrhythmics and electrolyte replacement fail to achieve rate and/or rhythm control,>4 mmol/l,1.0-1.2 mmol/l,Pharmacodynamic properties,,I do not regularly anti-coagulate critically ill patients with new-onset fast AF,I do not use stroke risk scores routinely in critically ill patients with new onset AF to assess the need for anticoagulation,"Subcutaneous Low Molecular Weight heparin in therapeutic dose,I do not regularly anti-coagulate critically ill patients with new onset fast AF",I do not routinely perform Echocardiography to guide treatment,Yes,"Amiodarone,DC cardioversion,ß-blocker",,No
31/10/2016 16:38,31/10/2016 16:42,IP Address,62.255.170.180,100,229,TRUE,31/10/2016 16:42,R_1dct93XttuBNc5K,,,,,50.83329773,-0.149993896,anonymous,District General Hospital,I do not know,8,Mixed ICU,,Trainee,5-10 years,Anaesthesia,"Independent of their heart rate I treat all patients who have developed new onset fast AF, even if the blood pressure remains stable",Rate control,Amiodarone,,Supplement electrolytes (magnesium and/or potassium) to a high normal level,>4.5 mmol/l,1.0-1.2 mmol/l,ICU drug policy,,I do not regularly anti-coagulate critically ill patients with new-onset fast AF,"I do not use stroke risk scores routinely in critically ill patients with new onset AF to assess the need for anticoagulation,I regularly calculate a risk score (e. g. CHAD2, CHA2DS2-VASc) to assess the need for anti-coagulation,Stroke risk scores inaccurately reflect the risk of embolic events in critically ill patients with new-onset atrial fibrillation due to prothrombotic changes associated with critical illness,Modified risk scores should be developed for critically ill patients with new-onset atrial fibrillation","Subcutaneous Low Molecular Weight heparin in therapeutic dose,I do not regularly anti-coagulate critically ill patients with new onset fast AF",I regularly perform or request transthoracic echocardiography,Yes,"Amiodarone,ß-blocker,Diltiazem",,No
31/10/2016 16:01,31/10/2016 16:45,IP Address,93.66.225.80,100,2668,TRUE,31/10/2016 16:45,R_1dbkXEPq9FrYBk0,,,,,45.64329529,13.79029846,anonymous,Tertiary Referral Centre or University Hospital,I do not know,48,Predominantly surgical,,Trainee,1-3 years,Anaesthesia,120-139/beats per min,Rhythm control,Amiodarone,,Supplement electrolytes to a high normal level and anti-arrhythmics,>4.5 mmol/l,1.0-1.2 mmol/l,Pharmacokinetic advantages,,New onset AF within 48 hours,Modified risk scores should be developed for critically ill patients with new-onset atrial fibrillation,Subcutaneous Low Molecular Weight heparin in therapeutic dose,I regularly perform or request transthoracic echocardiography,Yes,"Amiodarone,DC cardioversion,ß-blocker,Digoxin",,Yes
31/10/2016 16:42,31/10/2016 16:47,IP Address,86.187.231.27,100,276,TRUE,31/10/2016 16:47,R_cOxWCb64fzeY6EF,,,,,51.49639893,-0.122406006,anonymous,Tertiary Referral Centre or University Hospital,1000-2000,25,Mixed ICU,,Trainee,1-3 years,Anaesthesia,"Independent of their heart rate I treat all patients who have developed new onset fast AF, even if the blood pressure remains stable",Rate control,Amiodarone,,Supplement electrolytes to a high normal level and anti-arrhythmics,>4 mmol/l,1.0-1.2 mmol/l,ICU drug policy,,I do not regularly anti-coagulate critically ill patients with new-onset fast AF,I do not use stroke risk scores routinely in critically ill patients with new onset AF to assess the need for anticoagulation,I do not regularly anti-coagulate critically ill patients with new onset fast AF,I do not routinely perform Echocardiography to guide treatment,No,"Amiodarone,DC cardioversion,Digoxin",,No
31/10/2016 16:45,31/10/2016 16:48,IP Address,82.132.228.170,100,205,TRUE,31/10/2016 16:48,R_Q0zrEJGuANjSIGl,,,,,51.49639893,-0.122406006,anonymous,Tertiary Referral Centre or University Hospital,<500,16,Mixed ICU,,Trainee,1-3 years,Intensive Care Medicine only,120-139/beats per min,Rhythm control,Amiodarone,,Supplement electrolytes to a high normal level and anti-arrhythmics,>4.5 mmol/l,1.0-1.2 mmol/l,ICU drug policy,,I do not regularly anti-coagulate critically ill patients with new-onset fast AF,I do not use stroke risk scores routinely in critically ill patients with new onset AF to assess the need for anticoagulation,I do not regularly anti-coagulate critically ill patients with new onset fast AF,I regularly perform or request transthoracic echocardiography,Yes,"Amiodarone,DC cardioversion,ß-blocker,Digoxin",,Yes
31/10/2016 16:44,31/10/2016 16:50,IP Address,149.254.248.51,100,313,TRUE,31/10/2016 16:50,R_OCHhVVYHBxSsKmB,,,,,53.5,-2.216705322,anonymous,Tertiary Referral Centre or University Hospital,1000-2000,24,Mixed ICU,,Consultant,More than 10 years,Anaesthesia,140-159/beats per min,Rate control,Amiodarone,,Supplement electrolytes (magnesium and/or potassium) to a high normal level,>4 mmol/l,1.0-1.2 mmol/l,Pharmacodynamic properties,,I do not regularly anti-coagulate critically ill patients with new-onset fast AF,I do not use stroke risk scores routinely in critically ill patients with new onset AF to assess the need for anticoagulation,Subcutaneous Low Molecular Weight heparin in therapeutic dose,I do not routinely perform Echocardiography to guide treatment,Yes,"Amiodarone,ß-blocker",,No
31/10/2016 16:46,31/10/2016 16:50,IP Address,31.49.225.4,100,208,TRUE,31/10/2016 16:50,R_3Pc4otRzqMtU5E4,,,,,53.41700745,-2.231506348,anonymous,Tertiary Referral Centre or University Hospital,500-1000,16,Specialist ICU (please name specialty):,Cardiac,Consultant,More than 10 years,Anaesthesia,100-119/beats per min,Rate control,Amiodarone,,Supplement electrolytes to a high normal level and anti-arrhythmics,>4.5 mmol/l,I do not aim for a specific serum magnesium level,Pharmacodynamic properties,,New onset AF within 48 hours,I do not use stroke risk scores routinely in critically ill patients with new onset AF to assess the need for anticoagulation,"Subcutaneous Low Molecular Weight heparin in therapeutic dose,Use of novel oral anti-coagulants (NOACs),Use of warfarin","I regularly perform or request transthoracic echocardiography,I regularly perform or request transoesophageal echocardiography",Yes,Amiodarone,,No
31/10/2016 16:37,31/10/2016 16:50,IP Address,161.17.0.1,100,783,TRUE,31/10/2016 16:50,R_4PzNgP2UNI1WGwt,,,,,51.51420593,-0.093093872,anonymous,District General Hospital,I do not know,12,Mixed ICU,,Trainee,1-3 years,Anaesthesia,"Independent of their heart rate I treat all patients who have developed new onset fast AF, even if the blood pressure remains stable",Rate control,Amiodarone,,Supplement electrolytes to a high normal level and anti-arrhythmics,>4.5 mmol/l,1.0-1.2 mmol/l,"Pharmacokinetic advantages,Pharmacodynamic properties,Adverse effect profile",,I do not regularly anti-coagulate critically ill patients with new-onset fast AF,"I do not use stroke risk scores routinely in critically ill patients with new onset AF to assess the need for anticoagulation,Stroke risk scores inaccurately reflect the risk of embolic events in critically ill patients with new-onset atrial fibrillation due to prothrombotic changes associated with critical illness,Stroke risk scores favour anti-coagulation despite a higher risk of bleeding in critical illness,Modified risk scores should be developed for critically ill patients with new-onset atrial fibrillation","Intravenous High Molecular Weight heparin in therapeutic dose,Subcutaneous Low Molecular Weight heparin in therapeutic dose,I do not regularly anti-coagulate critically ill patients with new onset fast AF",I do not routinely perform Echocardiography to guide treatment,Yes,"Amiodarone,DC cardioversion,ß-blocker,Flecainide,Diltiazem,Digoxin",,Yes
31/10/2016 16:47,31/10/2016 16:52,IP Address,86.46.21.135,100,302,TRUE,31/10/2016 16:52,R_2Bbbu3P730gXlFS,,,,,53.33309937,-6.248901367,anonymous,Teaching Hospital,<500,5,Mixed ICU,,Consultant,5-10 years,Anaesthesia,120-139/beats per min,Rate control,Amiodarone,,DC cardioversion when anti-arrhythmics and electrolyte replacement fail to achieve rate and/or rhythm control,>4.5 mmol/l,1.0-1.2 mmol/l,Pharmacokinetic advantages,,Before DC cardioversion,Modified risk scores should be developed for critically ill patients with new-onset atrial fibrillation,Subcutaneous Low Molecular Weight heparin in therapeutic dose,I regularly perform or request transthoracic echocardiography,No,Amiodarone,,No
31/10/2016 16:49,31/10/2016 16:53,IP Address,109.151.133.3,100,253,TRUE,31/10/2016 16:53,R_2dRf7SWBzNk62gz,,,,,51.91670227,-0.649993896,anonymous,District General Hospital,1000-2000,16,Mixed ICU,,Consultant,More than 10 years,Anaesthesia,120-139/beats per min,Rhythm control,Amiodarone,,Supplement electrolytes to a high normal level and anti-arrhythmics,>4.5 mmol/l,1.0-1.2 mmol/l,"Pharmacokinetic advantages,Pharmacodynamic properties,Adverse effect profile",,I do not regularly anti-coagulate critically ill patients with new-onset fast AF,"I do not use stroke risk scores routinely in critically ill patients with new onset AF to assess the need for anticoagulation,Modified risk scores should be developed for critically ill patients with new-onset atrial fibrillation","Intravenous High Molecular Weight heparin in therapeutic dose,Subcutaneous Low Molecular Weight heparin in therapeutic dose,Use of novel oral anti-coagulants (NOACs),Use of warfarin,I do not regularly anti-coagulate critically ill patients with new onset fast AF",I regularly perform or request transthoracic echocardiography,Yes,Amiodarone,,No
31/10/2016 16:47,31/10/2016 16:55,IP Address,185.16.225.181,100,494,TRUE,31/10/2016 16:55,R_1BVslJME0nNJWn1,,,,,53.75,-2.483306885,anonymous,Teaching Hospital,500-1000,14,Mixed ICU,,Consultant,5-10 years,Anaesthesia,140-159/beats per min,Rate control,Amiodarone,,Supplement electrolytes to a high normal level and anti-arrhythmics,>4.5 mmol/l,>1.2 mmol/l,"Availability from hospital pharmacy,ICU drug policy,Adverse effect profile",,I do not regularly anti-coagulate critically ill patients with new-onset fast AF,"I do not use stroke risk scores routinely in critically ill patients with new onset AF to assess the need for anticoagulation,Stroke risk scores inaccurately reflect the risk of embolic events in critically ill patients with new-onset atrial fibrillation due to prothrombotic changes associated with critical illness,Modified risk scores should be developed for critically ill patients with new-onset atrial fibrillation",I do not regularly anti-coagulate critically ill patients with new onset fast AF,I regularly perform or request transthoracic echocardiography,Yes,"Amiodarone,Other anti-arrhythmics (e. g. verapamil, sotalol): Please specify:",high dose magnesium,No
31/10/2016 16:52,31/10/2016 16:58,IP Address,81.103.228.154,100,329,TRUE,31/10/2016 16:58,R_25FoXbzcQ2HWoH2,,,,,50.69999695,-3.533294678,anonymous,Tertiary Referral Centre or University Hospital,I do not know,25,Mixed ICU,,Trainee,5-10 years,Anaesthesia,120-139/beats per min,Rate control,Amiodarone,,Supplement electrolytes to a high normal level and anti-arrhythmics,>4.5 mmol/l,1.0-1.2 mmol/l,Adverse effect profile,,I do not regularly anti-coagulate critically ill patients with new-onset fast AF,Stroke risk scores favour anti-coagulation despite a higher risk of bleeding in critical illness,"Subcutaneous Low Molecular Weight heparin in therapeutic dose,I do not regularly anti-coagulate critically ill patients with new onset fast AF",I regularly perform or request transthoracic echocardiography,Yes,"Amiodarone,ß-blocker",,Yes
31/10/2016 16:56,31/10/2016 16:59,IP Address,152.78.59.182,100,181,TRUE,31/10/2016 16:59,R_3F3EIjV8gF2lHd0,,,,,50.8999939,-1.399993896,anonymous,Tertiary Referral Centre or University Hospital,1000-2000,22,Mixed ICU,,Consultant,More than 10 years,Anaesthesia,100-119/beats per min,Rhythm control,Amiodarone,,Supplement electrolytes to a high normal level and anti-arrhythmics,>4.5 mmol/l,1.0-1.2 mmol/l,"Availability from hospital pharmacy,ICU drug policy,Pharmacodynamic properties",,I do not regularly anti-coagulate critically ill patients with new-onset fast AF,I do not use stroke risk scores routinely in critically ill patients with new onset AF to assess the need for anticoagulation,I do not regularly anti-coagulate critically ill patients with new onset fast AF,I do not routinely perform Echocardiography to guide treatment,Yes,Amiodarone,,No
31/10/2016 16:56,31/10/2016 17:00,IP Address,86.146.53.104,100,215,TRUE,31/10/2016 17:00,R_2AETeJBgw7jSG3o,,,,,51.75,-0.983306885,anonymous,Teaching Hospital,500-1000,9,Mixed ICU,,Consultant,5-10 years,Anaesthesia,120-139/beats per min,Rhythm control,Amiodarone,,Supplement electrolytes to a high normal level and anti-arrhythmics,>4 mmol/l,1.0-1.2 mmol/l,"Availability from hospital pharmacy,Pharmacokinetic advantages",,I do not regularly anti-coagulate critically ill patients with new-onset fast AF,Modified risk scores should be developed for critically ill patients with new-onset atrial fibrillation,I do not regularly anti-coagulate critically ill patients with new onset fast AF,I only regularly perform Echocardiography in patients with cardiac history,Yes,"Amiodarone,ß-blocker",,Yes
31/10/2016 16:53,31/10/2016 17:01,IP Address,86.161.54.26,100,432,TRUE,31/10/2016 17:01,R_3JypJkyDXGcExSa,,,,,51.02009583,0.258407593,anonymous,Tertiary Referral Centre or University Hospital,500-1000,8,Specialist ICU (please name specialty):,Cardiac surgery ,Consultant,More than 10 years,Anaesthesia,"Independent of their heart rate I treat all patients who have developed new onset fast AF, even if the blood pressure remains stable",Rhythm control,Amiodarone,,Supplement electrolytes to a high normal level and anti-arrhythmics,>4.5 mmol/l,I do not aim for a specific serum magnesium level,"ICU drug policy,Pharmacodynamic properties",,New onset AF within 72 hours,"I do not use stroke risk scores routinely in critically ill patients with new onset AF to assess the need for anticoagulation,Stroke risk scores inaccurately reflect the risk of embolic events in critically ill patients with new-onset atrial fibrillation due to prothrombotic changes associated with critical illness,Modified risk scores should be developed for critically ill patients with new-onset atrial fibrillation","Intravenous High Molecular Weight heparin in therapeutic dose,Subcutaneous Low Molecular Weight heparin in therapeutic dose",I do not routinely perform Echocardiography to guide treatment,No,Amiodarone,,No
31/10/2016 16:58,31/10/2016 17:02,IP Address,88.87.168.225,100,268,TRUE,31/10/2016 17:02,R_3lQAHxGbqeEOfVO,,,,,52.74139404,-8.774200439,anonymous,District General Hospital,500-1000,02-Jun,Mixed ICU,,Consultant,More than 10 years,Anaesthesia,"Independent of their heart rate I treat all patients who have developed new onset fast AF, even if the blood pressure remains stable",Rhythm control,Amiodarone,,DC cardioversion when anti-arrhythmics and electrolyte replacement fail to achieve rate and/or rhythm control,>4 mmol/l,1.0-1.2 mmol/l,"Pharmacokinetic advantages,Pharmacodynamic properties,Adverse effect profile",,I do not regularly anti-coagulate critically ill patients with new-onset fast AF,Modified risk scores should be developed for critically ill patients with new-onset atrial fibrillation,Subcutaneous Low Molecular Weight heparin in therapeutic dose,I regularly perform or request transoesophageal echocardiography,Yes,Amiodarone,,No
31/10/2016 16:45,31/10/2016 17:03,IP Address,217.158.121.130,100,1053,TRUE,31/10/2016 17:03,R_1lAG77t0LBi19jr,,,,,51.4927063,-0.257995605,anonymous,District General Hospital,>2000,26,Mixed ICU,,Trainee,3-5 years,Anaesthesia,100-119/beats per min,Rate control,Amiodarone,,Supplement electrolytes to a high normal level and anti-arrhythmics,>4.5 mmol/l,1.0-1.2 mmol/l,"Pharmacokinetic advantages,Pharmacodynamic properties",,I do not regularly anti-coagulate critically ill patients with new-onset fast AF,I do not use stroke risk scores routinely in critically ill patients with new onset AF to assess the need for anticoagulation,I do not regularly anti-coagulate critically ill patients with new onset fast AF,I do not routinely perform Echocardiography to guide treatment,Yes,"Amiodarone,ß-blocker,Digoxin",,No
31/10/2016 16:59,31/10/2016 17:03,IP Address,81.157.13.207,100,240,TRUE,31/10/2016 17:03,R_3rUH1MSAZaIN1pi,,,,,51.3881073,-0.507797241,anonymous,District General Hospital,1000-2000,12,Mixed ICU,,SAS,5-10 years,Anaesthesia,120-139/beats per min,Rate control,Amiodarone,,Supplement electrolytes to a high normal level and DC cardioversion,>4.5 mmol/l,1.0-1.2 mmol/l,ICU drug policy,,New onset AF within 48 hours,"I regularly calculate a risk score (e. g. CHAD2, CHA2DS2-VASc) to assess the need for anti-coagulation",Subcutaneous Low Molecular Weight heparin in therapeutic dose,I regularly perform or request transthoracic echocardiography,Yes,Amiodarone,,Yes
31/10/2016 16:58,31/10/2016 17:04,IP Address,128.40.68.216,100,334,TRUE,31/10/2016 17:04,R_3fw4ZupZ9lOncom,,,,,51.51420593,-0.093093872,anonymous,District General Hospital,500-1000,15,Mixed ICU,,Consultant,More than 10 years,Intensive Care Medicine only,140-159/beats per min,Rhythm control,Amiodarone,,Supplement electrolytes to a high normal level and anti-arrhythmics,>4.5 mmol/l,I do not aim for a specific serum magnesium level,"Pharmacokinetic advantages,Adverse effect profile",,I do not regularly anti-coagulate critically ill patients with new-onset fast AF,"I do not use stroke risk scores routinely in critically ill patients with new onset AF to assess the need for anticoagulation,Stroke risk scores favour anti-coagulation despite a higher risk of bleeding in critical illness","Intravenous High Molecular Weight heparin in therapeutic dose,Subcutaneous Low Molecular Weight heparin in therapeutic dose,I do not regularly anti-coagulate critically ill patients with new onset fast AF",I do not routinely perform Echocardiography to guide treatment,Yes,"ß-blocker,Other anti-arrhythmics (e. g. verapamil, sotalol): Please specify:",Sotolol (due to added class IV effects),Yes
31/10/2016 17:00,31/10/2016 17:05,IP Address,188.172.151.252,100,289,TRUE,31/10/2016 17:05,R_2Sv1o8fq0i1ZsAy,,,,,51.5,-0.050003052,anonymous,Teaching Hospital,>2000,50+,Mixed ICU,,Trainee,5-10 years,Acute medicine,"Independent of their heart rate I treat all patients who have developed new onset fast AF, even if the blood pressure remains stable",Rate control,ß-blocker,,Supplement electrolytes (magnesium and/or potassium) to a high normal level,>4 mmol/l,1.0-1.2 mmol/l,"Other, please specify:",It often treats the cause,I do not regularly anti-coagulate critically ill patients with new-onset fast AF,"I do not use stroke risk scores routinely in critically ill patients with new onset AF to assess the need for anticoagulation,Stroke risk scores favour anti-coagulation despite a higher risk of bleeding in critical illness,Modified risk scores should be developed for critically ill patients with new-onset atrial fibrillation","Intravenous High Molecular Weight heparin in therapeutic dose,Subcutaneous Low Molecular Weight heparin in therapeutic dose",I regularly perform or request transthoracic echocardiography,No,"Amiodarone,DC cardioversion,ß-blocker,Flecainide,Diltiazem,Digoxin",,No
31/10/2016 17:01,31/10/2016 17:07,IP Address,194.82.50.2,100,330,TRUE,31/10/2016 17:07,R_3gMmAT5NL7Zv9wD,,,,,51.51420593,-0.093093872,anonymous,Tertiary Referral Centre or University Hospital,1000-2000,21,Mixed ICU,,Consultant,More than 10 years,Anaesthesia,120-139/beats per min,Rhythm control,ß-blocker,,Supplement electrolytes to a high normal level and DC cardioversion,>4 mmol/l,1.0-1.2 mmol/l,"Pharmacokinetic advantages,Pharmacodynamic properties,Adverse effect profile",,I do not regularly anti-coagulate critically ill patients with new-onset fast AF,"I regularly calculate a risk score (e. g. CHAD2, CHA2DS2-VASc) to assess the need for anti-coagulation",Subcutaneous Low Molecular Weight heparin in therapeutic dose,I regularly perform or request transthoracic echocardiography,Yes,"DC cardioversion,ß-blocker",,No
31/10/2016 16:33,31/10/2016 17:07,IP Address,86.185.42.73,100,2044,TRUE,31/10/2016 17:07,R_2BsOQyavqE5uZrz,,,,,54.99139404,-1.559692383,anonymous,Tertiary Referral Centre or University Hospital,1000-2000,22,Mixed ICU,,Consultant,3-5 years,Anaesthesia,"Independent of their heart rate I treat all patients who have developed new onset fast AF, even if the blood pressure remains stable",Rate control,Amiodarone,,Supplement electrolytes to a high normal level and anti-arrhythmics,>4.5 mmol/l,1.0-1.2 mmol/l,"Other, please specify:","I try not to use amiodarone but frequently find trainees start it overnight. I tend to use electrolytes/BB, dig or diltiazem before resorting to amiodarone. But I may be old-fashioned.",I do not regularly anti-coagulate critically ill patients with new-onset fast AF,"I do not use stroke risk scores routinely in critically ill patients with new onset AF to assess the need for anticoagulation,Stroke risk scores favour anti-coagulation despite a higher risk of bleeding in critical illness,Modified risk scores should be developed for critically ill patients with new-onset atrial fibrillation","Subcutaneous Low Molecular Weight heparin in therapeutic dose,I do not regularly anti-coagulate critically ill patients with new onset fast AF",I regularly perform or request transthoracic echocardiography,Yes,Diltiazem,,Yes
31/10/2016 17:03,31/10/2016 17:09,IP Address,159.86.191.18,100,413,TRUE,31/10/2016 17:09,R_9v5JCt61ZCde8Bf,,,,,51.60139465,-3.344696045,anonymous,District General Hospital,500-1000,11,Mixed ICU,,Consultant,More than 10 years,Anaesthesia,"Independent of their heart rate I treat all patients who have developed new onset fast AF, even if the blood pressure remains stable",Rhythm control,Amiodarone,,Supplement electrolytes (magnesium and/or potassium) to a high normal level,>4.5 mmol/l,1.0-1.2 mmol/l,Pharmacodynamic properties,,I do not regularly anti-coagulate critically ill patients with new-onset fast AF,"I do not use stroke risk scores routinely in critically ill patients with new onset AF to assess the need for anticoagulation,Modified risk scores should be developed for critically ill patients with new-onset atrial fibrillation","Subcutaneous Low Molecular Weight heparin in therapeutic dose,I do not regularly anti-coagulate critically ill patients with new onset fast AF",I do not routinely perform Echocardiography to guide treatment,Yes,Amiodarone,,No
31/10/2016 17:04,31/10/2016 17:09,IP Address,159.92.238.53,100,305,TRUE,31/10/2016 17:09,R_esufKCHxmSogsUh,,,,,51.49789429,-0.066101074,anonymous,Tertiary Referral Centre or University Hospital,>2000,65,Mixed ICU,,Trainee,3-5 years,Anaesthesia,120-139/beats per min,Rate control,Amiodarone,,DC cardioversion when anti-arrhythmics and electrolyte replacement fail to achieve rate and/or rhythm control,>4.5 mmol/l,>1.2 mmol/l,"Availability from hospital pharmacy,ICU drug policy",,New onset AF within 48 hours,Stroke risk scores inaccurately reflect the risk of embolic events in critically ill patients with new-onset atrial fibrillation due to prothrombotic changes associated with critical illness,"Intravenous High Molecular Weight heparin in therapeutic dose,Subcutaneous Low Molecular Weight heparin in therapeutic dose",I do not routinely perform Echocardiography to guide treatment,Yes,"Amiodarone,DC cardioversion,ß-blocker",,Yes
31/10/2016 17:07,31/10/2016 17:10,IP Address,165.225.80.136,100,190,TRUE,31/10/2016 17:10,R_51m6SAahp42Foxf,,,,,51.51420593,-0.093093872,anonymous,District General Hospital,1000-2000,25,Mixed ICU,,Consultant,More than 10 years,Anaesthesia,"Independent of their heart rate I treat all patients who have developed new onset fast AF, even if the blood pressure remains stable",Rate control,Amiodarone,,DC cardioversion when anti-arrhythmics and electrolyte replacement fail to achieve rate and/or rhythm control,>4.5 mmol/l,>1.2 mmol/l,"Other, please specify:",personal preference,New onset AF within 24 hours,I do not use stroke risk scores routinely in critically ill patients with new onset AF to assess the need for anticoagulation,Subcutaneous Low Molecular Weight heparin in therapeutic dose,I regularly perform or request transthoracic echocardiography,Yes,"Amiodarone,DC cardioversion,ß-blocker,Digoxin",,No
31/10/2016 17:07,31/10/2016 17:12,IP Address,194.176.105.146,100,255,TRUE,31/10/2016 17:12,R_cGDSBdOrNOYMXf3,,,,,51.51420593,-0.093093872,anonymous,Teaching Hospital,1000-2000,32,Mixed ICU,,Consultant,More than 10 years,Anaesthesia,"Independent of their heart rate I treat all patients who have developed new onset fast AF, even if the blood pressure remains stable",Rhythm control,Amiodarone,,Supplement electrolytes to a high normal level and anti-arrhythmics,>4.5 mmol/l,I do not aim for a specific serum magnesium level,Pharmacodynamic properties,,I do not regularly anti-coagulate critically ill patients with new-onset fast AF,I do not use stroke risk scores routinely in critically ill patients with new onset AF to assess the need for anticoagulation,I do not regularly anti-coagulate critically ill patients with new onset fast AF,I do not routinely perform Echocardiography to guide treatment,Yes,"Amiodarone,ß-blocker",,No
31/10/2016 17:08,31/10/2016 17:14,IP Address,92.237.47.55,100,332,TRUE,31/10/2016 17:14,R_1pnkqYwejE3hoKK,,,,,51.72120667,0.486495972,anonymous,Tertiary Referral Centre or University Hospital,500-1000,25,Specialist ICU (please name specialty):,Haemato-oncology,SAS,More than 10 years,Anaesthesia,"Independent of their heart rate I treat all patients who have developed new onset fast AF, even if the blood pressure remains stable",Rhythm control,Amiodarone,,DC cardioversion when anti-arrhythmics and electrolyte replacement fail to achieve rate and/or rhythm control,>4.5 mmol/l,1.0-1.2 mmol/l,Pharmacokinetic advantages,,I do not regularly anti-coagulate critically ill patients with new-onset fast AF,"I do not use stroke risk scores routinely in critically ill patients with new onset AF to assess the need for anticoagulation,Stroke risk scores inaccurately reflect the risk of embolic events in critically ill patients with new-onset atrial fibrillation due to prothrombotic changes associated with critical illness,Modified risk scores should be developed for critically ill patients with new-onset atrial fibrillation",I do not regularly anti-coagulate critically ill patients with new onset fast AF,I do not routinely perform Echocardiography to guide treatment,Yes,Amiodarone,,No
31/10/2016 17:00,31/10/2016 17:15,IP Address,5.70.236.231,100,927,TRUE,31/10/2016 17:15,R_2wglDRm6hOxkZOC,,,,,53.36669922,-1.5,anonymous,Teaching Hospital,1000-2000,30,Mixed ICU,,Trainee,3-5 years,Anaesthesia,120-139/beats per min,Rate control,Digoxin,,Supplement electrolytes to a high normal level and anti-arrhythmics,>4.5 mmol/l,I do not aim for a specific serum magnesium level,"ICU drug policy,Pharmacodynamic properties",,I do not regularly anti-coagulate critically ill patients with new-onset fast AF,"Stroke risk scores inaccurately reflect the risk of embolic events in critically ill patients with new-onset atrial fibrillation due to prothrombotic changes associated with critical illness,Modified risk scores should be developed for critically ill patients with new-onset atrial fibrillation",I do not regularly anti-coagulate critically ill patients with new onset fast AF,I only regularly perform Echocardiography in patients with cardiac history,Yes,Amiodarone,,No
31/10/2016 17:12,31/10/2016 17:16,IP Address,86.25.129.69,100,276,TRUE,31/10/2016 17:16,R_x4nNtOWmIt8naJr,,,,,51.43330383,-0.216705322,anonymous,Tertiary Referral Centre or University Hospital,1000-2000,18,Mixed ICU,,Consultant,More than 10 years,Anaesthesia,"Independent of their heart rate I treat all patients who have developed new onset fast AF, even if the blood pressure remains stable",Rhythm control,Amiodarone,,DC cardioversion when anti-arrhythmics and electrolyte replacement fail to achieve rate and/or rhythm control,>4 mmol/l,1.0-1.2 mmol/l,ICU drug policy,,Before DC cardioversion,I do not use stroke risk scores routinely in critically ill patients with new onset AF to assess the need for anticoagulation,"Subcutaneous Low Molecular Weight heparin in therapeutic dose,I do not regularly anti-coagulate critically ill patients with new onset fast AF",I do not routinely perform Echocardiography to guide treatment,No,DC cardioversion,,No
31/10/2016 17:09,31/10/2016 17:17,IP Address,159.92.238.53,100,460,TRUE,31/10/2016 17:17,R_pKK7c9cLnwxZHtT,,,,,51.49789429,-0.066101074,anonymous,Teaching Hospital,>2000,81,Specialist ICU (please name specialty):,5 CCUs- all of above,Consultant,More than 10 years,Anaesthesia,100-119/beats per min,Rhythm control,Amiodarone,,Supplement electrolytes to a high normal level and anti-arrhythmics,>4.5 mmol/l,>1.2 mmol/l,"Other, please specify:",Experience and protocol,I do not regularly anti-coagulate critically ill patients with new-onset fast AF,I do not use stroke risk scores routinely in critically ill patients with new onset AF to assess the need for anticoagulation,I do not regularly anti-coagulate critically ill patients with new onset fast AF,I do not routinely perform Echocardiography to guide treatment,Yes,"Amiodarone,ß-blocker,Digoxin",,No
31/10/2016 17:16,31/10/2016 17:21,IP Address,159.86.186.99,100,317,TRUE,31/10/2016 17:21,R_2V2OtOoiTpv51Yd,,,,,53.22650146,-4.134597778,anonymous,District General Hospital,500-1000,13,Mixed ICU,,Trainee,1-3 years,Acute medicine,"Independent of their heart rate I treat all patients who have developed new onset fast AF, even if the blood pressure remains stable",Rhythm control,Amiodarone,,Supplement electrolytes to a high normal level and anti-arrhythmics,>4 mmol/l,I do not aim for a specific serum magnesium level,"Availability from hospital pharmacy,Pharmacokinetic advantages",,I do not regularly anti-coagulate critically ill patients with new-onset fast AF,"Stroke risk scores inaccurately reflect the risk of embolic events in critically ill patients with new-onset atrial fibrillation due to prothrombotic changes associated with critical illness,Stroke risk scores favour anti-coagulation despite a higher risk of bleeding in critical illness,Modified risk scores should be developed for critically ill patients with new-onset atrial fibrillation",Subcutaneous Low Molecular Weight heparin in therapeutic dose,I regularly perform or request transthoracic echocardiography,Yes,"Amiodarone,DC cardioversion,Flecainide,Diltiazem",,Yes
31/10/2016 17:14,31/10/2016 17:22,IP Address,194.176.105.138,100,516,TRUE,31/10/2016 17:22,R_DCXYmgLKzyQ5RVn,,,,,51.51420593,-0.093093872,anonymous,District General Hospital,500-1000,8,Mixed ICU,,Consultant,More than 10 years,Anaesthesia,120-139/beats per min,Rate control,Amiodarone,,Supplement electrolytes to a high normal level and anti-arrhythmics,>4.5 mmol/l,1.0-1.2 mmol/l,Pharmacodynamic properties,,I do not regularly anti-coagulate critically ill patients with new-onset fast AF,"I do not use stroke risk scores routinely in critically ill patients with new onset AF to assess the need for anticoagulation,Modified risk scores should be developed for critically ill patients with new-onset atrial fibrillation",I do not regularly anti-coagulate critically ill patients with new onset fast AF,I only regularly perform Echocardiography in patients with cardiac history,Yes,Amiodarone,,No
31/10/2016 17:17,31/10/2016 17:24,IP Address,92.40.2.186,100,421,TRUE,31/10/2016 17:24,R_3JDT0pETUKC9S2f,,,,,51.49639893,-0.122406006,anonymous,District General Hospital,500-1000,22,Mixed ICU,,Trainee,3-5 years,Anaesthesia,"Independent of their heart rate I treat all patients who have developed new onset fast AF, even if the blood pressure remains stable",Rate control,Amiodarone,,Supplement electrolytes to a high normal level and anti-arrhythmics,>4 mmol/l,1.0-1.2 mmol/l,"ICU drug policy,Pharmacokinetic advantages,Pharmacodynamic properties",,I do not regularly anti-coagulate critically ill patients with new-onset fast AF,I do not use stroke risk scores routinely in critically ill patients with new onset AF to assess the need for anticoagulation,I do not regularly anti-coagulate critically ill patients with new onset fast AF,I only regularly perform Echocardiography in patients with cardiac history,Yes,ß-blocker,,No
31/10/2016 17:18,31/10/2016 17:25,IP Address,188.29.165.176,100,397,TRUE,31/10/2016 17:25,R_2338S5bGoK0zVFn,,,,,51.51420593,-0.093093872,anonymous,Teaching Hospital,I do not know,Level 2 = 4 / level 3 = 7,Mixed ICU,,Trainee,1-3 years,Anaesthesia,120-139/beats per min,Rate control,Amiodarone,,Supplement electrolytes (magnesium and/or potassium) to a high normal level,>4.5 mmol/l,1.0-1.2 mmol/l,Pharmacodynamic properties,,New onset AF within 48 hours,I do not use stroke risk scores routinely in critically ill patients with new onset AF to assess the need for anticoagulation,"Intravenous High Molecular Weight heparin in therapeutic dose,Subcutaneous Low Molecular Weight heparin in therapeutic dose",I regularly perform or request transthoracic echocardiography,No,Amiodarone,,Yes
31/10/2016 17:15,31/10/2016 17:26,IP Address,94.197.120.173,100,656,TRUE,31/10/2016 17:26,R_1IAg2wNwJOmEtoW,,,,,52.53329468,-1.816696167,anonymous,District General Hospital,1000-2000,15,Predominantly medical,,Consultant,More than 10 years,Anaesthesia,100-119/beats per min,Rhythm control,Amiodarone,,Supplement electrolytes to a high normal level and anti-arrhythmics,>4 mmol/l,0.75-1 mmol/l,"Other, please specify:",Experience of practice working,New onset AF within 72 hours,"Stroke risk scores inaccurately reflect the risk of embolic events in critically ill patients with new-onset atrial fibrillation due to prothrombotic changes associated with critical illness,Stroke risk scores favour anti-coagulation despite a higher risk of bleeding in critical illness",Intravenous High Molecular Weight heparin in therapeutic dose,I regularly perform or request transthoracic echocardiography,Yes,"Amiodarone,DC cardioversion,ß-blocker",,No
31/10/2016 17:17,31/10/2016 17:27,IP Address,213.205.198.16,100,589,TRUE,31/10/2016 17:27,R_2ARJeRQ5M0rEhmu,,,,,51.57650757,-0.397399902,anonymous,District General Hospital,1000-2000,12,Mixed ICU,,Trainee,1-3 years,Anaesthesia,120-139/beats per min,Rate control,Digoxin,,Supplement electrolytes to a high normal level and anti-arrhythmics,>4 mmol/l,1.0-1.2 mmol/l,"Pharmacokinetic advantages,Pharmacodynamic properties,Adverse effect profile",,New onset AF within 48 hours,"I regularly calculate a risk score (e. g. CHAD2, CHA2DS2-VASc) to assess the need for anti-coagulation,Stroke risk scores inaccurately reflect the risk of embolic events in critically ill patients with new-onset atrial fibrillation due to prothrombotic changes associated with critical illness",Subcutaneous Low Molecular Weight heparin in therapeutic dose,I regularly perform or request transthoracic echocardiography,Yes,"Amiodarone,DC cardioversion,ß-blocker,Flecainide,Digoxin",,No
31/10/2016 17:24,31/10/2016 17:28,IP Address,62.255.13.162,100,210,TRUE,31/10/2016 17:28,R_2Uiws3u9rfsHaBz,,,,,51.44999695,-2.583297729,anonymous,Tertiary Referral Centre or University Hospital,1000-2000,42,Mixed ICU,,Trainee,1-3 years,Intensive Care Medicine only,120-139/beats per min,Rate control,Amiodarone,,Supplement electrolytes (magnesium and/or potassium) to a high normal level,>4.5 mmol/l,1.0-1.2 mmol/l,"Pharmacodynamic properties,Adverse effect profile",,I do not regularly anti-coagulate critically ill patients with new-onset fast AF,"I do not use stroke risk scores routinely in critically ill patients with new onset AF to assess the need for anticoagulation,Modified risk scores should be developed for critically ill patients with new-onset atrial fibrillation",I do not regularly anti-coagulate critically ill patients with new onset fast AF,I regularly perform or request transthoracic echocardiography,Yes,"Amiodarone,DC cardioversion,ß-blocker",,No
31/10/2016 17:23,31/10/2016 17:28,IP Address,84.92.59.232,100,313,TRUE,31/10/2016 17:28,R_4NQsbJN3MElRYhr,,,,,51.49639893,-0.122406006,anonymous,Tertiary Referral Centre or University Hospital,>2000,60,Mixed ICU,,Consultant,More than 10 years,Anaesthesia,120-139/beats per min,Rhythm control,Amiodarone,,Supplement electrolytes (magnesium and/or potassium) to a high normal level,>4.5 mmol/l,1.0-1.2 mmol/l,Pharmacokinetic advantages,,I do not regularly anti-coagulate critically ill patients with new-onset fast AF,I do not use stroke risk scores routinely in critically ill patients with new onset AF to assess the need for anticoagulation,"Intravenous High Molecular Weight heparin in therapeutic dose,Subcutaneous Low Molecular Weight heparin in therapeutic dose,I do not regularly anti-coagulate critically ill patients with new onset fast AF",I do not routinely perform Echocardiography to guide treatment,Yes,ß-blocker,,Yes
31/10/2016 17:27,31/10/2016 17:36,IP Address,49.183.83.33,100,546,TRUE,31/10/2016 17:36,R_22mhZ9cnLngyr8r,,,,,-37.78329468,144.916687,anonymous,Tertiary Referral Centre or University Hospital,>2000,36,Mixed ICU,,Trainee,3-5 years,Anaesthesia,"Independent of their heart rate I treat all patients who have developed new onset fast AF, even if the blood pressure remains stable",Rhythm control,Amiodarone,,Supplement electrolytes to a high normal level and anti-arrhythmics,>4 mmol/l,1.0-1.2 mmol/l,"Other, please specify:",Patient selection,New onset AF within 48 hours,"I regularly calculate a risk score (e. g. CHAD2, CHA2DS2-VASc) to assess the need for anti-coagulation,Stroke risk scores favour anti-coagulation despite a higher risk of bleeding in critical illness,Modified risk scores should be developed for critically ill patients with new-onset atrial fibrillation","Intravenous High Molecular Weight heparin in therapeutic dose,Use of warfarin","I do not routinely perform Echocardiography to guide treatment,I only regularly perform Echocardiography in patients with cardiac history",Yes,"Amiodarone,ß-blocker,Digoxin",,No
31/10/2016 17:32,31/10/2016 17:37,IP Address,82.132.247.234,100,289,TRUE,31/10/2016 17:37,R_2Sjd4V0XlBSXhkZ,,,,,51.49639893,-0.122406006,anonymous,Tertiary Referral Centre or University Hospital,>2000,26,Specialist ICU (please name specialty):,Cardiothoracic,Consultant,More than 10 years,Anaesthesia,"Independent of their heart rate I treat all patients who have developed new onset fast AF, even if the blood pressure remains stable",Rhythm control,ß-blocker,,DC cardioversion when anti-arrhythmics and electrolyte replacement fail to achieve rate and/or rhythm control,>4.5 mmol/l,1.0-1.2 mmol/l,"Pharmacokinetic advantages,Pharmacodynamic properties,Adverse effect profile",,New onset AF within 48 hours,"I regularly calculate a risk score (e. g. CHAD2, CHA2DS2-VASc) to assess the need for anti-coagulation,Stroke risk scores inaccurately reflect the risk of embolic events in critically ill patients with new-onset atrial fibrillation due to prothrombotic changes associated with critical illness,Stroke risk scores favour anti-coagulation despite a higher risk of bleeding in critical illness,Modified risk scores should be developed for critically ill patients with new-onset atrial fibrillation","Intravenous High Molecular Weight heparin in therapeutic dose,Subcutaneous Low Molecular Weight heparin in therapeutic dose",I regularly perform or request transoesophageal echocardiography,No,"Amiodarone,DC cardioversion,ß-blocker",,No
31/10/2016 17:35,31/10/2016 17:38,IP Address,62.25.77.200,100,227,TRUE,31/10/2016 17:38,R_3neMK5h7LRE1IJ0,,,,,51.6000061,-0.216705322,anonymous,Tertiary Referral Centre or University Hospital,1000-2000,4,Mixed ICU,,Trainee,5-10 years,Anaesthesia,"Independent of their heart rate I treat all patients who have developed new onset fast AF, even if the blood pressure remains stable",I have no primary treatment goal in these patients,Amiodarone,,DC cardioversion when anti-arrhythmics and electrolyte replacement fail to achieve rate and/or rhythm control,>5 mmol/l,>1.2 mmol/l,ICU drug policy,,I do not regularly anti-coagulate critically ill patients with new-onset fast AF,"I regularly calculate a risk score (e. g. CHAD2, CHA2DS2-VASc) to assess the need for anti-coagulation",Use of warfarin,I regularly perform or request transoesophageal echocardiography,No,Flecainide,,No
31/10/2016 17:32,31/10/2016 17:39,IP Address,109.149.143.4,100,464,TRUE,31/10/2016 17:39,R_3lYoc5SHyvT2BZv,,,,,50.8500061,-1.783294678,anonymous,District General Hospital,500-1000,12,Mixed ICU,,Consultant,More than 10 years,Anaesthesia,100-119/beats per min,Rate control,Amiodarone,,DC cardioversion when anti-arrhythmics and electrolyte replacement fail to achieve rate and/or rhythm control,>3.5mmol/l,1.0-1.2 mmol/l,Pharmacodynamic properties,,New onset AF within 48 hours,Modified risk scores should be developed for critically ill patients with new-onset atrial fibrillation,Subcutaneous Low Molecular Weight heparin in therapeutic dose,I regularly perform or request transthoracic echocardiography,Yes,"Amiodarone,ß-blocker,Flecainide,Digoxin",,No
31/10/2016 17:33,31/10/2016 17:40,IP Address,80.193.75.126,100,420,TRUE,31/10/2016 17:40,R_etCylzdmirGEwHr,,,,,53.43330383,-1.350006104,anonymous,District General Hospital,500-1000,13,Mixed ICU,,Consultant,More than 10 years,Anaesthesia,120-139/beats per min,Rhythm control,Amiodarone,,DC cardioversion when anti-arrhythmics and electrolyte replacement fail to achieve rate and/or rhythm control,>4.5 mmol/l,1.0-1.2 mmol/l,"Availability from hospital pharmacy,Pharmacodynamic properties,Adverse effect profile",,New onset AF within 72 hours,I do not use stroke risk scores routinely in critically ill patients with new onset AF to assess the need for anticoagulation,"Intravenous High Molecular Weight heparin in therapeutic dose,I do not regularly anti-coagulate critically ill patients with new onset fast AF",I only regularly perform Echocardiography in patients with cardiac history,Yes,"Amiodarone,ß-blocker",,No
31/10/2016 17:00,31/10/2016 17:41,IP Address,194.176.105.152,100,2411,TRUE,31/10/2016 17:41,R_7OHXpJhkpW2zOId,,,,,51.51420593,-0.093093872,anonymous,District General Hospital,500-1000,31,Mixed ICU,,Consultant,More than 10 years,Anaesthesia,120-139/beats per min,Rhythm control,Amiodarone,,Supplement electrolytes to a high normal level and anti-arrhythmics,>4.5 mmol/l,1.0-1.2 mmol/l,"Pharmacokinetic advantages,Pharmacodynamic properties",,I do not regularly anti-coagulate critically ill patients with new-onset fast AF,"I do not use stroke risk scores routinely in critically ill patients with new onset AF to assess the need for anticoagulation,Stroke risk scores inaccurately reflect the risk of embolic events in critically ill patients with new-onset atrial fibrillation due to prothrombotic changes associated with critical illness","Subcutaneous Low Molecular Weight heparin in therapeutic dose,I do not regularly anti-coagulate critically ill patients with new onset fast AF",I only regularly perform Echocardiography in patients with cardiac history,Yes,"Amiodarone,DC cardioversion,ß-blocker,Digoxin",,No
31/10/2016 17:33,31/10/2016 17:41,IP Address,188.222.71.253,100,480,TRUE,31/10/2016 17:41,R_1Ngj1DK5m3YWnwj,,,,,50.44999695,-3.5,anonymous,District General Hospital,500-1000,9,Mixed ICU,,SAS,More than 10 years,Anaesthesia,"Independent of their heart rate I treat all patients who have developed new onset fast AF, even if the blood pressure remains stable",Rate control,Amiodarone,,Supplement electrolytes to a high normal level and anti-arrhythmics,>4.5 mmol/l,0.75-1 mmol/l,ICU drug policy,,I do not regularly anti-coagulate critically ill patients with new-onset fast AF,Modified risk scores should be developed for critically ill patients with new-onset atrial fibrillation,I do not regularly anti-coagulate critically ill patients with new onset fast AF,I regularly perform or request transthoracic echocardiography,Yes,Amiodarone,,Yes
31/10/2016 17:40,31/10/2016 17:45,IP Address,64.134.176.178,100,331,TRUE,31/10/2016 17:45,R_Rem4pD62JgNAvQd,,,,,37.75100708,-97.8219986,anonymous,Tertiary Referral Centre or University Hospital,1000-2000,53,Predominantly surgical,,Consultant,More than 10 years,Anaesthesia,120-139/beats per min,Rhythm control,Amiodarone,,Supplement electrolytes (magnesium and/or potassium) to a high normal level,>4.5 mmol/l,I do not aim for a specific serum magnesium level,Adverse effect profile,,I do not regularly anti-coagulate critically ill patients with new-onset fast AF,Stroke risk scores inaccurately reflect the risk of embolic events in critically ill patients with new-onset atrial fibrillation due to prothrombotic changes associated with critical illness,I do not regularly anti-coagulate critically ill patients with new onset fast AF,I do not routinely perform Echocardiography to guide treatment,Yes,ß-blocker,,Yes
31/10/2016 17:39,31/10/2016 17:45,IP Address,194.176.105.142,100,341,TRUE,31/10/2016 17:45,R_2c1xmDd0vO5cTw5,,,,,51.51420593,-0.093093872,anonymous,District General Hospital,500-1000,13,Mixed ICU,,Consultant,More than 10 years,Anaesthesia,100-119/beats per min,Rate control,Amiodarone,,Supplement electrolytes (magnesium and/or potassium) to a high normal level,>4.5 mmol/l,1.0-1.2 mmol/l,Adverse effect profile,,I do not regularly anti-coagulate critically ill patients with new-onset fast AF,I do not use stroke risk scores routinely in critically ill patients with new onset AF to assess the need for anticoagulation,I do not regularly anti-coagulate critically ill patients with new onset fast AF,I do not routinely perform Echocardiography to guide treatment,Yes,"Amiodarone,DC cardioversion,ß-blocker,Digoxin",,No
31/10/2016 17:39,31/10/2016 17:47,IP Address,94.0.231.227,100,523,TRUE,31/10/2016 17:47,R_2UYMDA511g3Ws5y,,,,,55.94999695,-3.199996948,anonymous,Tertiary Referral Centre or University Hospital,>2000,28,Mixed ICU,,Trainee,1-3 years,Anaesthesia,140-159/beats per min,Rate control,ß-blocker,,Supplement electrolytes (magnesium and/or potassium) to a high normal level,>4.5 mmol/l,>1.2 mmol/l,Pharmacokinetic advantages,,I do not regularly anti-coagulate critically ill patients with new-onset fast AF,Modified risk scores should be developed for critically ill patients with new-onset atrial fibrillation,Subcutaneous Low Molecular Weight heparin in therapeutic dose,I do not routinely perform Echocardiography to guide treatment,Yes,ß-blocker,,Yes
31/10/2016 17:45,31/10/2016 17:50,IP Address,81.149.106.97,100,281,TRUE,31/10/2016 17:50,R_21bHSfdiRgxD3wt,,,,,53.35040283,-2.544906616,anonymous,District General Hospital,<500,16,Predominantly medical,,Consultant,More than 10 years,Anaesthesia,"Independent of their heart rate I treat all patients who have developed new onset fast AF, even if the blood pressure remains stable",Rhythm control,ß-blocker,,Supplement electrolytes (magnesium and/or potassium) to a high normal level,>4.5 mmol/l,I do not aim for a specific serum magnesium level,"Pharmacokinetic advantages,Pharmacodynamic properties,Adverse effect profile",,After starting anti-arrhythmic medication,I do not use stroke risk scores routinely in critically ill patients with new onset AF to assess the need for anticoagulation,Subcutaneous Low Molecular Weight heparin in therapeutic dose,I regularly perform or request transthoracic echocardiography,Yes,Amiodarone,,No
31/10/2016 17:52,31/10/2016 17:57,IP Address,85.255.232.205,100,283,TRUE,31/10/2016 17:57,R_UzjUKb16G38IvU5,,,,,51.49639893,-0.122406006,anonymous,District General Hospital,I do not know,10,Mixed ICU,,Trainee,5-10 years,Intensive Care Medicine only,"Independent of their heart rate I treat all patients who have developed new onset fast AF, even if the blood pressure remains stable",Rhythm control,Amiodarone,,DC cardioversion when anti-arrhythmics and electrolyte replacement fail to achieve rate and/or rhythm control,>4.5 mmol/l,>1.2 mmol/l,ICU drug policy,,I do not regularly anti-coagulate critically ill patients with new-onset fast AF,"I do not use stroke risk scores routinely in critically ill patients with new onset AF to assess the need for anticoagulation,Stroke risk scores favour anti-coagulation despite a higher risk of bleeding in critical illness,Modified risk scores should be developed for critically ill patients with new-onset atrial fibrillation",I do not regularly anti-coagulate critically ill patients with new onset fast AF,I do not routinely perform Echocardiography to guide treatment,Yes,"Amiodarone,DC cardioversion,ß-blocker,Digoxin",,Yes
31/10/2016 17:46,31/10/2016 17:59,IP Address,81.129.208.24,100,731,TRUE,31/10/2016 17:59,R_3lAMh1uK5pya17p,,,,,56.5,-2.966705322,anonymous,District General Hospital,I do not know,Don't know,Mixed ICU,,Consultant,5-10 years,Emergency Medicine,"Independent of their heart rate I treat all patients who have developed new onset fast AF, even if the blood pressure remains stable",I have no primary treatment goal in these patients,"Other anti-arrhythmics (e. g. Verapamil, sotalol): please specify:",Unknown,I only intervene if blood pressure drops or inotrope requirements increase,>4 mmol/l,I do not aim for a specific serum magnesium level,"Other, please specify:","The first rule is to find and then treat the cause. If septic, slowing the rate without return to sinus rhythm may cause or worsen heart failure. I say this as I do no Critical Care session and work only in EM now, but this is a common resus senario.",New onset AF within 72 hours,I do not use stroke risk scores routinely in critically ill patients with new onset AF to assess the need for anticoagulation,Subcutaneous Low Molecular Weight heparin in therapeutic dose,I only regularly perform Echocardiography in patients with cardiac history,Yes,"Amiodarone,DC cardioversion,Other anti-arrhythmics (e. g. verapamil, sotalol): Please specify:","Verapamil, sotalol",Yes
31/10/2016 17:57,31/10/2016 18:00,IP Address,109.148.207.35,100,186,TRUE,31/10/2016 18:00,R_3LjLuQN2XeQkIyq,,,,,52.92849731,-1.104293823,anonymous,District General Hospital,500-1000,12,Mixed ICU,,Trainee,1-3 years,Anaesthesia,120-139/beats per min,Rate control,Amiodarone,,Supplement electrolytes to a high normal level and anti-arrhythmics,>4.5 mmol/l,1.0-1.2 mmol/l,"Availability from hospital pharmacy,ICU drug policy",,I do not regularly anti-coagulate critically ill patients with new-onset fast AF,"I do not use stroke risk scores routinely in critically ill patients with new onset AF to assess the need for anticoagulation,Modified risk scores should be developed for critically ill patients with new-onset atrial fibrillation","Subcutaneous Low Molecular Weight heparin in therapeutic dose,I do not regularly anti-coagulate critically ill patients with new onset fast AF",I only regularly perform Echocardiography in patients with cardiac history,Yes,"Amiodarone,DC cardioversion,ß-blocker",,Yes
31/10/2016 17:49,31/10/2016 18:01,IP Address,62.25.77.200,100,689,TRUE,31/10/2016 18:01,R_Wetoj3wKpar7MS5,,,,,51.6000061,-0.216705322,anonymous,District General Hospital,500-1000,12,Mixed ICU,,Consultant,More than 10 years,Anaesthesia,"Independent of their heart rate I treat all patients who have developed new onset fast AF, even if the blood pressure remains stable",Rate control,Amiodarone,,Supplement electrolytes (magnesium and/or potassium) to a high normal level,>4.5 mmol/l,0.75-1 mmol/l,"Other, please specify:",habit,I do not regularly anti-coagulate critically ill patients with new-onset fast AF,"I do not use stroke risk scores routinely in critically ill patients with new onset AF to assess the need for anticoagulation,Modified risk scores should be developed for critically ill patients with new-onset atrial fibrillation","Intravenous High Molecular Weight heparin in therapeutic dose,Subcutaneous Low Molecular Weight heparin in therapeutic dose,I do not regularly anti-coagulate critically ill patients with new onset fast AF",I regularly perform or request transthoracic echocardiography,Yes,"Amiodarone,DC cardioversion,ß-blocker",,Yes
31/10/2016 17:58,31/10/2016 18:04,IP Address,109.152.18.239,100,335,TRUE,31/10/2016 18:04,R_1mOFROxBYmVbk2Z,,,,,51.78329468,0.633300781,anonymous,District General Hospital,500-1000,18,Mixed ICU,,Consultant,More than 10 years,Anaesthesia,"Independent of their heart rate I treat all patients who have developed new onset fast AF, even if the blood pressure remains stable",Rate control,Amiodarone,,Supplement electrolytes to a high normal level and anti-arrhythmics,>4.5 mmol/l,I do not aim for a specific serum magnesium level,Pharmacodynamic properties,,I do not regularly anti-coagulate critically ill patients with new-onset fast AF,"I do not use stroke risk scores routinely in critically ill patients with new onset AF to assess the need for anticoagulation,Stroke risk scores inaccurately reflect the risk of embolic events in critically ill patients with new-onset atrial fibrillation due to prothrombotic changes associated with critical illness,Stroke risk scores favour anti-coagulation despite a higher risk of bleeding in critical illness",I do not regularly anti-coagulate critically ill patients with new onset fast AF,I regularly perform or request transthoracic echocardiography,Yes,"Amiodarone,ß-blocker,Flecainide,Digoxin",,No
31/10/2016 18:02,31/10/2016 18:05,IP Address,86.187.237.121,100,210,TRUE,31/10/2016 18:05,R_0GuJ6HI9fFkiEW9,,,,,51.49639893,-0.122406006,anonymous,Tertiary Referral Centre or University Hospital,500-1000,9,Mixed ICU,,Consultant,More than 10 years,Anaesthesia,"Independent of their heart rate I treat all patients who have developed new onset fast AF, even if the blood pressure remains stable",Rhythm control,Amiodarone,,DC cardioversion when anti-arrhythmics and electrolyte replacement fail to achieve rate and/or rhythm control,>4 mmol/l,1.0-1.2 mmol/l,Adverse effect profile,,New onset AF within 48 hours,I do not use stroke risk scores routinely in critically ill patients with new onset AF to assess the need for anticoagulation,Subcutaneous Low Molecular Weight heparin in therapeutic dose,I do not routinely perform Echocardiography to guide treatment,Yes,"DC cardioversion,Flecainide,Other anti-arrhythmics (e. g. verapamil, sotalol): Please specify:",Ibutilide,No
31/10/2016 18:04,31/10/2016 18:11,IP Address,2.31.234.227,100,381,TRUE,31/10/2016 18:11,R_2EHq0wo22Ms4nwE,,,,,51.45210266,-0.06149292,anonymous,Tertiary Referral Centre or University Hospital,>2000,21,Mixed ICU,,Consultant,More than 10 years,Intensive Care Medicine only,100-119/beats per min,Rate control,Digoxin,,Supplement electrolytes to a high normal level and anti-arrhythmics,>4.5 mmol/l,1.0-1.2 mmol/l,"Availability from hospital pharmacy,Pharmacokinetic advantages,Adverse effect profile",,New onset AF within 72 hours,I do not use stroke risk scores routinely in critically ill patients with new onset AF to assess the need for anticoagulation,"Intravenous High Molecular Weight heparin in therapeutic dose,Subcutaneous Low Molecular Weight heparin in therapeutic dose",I regularly perform or request transthoracic echocardiography,Yes,"Amiodarone,DC cardioversion,ß-blocker,Digoxin",,Yes
31/10/2016 18:06,31/10/2016 18:12,IP Address,77.100.92.38,100,401,TRUE,31/10/2016 18:12,R_1jdkUrsgrF8Eem8,,,,,51.44540405,-0.329696655,anonymous,Tertiary Referral Centre or University Hospital,500-1000,16,Mixed ICU,,Consultant,More than 10 years,Intensive Care Medicine only,"Independent of their heart rate I treat all patients who have developed new onset fast AF, even if the blood pressure remains stable",Rate control,Amiodarone,,Supplement electrolytes (magnesium and/or potassium) to a high normal level,>4.5 mmol/l,1.0-1.2 mmol/l,Pharmacokinetic advantages,,New onset AF within 48 hours,I do not use stroke risk scores routinely in critically ill patients with new onset AF to assess the need for anticoagulation,"Intravenous High Molecular Weight heparin in therapeutic dose,Subcutaneous Low Molecular Weight heparin in therapeutic dose,Use of novel oral anti-coagulants (NOACs)",I do not routinely perform Echocardiography to guide treatment,Yes,Amiodarone,,Yes
31/10/2016 18:08,31/10/2016 18:14,IP Address,92.40.249.31,100,341,TRUE,31/10/2016 18:14,R_30es6bh7qyRZ1Rf,,,,,51.49639893,-0.122406006,anonymous,District General Hospital,500-1000,16,Mixed ICU,,Consultant,1-3 years,Anaesthesia,"Independent of their heart rate I treat all patients who have developed new onset fast AF, even if the blood pressure remains stable",Rhythm control,Amiodarone,,Supplement electrolytes to a high normal level and DC cardioversion,>4 mmol/l,1.0-1.2 mmol/l,Availability from hospital pharmacy,,I do not regularly anti-coagulate critically ill patients with new-onset fast AF,Stroke risk scores inaccurately reflect the risk of embolic events in critically ill patients with new-onset atrial fibrillation due to prothrombotic changes associated with critical illness,I do not regularly anti-coagulate critically ill patients with new onset fast AF,I only regularly perform Echocardiography in patients with cardiac history,No,"Amiodarone,Flecainide",,No
31/10/2016 18:09,31/10/2016 18:15,IP Address,90.198.11.108,100,342,TRUE,31/10/2016 18:15,R_272Ps3yiENgRVTD,,,,,53.41670227,-3,anonymous,District General Hospital,500-1000,15,Mixed ICU,,Consultant,5-10 years,Anaesthesia,120-139/beats per min,Rhythm control,Amiodarone,,Supplement electrolytes to a high normal level and anti-arrhythmics,>4.5 mmol/l,1.0-1.2 mmol/l,"Availability from hospital pharmacy,Pharmacodynamic properties",,New onset AF within 48 hours,"Stroke risk scores favour anti-coagulation despite a higher risk of bleeding in critical illness,Modified risk scores should be developed for critically ill patients with new-onset atrial fibrillation","Intravenous High Molecular Weight heparin in therapeutic dose,Subcutaneous Low Molecular Weight heparin in therapeutic dose",I regularly perform or request transthoracic echocardiography,Yes,Flecainide,,No
31/10/2016 18:06,31/10/2016 18:18,IP Address,81.254.46.118,100,700,TRUE,31/10/2016 18:18,R_ZxvKbMhQXjagrux,,,,,50.63299561,3.05859375,anonymous,Teaching Hospital,500-1000,15,Mixed ICU,,Consultant,More than 10 years,Anaesthesia,120-139/beats per min,Rate control,Amiodarone,,DC cardioversion when anti-arrhythmics and electrolyte replacement fail to achieve rate and/or rhythm control,>4.5 mmol/l,1.0-1.2 mmol/l,"Pharmacokinetic advantages,Pharmacodynamic properties,Adverse effect profile",,New onset AF within 48 hours,"I regularly calculate a risk score (e. g. CHAD2, CHA2DS2-VASc) to assess the need for anti-coagulation,Modified risk scores should be developed for critically ill patients with new-onset atrial fibrillation",Intravenous High Molecular Weight heparin in therapeutic dose,I regularly perform or request transthoracic echocardiography,Yes,ß-blocker,,Yes
31/10/2016 18:16,31/10/2016 18:20,IP Address,194.176.105.138,100,264,TRUE,31/10/2016 18:20,R_2rCpbU2YeCucW6H,,,,,51.51420593,-0.093093872,anonymous,Teaching Hospital,500-1000,13,Predominantly surgical,,Consultant,5-10 years,Anaesthesia,>160/beats per min,Rate control,Amiodarone,,Supplement electrolytes to a high normal level and anti-arrhythmics,>4 mmol/l,0.75-1 mmol/l,Pharmacodynamic properties,,I do not regularly anti-coagulate critically ill patients with new-onset fast AF,"I do not use stroke risk scores routinely in critically ill patients with new onset AF to assess the need for anticoagulation,Stroke risk scores inaccurately reflect the risk of embolic events in critically ill patients with new-onset atrial fibrillation due to prothrombotic changes associated with critical illness,Modified risk scores should be developed for critically ill patients with new-onset atrial fibrillation",I do not regularly anti-coagulate critically ill patients with new onset fast AF,I do not routinely perform Echocardiography to guide treatment,Yes,ß-blocker,,Yes
31/10/2016 18:16,31/10/2016 18:21,IP Address,95.149.181.101,100,311,TRUE,31/10/2016 18:21,R_2BmpXwOsacFpGEP,,,,,50.26170349,-5.043304443,anonymous,Teaching Hospital,1000-2000,15,Mixed ICU,,Trainee,1-3 years,Anaesthesia,120-139/beats per min,Rate control,Amiodarone,,DC cardioversion when anti-arrhythmics and electrolyte replacement fail to achieve rate and/or rhythm control,>4.5 mmol/l,1.0-1.2 mmol/l,"ICU drug policy,Pharmacodynamic properties,Adverse effect profile",,New onset AF within 72 hours,"I do not use stroke risk scores routinely in critically ill patients with new onset AF to assess the need for anticoagulation,Modified risk scores should be developed for critically ill patients with new-onset atrial fibrillation",Subcutaneous Low Molecular Weight heparin in therapeutic dose,I regularly perform or request transthoracic echocardiography,Yes,"Amiodarone,ß-blocker",,No
31/10/2016 18:16,31/10/2016 18:22,IP Address,81.156.73.137,100,342,TRUE,31/10/2016 18:22,R_6G4osQkyduW83Tj,,,,,53.35040283,-2.544906616,anonymous,District General Hospital,500-1000,18,Mixed ICU,,Consultant,More than 10 years,Anaesthesia,100-119/beats per min,Rate control,Amiodarone,,Supplement electrolytes to a high normal level and DC cardioversion,>4.5 mmol/l,1.0-1.2 mmol/l,"Availability from hospital pharmacy,ICU drug policy,Cost,Pharmacokinetic advantages,Pharmacodynamic properties,Adverse effect profile",,New onset AF within 48 hours,I do not use stroke risk scores routinely in critically ill patients with new onset AF to assess the need for anticoagulation,"Subcutaneous Low Molecular Weight heparin in therapeutic dose,Use of warfarin",I regularly perform or request transthoracic echocardiography,Yes,Amiodarone,,No
31/10/2016 18:19,31/10/2016 18:23,IP Address,213.205.198.164,100,255,TRUE,31/10/2016 18:23,R_3s6YlBbP6Pkq6RA,,,,,51.57650757,-0.397399902,anonymous,District General Hospital,1000-2000,24,Mixed ICU,,Consultant,5-10 years,Anaesthesia,"Independent of their heart rate I treat all patients who have developed new onset fast AF, even if the blood pressure remains stable",Rate control,Amiodarone,,Supplement electrolytes to a high normal level and anti-arrhythmics,>4.5 mmol/l,I do not aim for a specific serum magnesium level,ICU drug policy,,I do not regularly anti-coagulate critically ill patients with new-onset fast AF,"I regularly calculate a risk score (e. g. CHAD2, CHA2DS2-VASc) to assess the need for anti-coagulation","Intravenous High Molecular Weight heparin in therapeutic dose,I do not regularly anti-coagulate critically ill patients with new onset fast AF",I regularly perform or request transthoracic echocardiography,Yes,"Amiodarone,Digoxin",,Yes
31/10/2016 18:22,31/10/2016 18:25,IP Address,109.152.219.110,100,158,TRUE,31/10/2016 18:25,R_1MS7MvvKeKNYV8k,,,,,50.86669922,-0.016693115,anonymous,Tertiary Referral Centre or University Hospital,1000-2000,25,Mixed ICU,,Trainee,5-10 years,Anaesthesia,120-139/beats per min,Rate control,Amiodarone,,Supplement electrolytes to a high normal level and DC cardioversion,>5 mmol/l,>1.2 mmol/l,"Availability from hospital pharmacy,ICU drug policy,Pharmacokinetic advantages,Pharmacodynamic properties,Adverse effect profile",,New onset AF within 72 hours,"I do not use stroke risk scores routinely in critically ill patients with new onset AF to assess the need for anticoagulation,Modified risk scores should be developed for critically ill patients with new-onset atrial fibrillation",Subcutaneous Low Molecular Weight heparin in therapeutic dose,I do not routinely perform Echocardiography to guide treatment,Yes,"Amiodarone,DC cardioversion,ß-blocker",,Yes
31/10/2016 18:18,31/10/2016 18:25,IP Address,85.255.235.226,100,427,TRUE,31/10/2016 18:25,R_1DHBJERoP8MIBAa,,,,,51.49639893,-0.122406006,anonymous,District General Hospital,1000-2000,13,Mixed ICU,,Trainee,3-5 years,Anaesthesia,"Independent of their heart rate I treat all patients who have developed new onset fast AF, even if the blood pressure remains stable",I have no primary treatment goal in these patients,ß-blocker,,Supplement electrolytes (magnesium and/or potassium) to a high normal level,>4.5 mmol/l,1.0-1.2 mmol/l,"Pharmacokinetic advantages,Pharmacodynamic properties,Adverse effect profile",,Before starting anti-arrhythmic medication,"I regularly calculate a risk score (e. g. CHAD2, CHA2DS2-VASc) to assess the need for anti-coagulation,Stroke risk scores inaccurately reflect the risk of embolic events in critically ill patients with new-onset atrial fibrillation due to prothrombotic changes associated with critical illness,Modified risk scores should be developed for critically ill patients with new-onset atrial fibrillation",Subcutaneous Low Molecular Weight heparin in therapeutic dose,I regularly perform or request transthoracic echocardiography,Yes,ß-blocker,,No
31/10/2016 18:20,31/10/2016 18:26,IP Address,86.164.27.215,100,347,TRUE,31/10/2016 18:26,R_3ptlJ82IDks29kd,,,,,55.77330017,-4.333404541,anonymous,Tertiary Referral Centre or University Hospital,1000-2000,54,Mixed ICU,,Consultant,3-5 years,Anaesthesia,"Independent of their heart rate I treat all patients who have developed new onset fast AF, even if the blood pressure remains stable",Rhythm control,Amiodarone,,DC cardioversion when anti-arrhythmics and electrolyte replacement fail to achieve rate and/or rhythm control,>4.5 mmol/l,1.0-1.2 mmol/l,"Availability from hospital pharmacy,Pharmacodynamic properties",,I do not regularly anti-coagulate critically ill patients with new-onset fast AF,"I do not use stroke risk scores routinely in critically ill patients with new onset AF to assess the need for anticoagulation,Stroke risk scores inaccurately reflect the risk of embolic events in critically ill patients with new-onset atrial fibrillation due to prothrombotic changes associated with critical illness,Stroke risk scores favour anti-coagulation despite a higher risk of bleeding in critical illness,Modified risk scores should be developed for critically ill patients with new-onset atrial fibrillation",I do not regularly anti-coagulate critically ill patients with new onset fast AF,I regularly perform or request transthoracic echocardiography,Yes,"Amiodarone,DC cardioversion,ß-blocker",,No
31/10/2016 18:28,31/10/2016 18:31,IP Address,81.102.153.215,100,183,TRUE,31/10/2016 18:31,R_1QayHM7ZJrw3vki,,,,,53.80000305,-1.583297729,anonymous,District General Hospital,500-1000,13,Mixed ICU,,Consultant,More than 10 years,Anaesthesia,"Independent of their heart rate I treat all patients who have developed new onset fast AF, even if the blood pressure remains stable",Rhythm control,Amiodarone,,Supplement electrolytes to a high normal level and DC cardioversion,>4.5 mmol/l,1.0-1.2 mmol/l,"Other, please specify:",I wouldn't use antiarrhytmics first line,New onset AF within 48 hours,"I regularly calculate a risk score (e. g. CHAD2, CHA2DS2-VASc) to assess the need for anti-coagulation",Subcutaneous Low Molecular Weight heparin in therapeutic dose,I regularly perform or request transthoracic echocardiography,Yes,"Amiodarone,DC cardioversion,Diltiazem",,No
31/10/2016 18:28,31/10/2016 18:32,IP Address,194.176.105.168,100,194,TRUE,31/10/2016 18:32,R_eEvJJ6TyZ34zSUl,,,,,51.44999695,-0.416702271,anonymous,Tertiary Referral Centre or University Hospital,1000-2000,70,Mixed ICU,,Consultant,5-10 years,Acute medicine,120-139/beats per min,Rhythm control,ß-blocker,,Supplement electrolytes (magnesium and/or potassium) to a high normal level,>4.5 mmol/l,1.0-1.2 mmol/l,"Other, please specify:",Effectiveness,I do not regularly anti-coagulate critically ill patients with new-onset fast AF,I do not use stroke risk scores routinely in critically ill patients with new onset AF to assess the need for anticoagulation,"Subcutaneous Low Molecular Weight heparin in therapeutic dose,I do not regularly anti-coagulate critically ill patients with new onset fast AF",I do not routinely perform Echocardiography to guide treatment,Yes,ß-blocker,,Yes
31/10/2016 18:28,31/10/2016 18:32,IP Address,82.25.30.52,100,196,TRUE,31/10/2016 18:32,R_3EMbVgCS1X2Fu1U,,,,,53.42520142,-2.324401855,anonymous,Tertiary Referral Centre or University Hospital,1000-2000,48,Mixed ICU,,Consultant,More than 10 years,Anaesthesia,"Independent of their heart rate I treat all patients who have developed new onset fast AF, even if the blood pressure remains stable",Rhythm control,Amiodarone,,Supplement electrolytes to a high normal level and anti-arrhythmics,>4.5 mmol/l,1.0-1.2 mmol/l,"Other, please specify:",trial and error,I do not regularly anti-coagulate critically ill patients with new-onset fast AF,I do not use stroke risk scores routinely in critically ill patients with new onset AF to assess the need for anticoagulation,I do not regularly anti-coagulate critically ill patients with new onset fast AF,I regularly perform or request transthoracic echocardiography,No,Amiodarone,,No
31/10/2016 18:27,31/10/2016 18:32,IP Address,86.174.7.148,100,310,TRUE,31/10/2016 18:32,R_xttKoib8j9iMbAJ,,,,,52.67550659,-2.76159668,anonymous,District General Hospital,500-1000,14,Mixed ICU,,Consultant,More than 10 years,Anaesthesia,120-139/beats per min,Rhythm control,"Other anti-arrhythmics (e. g. Verapamil, sotalol): please specify:",magnesium,Supplement electrolytes to a high normal level and DC cardioversion,>4.5 mmol/l,0.75-1 mmol/l,"Other, please specify:",Experience,New onset AF within 48 hours,"I do not use stroke risk scores routinely in critically ill patients with new onset AF to assess the need for anticoagulation,Modified risk scores should be developed for critically ill patients with new-onset atrial fibrillation","Intravenous High Molecular Weight heparin in therapeutic dose,Subcutaneous Low Molecular Weight heparin in therapeutic dose,Use of warfarin",I do not routinely perform Echocardiography to guide treatment,Yes,Amiodarone,,Yes
31/10/2016 18:28,31/10/2016 18:35,IP Address,86.0.92.100,100,384,TRUE,31/10/2016 18:35,R_3qIxROlOqF7vKw1,,,,,53.80000305,-1.583297729,anonymous,Tertiary Referral Centre or University Hospital,>2000,54,Specialist ICU (please name specialty):,Mixed plus neuro surgery,Trainee,3-5 years,Intensive Care Medicine only,"Independent of their heart rate I treat all patients who have developed new onset fast AF, even if the blood pressure remains stable",Rate control,Amiodarone,,Supplement electrolytes to a high normal level and anti-arrhythmics,>4.5 mmol/l,>1.2 mmol/l,Pharmacokinetic advantages,,I do not regularly anti-coagulate critically ill patients with new-onset fast AF,Stroke risk scores inaccurately reflect the risk of embolic events in critically ill patients with new-onset atrial fibrillation due to prothrombotic changes associated with critical illness,I do not regularly anti-coagulate critically ill patients with new onset fast AF,I do not routinely perform Echocardiography to guide treatment,Yes,"Amiodarone,DC cardioversion,ß-blocker,Digoxin",,Yes
31/10/2016 18:34,31/10/2016 18:38,IP Address,164.39.215.34,100,237,TRUE,31/10/2016 18:38,R_8nOWZXX1pOSdTSt,,,,,53.5,-2.216705322,anonymous,Tertiary Referral Centre or University Hospital,>2000,18,Specialist ICU (please name specialty):,"neuro, trauma and general",Consultant,5-10 years,Emergency Medicine,"Independent of their heart rate I treat all patients who have developed new onset fast AF, even if the blood pressure remains stable",Rate control,Amiodarone,,Supplement electrolytes to a high normal level and anti-arrhythmics,>4 mmol/l,I do not aim for a specific serum magnesium level,"Pharmacokinetic advantages,Pharmacodynamic properties",,I do not regularly anti-coagulate critically ill patients with new-onset fast AF,I do not use stroke risk scores routinely in critically ill patients with new onset AF to assess the need for anticoagulation,I do not regularly anti-coagulate critically ill patients with new onset fast AF,I do not routinely perform Echocardiography to guide treatment,Yes,"Amiodarone,DC cardioversion,ß-blocker,Flecainide",,No
31/10/2016 18:39,31/10/2016 18:44,IP Address,86.159.89.219,100,345,TRUE,31/10/2016 18:44,R_2S3jJZ4Reibh4Oe,,,,,51.5,-3.199996948,anonymous,District General Hospital,500-1000,8,Mixed ICU,,Consultant,More than 10 years,Anaesthesia,120-139/beats per min,Rate control,Amiodarone,,Supplement electrolytes to a high normal level and anti-arrhythmics,>4 mmol/l,1.0-1.2 mmol/l,"ICU drug policy,Adverse effect profile",,I do not regularly anti-coagulate critically ill patients with new-onset fast AF,"I do not use stroke risk scores routinely in critically ill patients with new onset AF to assess the need for anticoagulation,Stroke risk scores favour anti-coagulation despite a higher risk of bleeding in critical illness",I do not regularly anti-coagulate critically ill patients with new onset fast AF,I do not routinely perform Echocardiography to guide treatment,No,"Amiodarone,DC cardioversion",,Yes
31/10/2016 18:39,31/10/2016 18:45,IP Address,82.132.244.162,100,355,TRUE,31/10/2016 18:45,R_YXopEq7F0oP3lmh,,,,,51.49639893,-0.122406006,anonymous,Teaching Hospital,500-1000,36,Mixed ICU,,Consultant,5-10 years,Anaesthesia,120-139/beats per min,Rate control,Amiodarone,,Supplement electrolytes to a high normal level and anti-arrhythmics,>4.5 mmol/l,1.0-1.2 mmol/l,ICU drug policy,,I do not regularly anti-coagulate critically ill patients with new-onset fast AF,"I do not use stroke risk scores routinely in critically ill patients with new onset AF to assess the need for anticoagulation,Stroke risk scores inaccurately reflect the risk of embolic events in critically ill patients with new-onset atrial fibrillation due to prothrombotic changes associated with critical illness,Modified risk scores should be developed for critically ill patients with new-onset atrial fibrillation",Subcutaneous Low Molecular Weight heparin in therapeutic dose,I only regularly perform Echocardiography in patients with cardiac history,Yes,"Amiodarone,ß-blocker",,Yes
31/10/2016 18:40,31/10/2016 18:46,IP Address,90.214.205.106,100,366,TRUE,31/10/2016 18:46,R_2B4YTIyCMM6TtqJ,,,,,53.5,-2.216705322,anonymous,Tertiary Referral Centre or University Hospital,1000-2000,26,Specialist ICU (please name specialty):,Cardiothoracic,Consultant,More than 10 years,Anaesthesia,"Independent of their heart rate I treat all patients who have developed new onset fast AF, even if the blood pressure remains stable",Rhythm control,ß-blocker,,DC cardioversion when anti-arrhythmics and electrolyte replacement fail to achieve rate and/or rhythm control,>4.5 mmol/l,>1.2 mmol/l,"Other, please specify:",Found it to be superior over the years,New onset AF within 72 hours,I do not use stroke risk scores routinely in critically ill patients with new onset AF to assess the need for anticoagulation,"Intravenous High Molecular Weight heparin in therapeutic dose,Subcutaneous Low Molecular Weight heparin in therapeutic dose",I regularly perform or request transoesophageal echocardiography,Yes,ß-blocker,,No
31/10/2016 18:39,31/10/2016 18:47,IP Address,86.190.14.39,100,483,TRUE,31/10/2016 18:47,R_1hxRjtuqFvTUlgf,,,,,52.76589966,-0.886901855,anonymous,Teaching Hospital,1000-2000,24,Mixed ICU,,Consultant,More than 10 years,Anaesthesia,120-139/beats per min,Rate control,Amiodarone,,Supplement electrolytes to a high normal level and anti-arrhythmics,>4.5 mmol/l,1.0-1.2 mmol/l,"ICU drug policy,Pharmacodynamic properties",,New onset AF within 72 hours,"I do not use stroke risk scores routinely in critically ill patients with new onset AF to assess the need for anticoagulation,Stroke risk scores inaccurately reflect the risk of embolic events in critically ill patients with new-onset atrial fibrillation due to prothrombotic changes associated with critical illness,Modified risk scores should be developed for critically ill patients with new-onset atrial fibrillation",Subcutaneous Low Molecular Weight heparin in therapeutic dose,I do not routinely perform Echocardiography to guide treatment,Yes,"Amiodarone,ß-blocker",,No
31/10/2016 17:34,31/10/2016 18:51,IP Address,90.209.65.212,100,4628,TRUE,31/10/2016 18:51,R_2pSuDAZUOY2Gp0v,,,,,51.5,-0.366699219,anonymous,Teaching Hospital,>2000,16,Predominantly surgical,,Trainee,5-10 years,Anaesthesia,140-159/beats per min,Rhythm control,Amiodarone,,Supplement electrolytes to a high normal level and anti-arrhythmics,>4.5 mmol/l,>1.2 mmol/l,"Pharmacodynamic properties,Adverse effect profile",,I do not regularly anti-coagulate critically ill patients with new-onset fast AF,Modified risk scores should be developed for critically ill patients with new-onset atrial fibrillation,I do not regularly anti-coagulate critically ill patients with new onset fast AF,I regularly perform or request transthoracic echocardiography,Yes,"Amiodarone,DC cardioversion,ß-blocker,Digoxin",,No
31/10/2016 18:47,31/10/2016 18:51,IP Address,86.167.131.57,100,244,TRUE,31/10/2016 18:51,R_5hCQVJk7NHYMo1j,,,,,52.32910156,-0.903503418,anonymous,Tertiary Referral Centre or University Hospital,1000-2000,19,Mixed ICU,,Consultant,More than 10 years,Anaesthesia,"Independent of their heart rate I treat all patients who have developed new onset fast AF, even if the blood pressure remains stable",Rhythm control,Amiodarone,,Supplement electrolytes to a high normal level and anti-arrhythmics,>4.5 mmol/l,I do not aim for a specific serum magnesium level,"Pharmacokinetic advantages,Pharmacodynamic properties",,I do not regularly anti-coagulate critically ill patients with new-onset fast AF,I do not use stroke risk scores routinely in critically ill patients with new onset AF to assess the need for anticoagulation,I do not regularly anti-coagulate critically ill patients with new onset fast AF,"I do not routinely perform Echocardiography to guide treatment,I only regularly perform Echocardiography in patients with cardiac history",Yes,"Amiodarone,ß-blocker",,Yes
31/10/2016 18:45,31/10/2016 18:51,IP Address,94.173.130.174,100,379,TRUE,31/10/2016 18:51,R_3lFXTXGl9nWmh0T,,,,,52.46670532,-1.916702271,anonymous,Tertiary Referral Centre or University Hospital,>2000,80,Mixed ICU,,Consultant,More than 10 years,Anaesthesia,120-139/beats per min,Rate control,ß-blocker,,Supplement electrolytes to a high normal level and anti-arrhythmics,>4 mmol/l,1.0-1.2 mmol/l,Adverse effect profile,,New onset AF within 48 hours,Stroke risk scores favour anti-coagulation despite a higher risk of bleeding in critical illness,Subcutaneous Low Molecular Weight heparin in therapeutic dose,I do not routinely perform Echocardiography to guide treatment,Yes,ß-blocker,,No
31/10/2016 18:48,31/10/2016 18:53,IP Address,5.81.25.197,100,348,TRUE,31/10/2016 18:53,R_26o2PsaWj80DvS2,,,,,54.77400208,-3.430206299,anonymous,District General Hospital,500-1000,9,Mixed ICU,,Consultant,More than 10 years,Anaesthesia,"Independent of their heart rate I treat all patients who have developed new onset fast AF, even if the blood pressure remains stable",Rhythm control,Amiodarone,,Supplement electrolytes to a high normal level and anti-arrhythmics,>4.5 mmol/l,1.0-1.2 mmol/l,Pharmacodynamic properties,,I do not regularly anti-coagulate critically ill patients with new-onset fast AF,I do not use stroke risk scores routinely in critically ill patients with new onset AF to assess the need for anticoagulation,I do not regularly anti-coagulate critically ill patients with new onset fast AF,I do not routinely perform Echocardiography to guide treatment,No,"Amiodarone,DC cardioversion,ß-blocker,Digoxin",,Yes
31/10/2016 18:51,31/10/2016 18:55,IP Address,82.1.9.127,100,279,TRUE,31/10/2016 18:55,R_brSR17NA82C8BkV,,,,,53.75,-2.483306885,anonymous,Teaching Hospital,1000-2000,23,Mixed ICU,,Consultant,More than 10 years,Anaesthesia,120-139/beats per min,Rhythm control,Amiodarone,,Supplement electrolytes to a high normal level and anti-arrhythmics,>4.5 mmol/l,>1.2 mmol/l,Pharmacodynamic properties,,I do not regularly anti-coagulate critically ill patients with new-onset fast AF,Modified risk scores should be developed for critically ill patients with new-onset atrial fibrillation,Subcutaneous Low Molecular Weight heparin in therapeutic dose,I do not routinely perform Echocardiography to guide treatment,Yes,Amiodarone,,Yes
31/10/2016 18:56,31/10/2016 19:00,IP Address,83.216.139.35,100,248,TRUE,31/10/2016 19:00,R_1kFWutLRADfbT4e,,,,,53.03329468,-1.466705322,anonymous,District General Hospital,I do not know,12,Mixed ICU,,Trainee,1-3 years,Anaesthesia,140-159/beats per min,Rate control,Amiodarone,,DC cardioversion when anti-arrhythmics and electrolyte replacement fail to achieve rate and/or rhythm control,>4.5 mmol/l,1.0-1.2 mmol/l,"Pharmacokinetic advantages,Pharmacodynamic properties",,New onset AF within 48 hours,"I do not use stroke risk scores routinely in critically ill patients with new onset AF to assess the need for anticoagulation,Stroke risk scores inaccurately reflect the risk of embolic events in critically ill patients with new-onset atrial fibrillation due to prothrombotic changes associated with critical illness,Stroke risk scores favour anti-coagulation despite a higher risk of bleeding in critical illness,Modified risk scores should be developed for critically ill patients with new-onset atrial fibrillation","Intravenous High Molecular Weight heparin in therapeutic dose,Subcutaneous Low Molecular Weight heparin in therapeutic dose",I regularly perform or request transthoracic echocardiography,Yes,Amiodarone,,No
31/10/2016 18:52,31/10/2016 19:03,IP Address,81.141.124.166,100,676,TRUE,31/10/2016 19:03,R_OC2YvJu9ck7Paq5,,,,,51.3500061,-0.199996948,anonymous,District General Hospital,<500,4,Predominantly surgical,,Consultant,More than 10 years,Anaesthesia,100-119/beats per min,Rhythm control,ß-blocker,,DC cardioversion when anti-arrhythmics and electrolyte replacement fail to achieve rate and/or rhythm control,>4.5 mmol/l,I do not aim for a specific serum magnesium level,"Pharmacokinetic advantages,Pharmacodynamic properties,Adverse effect profile",,I do not regularly anti-coagulate critically ill patients with new-onset fast AF,"Stroke risk scores favour anti-coagulation despite a higher risk of bleeding in critical illness,Modified risk scores should be developed for critically ill patients with new-onset atrial fibrillation",I do not regularly anti-coagulate critically ill patients with new onset fast AF,I regularly perform or request transthoracic echocardiography,Yes,"Amiodarone,DC cardioversion,ß-blocker,Flecainide,Diltiazem,Digoxin",,No
31/10/2016 18:54,31/10/2016 19:04,IP Address,94.3.136.199,100,543,TRUE,31/10/2016 19:04,R_2aiqYjPA6D9PGW5,,,,,51.47439575,-0.215194702,anonymous,Tertiary Referral Centre or University Hospital,I do not know,42,Mixed ICU,,Trainee,<1 year,Acute medicine,120-139/beats per min,Rhythm control,Amiodarone,,DC cardioversion when anti-arrhythmics and electrolyte replacement fail to achieve rate and/or rhythm control,>4.5 mmol/l,>1.2 mmol/l,Adverse effect profile,,New onset AF within 24 hours,"I regularly calculate a risk score (e. g. CHAD2, CHA2DS2-VASc) to assess the need for anti-coagulation,Stroke risk scores inaccurately reflect the risk of embolic events in critically ill patients with new-onset atrial fibrillation due to prothrombotic changes associated with critical illness,Modified risk scores should be developed for critically ill patients with new-onset atrial fibrillation","Intravenous High Molecular Weight heparin in therapeutic dose,Subcutaneous Low Molecular Weight heparin in therapeutic dose",I regularly perform or request transthoracic echocardiography,No,"Amiodarone,DC cardioversion,Flecainide",,Yes
31/10/2016 19:02,31/10/2016 19:10,IP Address,86.163.123.69,100,451,TRUE,31/10/2016 19:10,R_2pJKSpJ1dZzhs3f,,,,,51.61669922,-0.100006104,anonymous,District General Hospital,<500,10,Mixed ICU,,Consultant,More than 10 years,Anaesthesia,120-139/beats per min,Rhythm control,Amiodarone,,Supplement electrolytes to a high normal level and anti-arrhythmics,>4.5 mmol/l,I do not aim for a specific serum magnesium level,Pharmacodynamic properties,,I do not regularly anti-coagulate critically ill patients with new-onset fast AF,"I do not use stroke risk scores routinely in critically ill patients with new onset AF to assess the need for anticoagulation,Stroke risk scores inaccurately reflect the risk of embolic events in critically ill patients with new-onset atrial fibrillation due to prothrombotic changes associated with critical illness","Subcutaneous Low Molecular Weight heparin in therapeutic dose,I do not regularly anti-coagulate critically ill patients with new onset fast AF",I do not routinely perform Echocardiography to guide treatment,Yes,Amiodarone,,Yes
31/10/2016 19:05,31/10/2016 19:11,IP Address,82.40.186.242,100,335,TRUE,31/10/2016 19:11,R_Dud7s9QfcIVFjnH,,,,,51.18330383,0.283294678,anonymous,District General Hospital,500-1000,20,Mixed ICU,,Consultant,More than 10 years,Anaesthesia,"Independent of their heart rate I treat all patients who have developed new onset fast AF, even if the blood pressure remains stable",Rhythm control,Amiodarone,,Supplement electrolytes to a high normal level and anti-arrhythmics,>4.5 mmol/l,1.0-1.2 mmol/l,Pharmacodynamic properties,,I do not regularly anti-coagulate critically ill patients with new-onset fast AF,"I do not use stroke risk scores routinely in critically ill patients with new onset AF to assess the need for anticoagulation,Stroke risk scores favour anti-coagulation despite a higher risk of bleeding in critical illness,Modified risk scores should be developed for critically ill patients with new-onset atrial fibrillation",I do not regularly anti-coagulate critically ill patients with new onset fast AF,I regularly perform or request transthoracic echocardiography,Yes,Amiodarone,,No
31/10/2016 19:06,31/10/2016 19:12,IP Address,86.167.244.238,100,319,TRUE,31/10/2016 19:12,R_2WGTmQSkLnyrGfr,,,,,51.49639893,-0.122406006,anonymous,District General Hospital,1000-2000,19,Mixed ICU,,Consultant,More than 10 years,Anaesthesia,120-139/beats per min,Rhythm control,Amiodarone,,Supplement electrolytes to a high normal level and anti-arrhythmics,>4 mmol/l,1.0-1.2 mmol/l,Adverse effect profile,,I do not regularly anti-coagulate critically ill patients with new-onset fast AF,"I do not use stroke risk scores routinely in critically ill patients with new onset AF to assess the need for anticoagulation,Stroke risk scores inaccurately reflect the risk of embolic events in critically ill patients with new-onset atrial fibrillation due to prothrombotic changes associated with critical illness,Stroke risk scores favour anti-coagulation despite a higher risk of bleeding in critical illness,Modified risk scores should be developed for critically ill patients with new-onset atrial fibrillation",Subcutaneous Low Molecular Weight heparin in therapeutic dose,I only regularly perform Echocardiography in patients with cardiac history,Yes,"Amiodarone,DC cardioversion,ß-blocker",,No
31/10/2016 19:07,31/10/2016 19:13,IP Address,85.255.236.55,100,335,TRUE,31/10/2016 19:13,R_3O6r1vsb1jeO232,,,,,51.49639893,-0.122406006,anonymous,District General Hospital,500-1000,9,Mixed ICU,,Consultant,More than 10 years,Anaesthesia,"Independent of their heart rate I treat all patients who have developed new onset fast AF, even if the blood pressure remains stable",Rhythm control,Amiodarone,,Supplement electrolytes to a high normal level and anti-arrhythmics,>4.5 mmol/l,0.75-1 mmol/l,Pharmacodynamic properties,,Before DC cardioversion,"I do not use stroke risk scores routinely in critically ill patients with new onset AF to assess the need for anticoagulation,Stroke risk scores inaccurately reflect the risk of embolic events in critically ill patients with new-onset atrial fibrillation due to prothrombotic changes associated with critical illness,Modified risk scores should be developed for critically ill patients with new-onset atrial fibrillation",I do not regularly anti-coagulate critically ill patients with new onset fast AF,I do not routinely perform Echocardiography to guide treatment,No,"Amiodarone,DC cardioversion,ß-blocker,Digoxin",,No
31/10/2016 19:11,31/10/2016 19:14,IP Address,86.134.217.201,100,161,TRUE,31/10/2016 19:14,R_29dib0N24S7hEjP,,,,,51.55000305,-0.050003052,anonymous,Tertiary Referral Centre or University Hospital,1000-2000,61,Predominantly surgical,,Consultant,More than 10 years,Anaesthesia,120-139/beats per min,Rate control,Digoxin,,Supplement electrolytes to a high normal level and DC cardioversion,>4.5 mmol/l,>1.2 mmol/l,ICU drug policy,,New onset AF within 48 hours,I do not use stroke risk scores routinely in critically ill patients with new onset AF to assess the need for anticoagulation,"Subcutaneous Low Molecular Weight heparin in therapeutic dose,I do not regularly anti-coagulate critically ill patients with new onset fast AF",I regularly perform or request transthoracic echocardiography,Yes,ß-blocker,,Yes
31/10/2016 19:13,31/10/2016 19:16,IP Address,86.175.110.103,100,212,TRUE,31/10/2016 19:17,R_1gIz15FeolGD28M,,,,,53.41670227,-3,anonymous,Teaching Hospital,1000-2000,31,Mixed ICU,,Consultant,More than 10 years,Anaesthesia,"Independent of their heart rate I treat all patients who have developed new onset fast AF, even if the blood pressure remains stable",Rate control,ß-blocker,,Supplement electrolytes to a high normal level and anti-arrhythmics,>4.5 mmol/l,1.0-1.2 mmol/l,"Availability from hospital pharmacy,Pharmacokinetic advantages,Pharmacodynamic properties,Adverse effect profile",,Before DC cardioversion,"I do not use stroke risk scores routinely in critically ill patients with new onset AF to assess the need for anticoagulation,Stroke risk scores inaccurately reflect the risk of embolic events in critically ill patients with new-onset atrial fibrillation due to prothrombotic changes associated with critical illness,Modified risk scores should be developed for critically ill patients with new-onset atrial fibrillation",Subcutaneous Low Molecular Weight heparin in therapeutic dose,I do not routinely perform Echocardiography to guide treatment,Yes,"Other anti-arrhythmics (e. g. verapamil, sotalol): Please specify:",sotalol,No
31/10/2016 19:19,31/10/2016 19:23,IP Address,46.255.119.7,100,238,TRUE,31/10/2016 19:23,R_2AFRCRXdX5TN301,,,,,51.51420593,-0.093093872,anonymous,Tertiary Referral Centre or University Hospital,1000-2000,16,Predominantly surgical,,Consultant,More than 10 years,Anaesthesia,140-159/beats per min,Rate control,ß-blocker,,Anti-arrhythmics only,>4.5 mmol/l,>1.2 mmol/l,Pharmacodynamic properties,,New onset AF within 24 hours,Stroke risk scores inaccurately reflect the risk of embolic events in critically ill patients with new-onset atrial fibrillation due to prothrombotic changes associated with critical illness,Subcutaneous Low Molecular Weight heparin in therapeutic dose,I regularly perform or request transthoracic echocardiography,Yes,ß-blocker,,No
31/10/2016 19:14,31/10/2016 19:27,IP Address,81.108.159.177,100,797,TRUE,31/10/2016 19:27,R_2uUk7Q3CwFuFtqI,,,,,54.94500732,-1.617492676,anonymous,Tertiary Referral Centre or University Hospital,1000-2000,22,Mixed ICU,,Trainee,5-10 years,Anaesthesia,"Independent of their heart rate I treat all patients who have developed new onset fast AF, even if the blood pressure remains stable",Rate control,Amiodarone,,Supplement electrolytes to a high normal level and anti-arrhythmics,>4.5 mmol/l,1.0-1.2 mmol/l,"Adverse effect profile,Other, please specify:",Amiod for relative CV tolerance,I do not regularly anti-coagulate critically ill patients with new-onset fast AF,Stroke risk scores favour anti-coagulation despite a higher risk of bleeding in critical illness,I do not regularly anti-coagulate critically ill patients with new onset fast AF,I only regularly perform Echocardiography in patients with cardiac history,Yes,"ß-blocker,Diltiazem,Other anti-arrhythmics (e. g. verapamil, sotalol): Please specify:",Interested to see if compatible with NADR dependent circ,No
31/10/2016 19:25,31/10/2016 19:32,IP Address,5.71.148.127,100,392,TRUE,31/10/2016 19:32,R_1ghgABG54za6vqc,,,,,51.75,-0.466705322,anonymous,Teaching Hospital,>2000,45,Mixed ICU,,Consultant,5-10 years,Anaesthesia,100-119/beats per min,Rate control,Amiodarone,,Supplement electrolytes to a high normal level and anti-arrhythmics,>4 mmol/l,1.0-1.2 mmol/l,"Pharmacodynamic properties,Adverse effect profile",,New onset AF within 72 hours,"I do not use stroke risk scores routinely in critically ill patients with new onset AF to assess the need for anticoagulation,Stroke risk scores inaccurately reflect the risk of embolic events in critically ill patients with new-onset atrial fibrillation due to prothrombotic changes associated with critical illness,Modified risk scores should be developed for critically ill patients with new-onset atrial fibrillation",Subcutaneous Low Molecular Weight heparin in therapeutic dose,I regularly perform or request transthoracic echocardiography,Yes,"Amiodarone,DC cardioversion,ß-blocker",,Yes
31/10/2016 19:31,31/10/2016 19:35,IP Address,86.178.198.231,100,280,TRUE,31/10/2016 19:35,R_1eVvPESgAU7iWgv,,,,,53.42520142,-2.324401855,anonymous,Teaching Hospital,>2000,18,Mixed ICU,,Trainee,5-10 years,Anaesthesia,120-139/beats per min,Rate control,Amiodarone,,Supplement electrolytes (magnesium and/or potassium) to a high normal level,>4.5 mmol/l,1.0-1.2 mmol/l,"ICU drug policy,Pharmacokinetic advantages,Pharmacodynamic properties,Adverse effect profile",,I do not regularly anti-coagulate critically ill patients with new-onset fast AF,Modified risk scores should be developed for critically ill patients with new-onset atrial fibrillation,"Intravenous High Molecular Weight heparin in therapeutic dose,Subcutaneous Low Molecular Weight heparin in therapeutic dose",I regularly perform or request transthoracic echocardiography,Yes,ß-blocker,,No
31/10/2016 19:35,31/10/2016 19:40,IP Address,86.141.184.228,100,302,TRUE,31/10/2016 19:40,R_YY9jQLTBJLHGO9r,,,,,51.6499939,-0.199996948,anonymous,Tertiary Referral Centre or University Hospital,>2000,34,Mixed ICU,,Consultant,5-10 years,Anaesthesia,120-139/beats per min,Rate control,Amiodarone,,Supplement electrolytes to a high normal level and DC cardioversion,>4.5 mmol/l,>1.2 mmol/l,"ICU drug policy,Cost,Pharmacokinetic advantages,Pharmacodynamic properties,Adverse effect profile",,New onset AF within 24 hours,I do not use stroke risk scores routinely in critically ill patients with new onset AF to assess the need for anticoagulation,"Intravenous High Molecular Weight heparin in therapeutic dose,Subcutaneous Low Molecular Weight heparin in therapeutic dose",I regularly perform or request transthoracic echocardiography,Yes,Amiodarone,,No
31/10/2016 19:24,31/10/2016 19:43,IP Address,86.187.166.216,100,1130,TRUE,31/10/2016 19:43,R_8iCiHwLkVHREkgN,,,,,51.55000305,-0.183303833,anonymous,District General Hospital,500-1000,10,Mixed ICU,,Consultant,More than 10 years,Anaesthesia,120-139/beats per min,Rate control,Digoxin,,Supplement electrolytes to a high normal level and anti-arrhythmics,>4.5 mmol/l,1.0-1.2 mmol/l,Adverse effect profile,,I do not regularly anti-coagulate critically ill patients with new-onset fast AF,Modified risk scores should be developed for critically ill patients with new-onset atrial fibrillation,I do not regularly anti-coagulate critically ill patients with new onset fast AF,I regularly perform or request transthoracic echocardiography,Yes,"Amiodarone,Diltiazem,Digoxin",,Yes
31/10/2016 19:38,31/10/2016 19:43,IP Address,79.77.250.178,100,341,TRUE,31/10/2016 19:43,R_1roHZsHynp27OoP,,,,,53.76669312,-2.716705322,anonymous,District General Hospital,500-1000,14,Mixed ICU,,Consultant,More than 10 years,Anaesthesia,120-139/beats per min,Rhythm control,Amiodarone,,Supplement electrolytes to a high normal level and DC cardioversion,>4.5 mmol/l,1.0-1.2 mmol/l,"ICU drug policy,Pharmacodynamic properties",,I do not regularly anti-coagulate critically ill patients with new-onset fast AF,"I do not use stroke risk scores routinely in critically ill patients with new onset AF to assess the need for anticoagulation,Stroke risk scores inaccurately reflect the risk of embolic events in critically ill patients with new-onset atrial fibrillation due to prothrombotic changes associated with critical illness,Modified risk scores should be developed for critically ill patients with new-onset atrial fibrillation",I do not regularly anti-coagulate critically ill patients with new onset fast AF,I regularly perform or request transthoracic echocardiography,Yes,"Amiodarone,DC cardioversion,Flecainide",,No
31/10/2016 19:39,31/10/2016 19:46,IP Address,81.159.192.243,100,423,TRUE,31/10/2016 19:46,R_3HFclTmoQVtrqR4,,,,,54.25480652,-0.47479248,anonymous,District General Hospital,500-1000,6,Mixed ICU,,Consultant,More than 10 years,Anaesthesia,120-139/beats per min,Rhythm control,Amiodarone,,Supplement electrolytes (magnesium and/or potassium) to a high normal level,>4.5 mmol/l,1.0-1.2 mmol/l,"Pharmacokinetic advantages,Pharmacodynamic properties,Adverse effect profile",,I do not regularly anti-coagulate critically ill patients with new-onset fast AF,"I do not use stroke risk scores routinely in critically ill patients with new onset AF to assess the need for anticoagulation,Stroke risk scores inaccurately reflect the risk of embolic events in critically ill patients with new-onset atrial fibrillation due to prothrombotic changes associated with critical illness",I do not regularly anti-coagulate critically ill patients with new onset fast AF,I regularly perform or request transthoracic echocardiography,Yes,Amiodarone,,No
31/10/2016 19:40,31/10/2016 19:46,IP Address,2.102.70.103,100,371,TRUE,31/10/2016 19:46,R_dprAkzWkW7c20VP,,,,,53.80000305,-1.583297729,anonymous,District General Hospital,1000-2000,14,Mixed ICU,,Consultant,5-10 years,Anaesthesia,"Independent of their heart rate I treat all patients who have developed new onset fast AF, even if the blood pressure remains stable",Rhythm control,"Other anti-arrhythmics (e. g. Verapamil, sotalol): please specify:",Magnesium,DC cardioversion when anti-arrhythmics and electrolyte replacement fail to achieve rate and/or rhythm control,>4.5 mmol/l,1.0-1.2 mmol/l,"Availability from hospital pharmacy,Pharmacodynamic properties,Adverse effect profile,Other, please specify:",Familiarity,New onset AF within 48 hours,I do not use stroke risk scores routinely in critically ill patients with new onset AF to assess the need for anticoagulation,"Intravenous High Molecular Weight heparin in therapeutic dose,Subcutaneous Low Molecular Weight heparin in therapeutic dose",I regularly perform or request transthoracic echocardiography,Yes,ß-blocker,,Yes
31/10/2016 19:40,31/10/2016 19:46,IP Address,118.208.75.174,100,392,TRUE,31/10/2016 19:46,R_3NHU1bTDoRiYEyK,,,,,-27.47099304,153.024292,anonymous,Teaching Hospital,500-1000,9,Predominantly medical,,Consultant,5-10 years,Anaesthesia,"Independent of their heart rate I treat all patients who have developed new onset fast AF, even if the blood pressure remains stable",Rate control,Amiodarone,,Supplement electrolytes to a high normal level and anti-arrhythmics,>4.5 mmol/l,>1.2 mmol/l,Pharmacodynamic properties,,I do not regularly anti-coagulate critically ill patients with new-onset fast AF,"I do not use stroke risk scores routinely in critically ill patients with new onset AF to assess the need for anticoagulation,Stroke risk scores inaccurately reflect the risk of embolic events in critically ill patients with new-onset atrial fibrillation due to prothrombotic changes associated with critical illness,Stroke risk scores favour anti-coagulation despite a higher risk of bleeding in critical illness,Modified risk scores should be developed for critically ill patients with new-onset atrial fibrillation","Intravenous High Molecular Weight heparin in therapeutic dose,Subcutaneous Low Molecular Weight heparin in therapeutic dose,Use of warfarin",I regularly perform or request transthoracic echocardiography,Yes,Amiodarone,,Yes
31/10/2016 19:43,31/10/2016 19:47,IP Address,81.157.246.31,100,256,TRUE,31/10/2016 19:47,R_3fl55A7Ayd38x9b,,,,,52.19999695,0.116699219,anonymous,Tertiary Referral Centre or University Hospital,1000-2000,18,Mixed ICU,,Consultant,More than 10 years,Anaesthesia,120-139/beats per min,Rate control,Amiodarone,,DC cardioversion when anti-arrhythmics and electrolyte replacement fail to achieve rate and/or rhythm control,>4 mmol/l,1.0-1.2 mmol/l,"Other, please specify:",Tradition,I do not regularly anti-coagulate critically ill patients with new-onset fast AF,"I do not use stroke risk scores routinely in critically ill patients with new onset AF to assess the need for anticoagulation,Modified risk scores should be developed for critically ill patients with new-onset atrial fibrillation",Subcutaneous Low Molecular Weight heparin in therapeutic dose,I do not routinely perform Echocardiography to guide treatment,Yes,ß-blocker,,Yes
31/10/2016 17:20,31/10/2016 19:49,IP Address,78.149.38.69,100,8888,TRUE,31/10/2016 19:49,R_3koXndAMhQpxYSw,,,,,50.44999695,-3.5,anonymous,Teaching Hospital,500-1000,13,Mixed ICU,,Consultant,5-10 years,Intensive Care Medicine only,100-119/beats per min,Rate control,ß-blocker,,Supplement electrolytes to a high normal level and anti-arrhythmics,>4.5 mmol/l,1.0-1.2 mmol/l,"Other, please specify:","Evidence to support beta blockers in heart failure, and in sepsis",I do not regularly anti-coagulate critically ill patients with new-onset fast AF,I do not use stroke risk scores routinely in critically ill patients with new onset AF to assess the need for anticoagulation,I do not regularly anti-coagulate critically ill patients with new onset fast AF,I regularly perform or request transthoracic echocardiography,Yes,"Other anti-arrhythmics (e. g. verapamil, sotalol): Please specify:",You'd want to study one vs another eg amiodarone vs beta blocker,No
31/10/2016 19:43,31/10/2016 19:50,IP Address,77.44.113.95,100,400,TRUE,31/10/2016 19:50,R_1hB92qsru20sVia,,,,,51.49639893,-0.122406006,anonymous,Tertiary Referral Centre or University Hospital,>2000,46,Mixed ICU,,Consultant,More than 10 years,Anaesthesia,140-159/beats per min,Rhythm control,Amiodarone,,Supplement electrolytes (magnesium and/or potassium) to a high normal level,>4.5 mmol/l,1.0-1.2 mmol/l,Pharmacodynamic properties,,I do not regularly anti-coagulate critically ill patients with new-onset fast AF,"I do not use stroke risk scores routinely in critically ill patients with new onset AF to assess the need for anticoagulation,Modified risk scores should be developed for critically ill patients with new-onset atrial fibrillation",I do not regularly anti-coagulate critically ill patients with new onset fast AF,I do not routinely perform Echocardiography to guide treatment,Yes,Amiodarone,,Yes
31/10/2016 19:49,31/10/2016 19:58,IP Address,86.24.220.244,100,505,TRUE,31/10/2016 19:58,R_1LjqIxTkcfwj671,,,,,55.94999695,-3.199996948,anonymous,Tertiary Referral Centre or University Hospital,1000-2000,21,Specialist ICU (please name specialty):,Cardiothoracic,Consultant,More than 10 years,Anaesthesia,140-159/beats per min,I have no primary treatment goal in these patients,Amiodarone,,Supplement electrolytes (magnesium and/or potassium) to a high normal level,>5 mmol/l,>1.2 mmol/l,"Other, please specify:",Amiodarone works,I do not regularly anti-coagulate critically ill patients with new-onset fast AF,"I do not use stroke risk scores routinely in critically ill patients with new onset AF to assess the need for anticoagulation,Stroke risk scores inaccurately reflect the risk of embolic events in critically ill patients with new-onset atrial fibrillation due to prothrombotic changes associated with critical illness","Intravenous High Molecular Weight heparin in therapeutic dose,Subcutaneous Low Molecular Weight heparin in therapeutic dose,Use of novel oral anti-coagulants (NOACs),Use of warfarin",I do not routinely perform Echocardiography to guide treatment,No,Amiodarone,,Yes
31/10/2016 18:52,31/10/2016 19:58,IP Address,51.6.50.36,100,3957,TRUE,31/10/2016 19:58,R_1OOyiQ5eBuO2SgR,,,,,51.14160156,0.827896118,anonymous,District General Hospital,500-1000,11,Mixed ICU,,Consultant,More than 10 years,Anaesthesia,120-139/beats per min,Rate control,Amiodarone,,Supplement electrolytes to a high normal level and anti-arrhythmics,>4.5 mmol/l,>1.2 mmol/l,"Availability from hospital pharmacy,Pharmacokinetic advantages",,I do not regularly anti-coagulate critically ill patients with new-onset fast AF,"I do not use stroke risk scores routinely in critically ill patients with new onset AF to assess the need for anticoagulation,Modified risk scores should be developed for critically ill patients with new-onset atrial fibrillation",I do not regularly anti-coagulate critically ill patients with new onset fast AF,I only regularly perform Echocardiography in patients with cardiac history,Yes,"Amiodarone,DC cardioversion,ß-blocker,Other anti-arrhythmics (e. g. verapamil, sotalol): Please specify:",Ivabradine,Yes
31/10/2016 19:57,31/10/2016 20:00,IP Address,159.117.1.11,100,176,TRUE,31/10/2016 20:00,R_1mQMuXAUmm0a3rb,,,,,-43.53410339,172.6369934,anonymous,Tertiary Referral Centre or University Hospital,1000-2000,23,Mixed ICU,,Consultant,More than 10 years,Intensive Care Medicine only,100-119/beats per min,Rate control,Amiodarone,,Supplement electrolytes to a high normal level and anti-arrhythmics,>4 mmol/l,1.0-1.2 mmol/l,ICU drug policy,,I do not regularly anti-coagulate critically ill patients with new-onset fast AF,"I do not use stroke risk scores routinely in critically ill patients with new onset AF to assess the need for anticoagulation,Modified risk scores should be developed for critically ill patients with new-onset atrial fibrillation","Subcutaneous Low Molecular Weight heparin in therapeutic dose,Use of warfarin,I do not regularly anti-coagulate critically ill patients with new onset fast AF",I do not routinely perform Echocardiography to guide treatment,Yes,"Amiodarone,DC cardioversion,ß-blocker,Digoxin",,No
31/10/2016 20:06,31/10/2016 20:13,IP Address,86.154.28.16,100,419,TRUE,31/10/2016 20:13,R_0rqdkh6HiGeE2kh,,,,,51.45019531,-2.650299072,anonymous,Tertiary Referral Centre or University Hospital,1000-2000,20,Mixed ICU,,Consultant,More than 10 years,Anaesthesia,"Independent of their heart rate I treat all patients who have developed new onset fast AF, even if the blood pressure remains stable",Rate control,Amiodarone,,Supplement electrolytes to a high normal level and anti-arrhythmics,>4.5 mmol/l,1.0-1.2 mmol/l,Pharmacodynamic properties,,I do not regularly anti-coagulate critically ill patients with new-onset fast AF,"I do not use stroke risk scores routinely in critically ill patients with new onset AF to assess the need for anticoagulation,Stroke risk scores favour anti-coagulation despite a higher risk of bleeding in critical illness,Modified risk scores should be developed for critically ill patients with new-onset atrial fibrillation","Intravenous High Molecular Weight heparin in therapeutic dose,I do not regularly anti-coagulate critically ill patients with new onset fast AF","I do not routinely perform Echocardiography to guide treatment,I only regularly perform Echocardiography in patients with cardiac history",Yes,"ß-blocker,Other anti-arrhythmics (e. g. verapamil, sotalol): Please specify:",Esmolol + noradrenaline + electrolytes,Yes
31/10/2016 18:01,31/10/2016 20:15,IP Address,217.44.130.208,100,8069,TRUE,31/10/2016 20:15,R_VXrKadv2lolpxsZ,,,,,51.68330383,-0.899993896,anonymous,Tertiary Referral Centre or University Hospital,1000-2000,24,Mixed ICU,,Consultant,5-10 years,Anaesthesia,120-139/beats per min,Rate control,Amiodarone,,Supplement electrolytes (magnesium and/or potassium) to a high normal level,>4.5 mmol/l,1.0-1.2 mmol/l,ICU drug policy,,New onset AF within 72 hours,I do not use stroke risk scores routinely in critically ill patients with new onset AF to assess the need for anticoagulation,Subcutaneous Low Molecular Weight heparin in therapeutic dose,I regularly perform or request transthoracic echocardiography,Yes,"Amiodarone,DC cardioversion,ß-blocker",,Yes
31/10/2016 20:08,31/10/2016 20:16,IP Address,86.157.163.157,100,445,TRUE,31/10/2016 20:16,R_2QMY3W6ubf1LucN,,,,,52.98330688,-0.016693115,anonymous,District General Hospital,500-1000,10,Mixed ICU,,Consultant,1-3 years,Anaesthesia,100-119/beats per min,Rhythm control,Amiodarone,,Supplement electrolytes to a high normal level and anti-arrhythmics,>4.5 mmol/l,1.0-1.2 mmol/l,"Pharmacokinetic advantages,Pharmacodynamic properties",,I do not regularly anti-coagulate critically ill patients with new-onset fast AF,Modified risk scores should be developed for critically ill patients with new-onset atrial fibrillation,I do not regularly anti-coagulate critically ill patients with new onset fast AF,I regularly perform or request transthoracic echocardiography,No,Amiodarone,,No
31/10/2016 20:11,31/10/2016 20:18,IP Address,82.132.186.216,100,457,TRUE,31/10/2016 20:18,R_2TTWEn4Qfo2PsEc,,,,,51.49639893,-0.122406006,anonymous,District General Hospital,<500,8,Mixed ICU,,Consultant,More than 10 years,Anaesthesia,"Independent of their heart rate I treat all patients who have developed new onset fast AF, even if the blood pressure remains stable",Rhythm control,Amiodarone,,Supplement electrolytes (magnesium and/or potassium) to a high normal level,>4 mmol/l,I do not aim for a specific serum magnesium level,Pharmacodynamic properties,,I do not regularly anti-coagulate critically ill patients with new-onset fast AF,"Stroke risk scores inaccurately reflect the risk of embolic events in critically ill patients with new-onset atrial fibrillation due to prothrombotic changes associated with critical illness,Modified risk scores should be developed for critically ill patients with new-onset atrial fibrillation",I do not regularly anti-coagulate critically ill patients with new onset fast AF,I regularly perform or request transthoracic echocardiography,Yes,"Amiodarone,DC cardioversion,ß-blocker,Digoxin",,Yes
31/10/2016 19:39,31/10/2016 20:19,IP Address,213.1.9.169,100,2400,TRUE,31/10/2016 20:19,R_rrHFgSK7FtPtLhf,,,,,52.08329773,1.166702271,anonymous,Teaching Hospital,500-1000,14,Mixed ICU,,Consultant,More than 10 years,Anaesthesia,120-139/beats per min,Rhythm control,Amiodarone,,DC cardioversion when anti-arrhythmics and electrolyte replacement fail to achieve rate and/or rhythm control,>4.5 mmol/l,1.0-1.2 mmol/l,ICU drug policy,,I do not regularly anti-coagulate critically ill patients with new-onset fast AF,"I do not use stroke risk scores routinely in critically ill patients with new onset AF to assess the need for anticoagulation,Stroke risk scores inaccurately reflect the risk of embolic events in critically ill patients with new-onset atrial fibrillation due to prothrombotic changes associated with critical illness,Modified risk scores should be developed for critically ill patients with new-onset atrial fibrillation","Subcutaneous Low Molecular Weight heparin in therapeutic dose,I do not regularly anti-coagulate critically ill patients with new onset fast AF",I regularly perform or request transthoracic echocardiography,Yes,"Amiodarone,DC cardioversion,ß-blocker",,Yes
31/10/2016 20:16,31/10/2016 20:20,IP Address,82.4.60.198,100,282,TRUE,31/10/2016 20:20,R_2VImCGjav8IgnD1,,,,,50.92219543,-1.000900269,anonymous,District General Hospital,1000-2000,24,Mixed ICU,,Consultant,5-10 years,Anaesthesia,100-119/beats per min,Rhythm control,Amiodarone,,Supplement electrolytes to a high normal level and anti-arrhythmics,>4.5 mmol/l,1.0-1.2 mmol/l,ICU drug policy,,I do not regularly anti-coagulate critically ill patients with new-onset fast AF,Modified risk scores should be developed for critically ill patients with new-onset atrial fibrillation,I do not regularly anti-coagulate critically ill patients with new onset fast AF,I regularly perform or request transthoracic echocardiography,Yes,Amiodarone,,Yes
31/10/2016 19:41,31/10/2016 20:37,IP Address,213.205.198.35,100,3361,TRUE,31/10/2016 20:37,R_Q3rIyoGHmi2uIb7,,,,,51.57650757,-0.397399902,anonymous,Tertiary Referral Centre or University Hospital,1000-2000,17,Specialist ICU (please name specialty):,Neuro,Trainee,5-10 years,Anaesthesia,"Independent of their heart rate I treat all patients who have developed new onset fast AF, even if the blood pressure remains stable",Rhythm control,Amiodarone,,DC cardioversion when anti-arrhythmics and electrolyte replacement fail to achieve rate and/or rhythm control,>4 mmol/l,1.0-1.2 mmol/l,"Pharmacokinetic advantages,Pharmacodynamic properties,Adverse effect profile",,I do not regularly anti-coagulate critically ill patients with new-onset fast AF,I do not use stroke risk scores routinely in critically ill patients with new onset AF to assess the need for anticoagulation,I do not regularly anti-coagulate critically ill patients with new onset fast AF,I do not routinely perform Echocardiography to guide treatment,Yes,"Amiodarone,DC cardioversion,ß-blocker,Digoxin",,No
31/10/2016 20:36,31/10/2016 20:40,IP Address,81.153.97.184,100,194,TRUE,31/10/2016 20:40,R_0uHlQ6XSsdCF1wl,,,,,50.98460388,-1.399002075,anonymous,Tertiary Referral Centre or University Hospital,500-1000,13,Specialist ICU (please name specialty):,Neuro,Consultant,5-10 years,Anaesthesia,120-139/beats per min,Rate control,Amiodarone,,Supplement electrolytes to a high normal level and anti-arrhythmics,>4.5 mmol/l,1.0-1.2 mmol/l,Pharmacokinetic advantages,,I do not regularly anti-coagulate critically ill patients with new-onset fast AF,"I do not use stroke risk scores routinely in critically ill patients with new onset AF to assess the need for anticoagulation,Stroke risk scores inaccurately reflect the risk of embolic events in critically ill patients with new-onset atrial fibrillation due to prothrombotic changes associated with critical illness,Stroke risk scores favour anti-coagulation despite a higher risk of bleeding in critical illness","Intravenous High Molecular Weight heparin in therapeutic dose,I do not regularly anti-coagulate critically ill patients with new onset fast AF",I regularly perform or request transthoracic echocardiography,Yes,"Amiodarone,Digoxin",,Yes
31/10/2016 20:35,31/10/2016 20:42,IP Address,5.198.28.141,100,394,TRUE,31/10/2016 20:42,R_3hyCPVMTdypwU2O,,,,,53.71670532,-0.333297729,anonymous,Teaching Hospital,1000-2000,22,Mixed ICU,,Consultant,5-10 years,Anaesthesia,"Independent of their heart rate I treat all patients who have developed new onset fast AF, even if the blood pressure remains stable",Rate control,Amiodarone,,Supplement electrolytes (magnesium and/or potassium) to a high normal level,>4.5 mmol/l,1.0-1.2 mmol/l,"Pharmacodynamic properties,Adverse effect profile",,I do not regularly anti-coagulate critically ill patients with new-onset fast AF,"I do not use stroke risk scores routinely in critically ill patients with new onset AF to assess the need for anticoagulation,Stroke risk scores inaccurately reflect the risk of embolic events in critically ill patients with new-onset atrial fibrillation due to prothrombotic changes associated with critical illness",Subcutaneous Low Molecular Weight heparin in therapeutic dose,I regularly perform or request transthoracic echocardiography,Yes,"ß-blocker,Digoxin",,Yes
31/10/2016 20:41,31/10/2016 20:48,IP Address,81.155.51.82,100,457,TRUE,31/10/2016 20:48,R_xhWMs8eYEYhEs6t,,,,,50.39639282,-4.138595581,anonymous,Teaching Hospital,1000-2000,26,Mixed ICU,,Consultant,More than 10 years,Anaesthesia,100-119/beats per min,Rhythm control,Amiodarone,,Supplement electrolytes (magnesium and/or potassium) to a high normal level,>4.5 mmol/l,>1.2 mmol/l,Pharmacodynamic properties,,New onset AF within 48 hours,I do not use stroke risk scores routinely in critically ill patients with new onset AF to assess the need for anticoagulation,"Intravenous High Molecular Weight heparin in therapeutic dose,Use of novel oral anti-coagulants (NOACs),I do not regularly anti-coagulate critically ill patients with new onset fast AF",I regularly perform or request transthoracic echocardiography,Yes,Amiodarone,,Yes
31/10/2016 20:47,31/10/2016 20:53,IP Address,81.135.222.65,100,350,TRUE,31/10/2016 20:53,R_2QGoOCLLWKDAB1H,,,,,54.68330383,-1.600006104,anonymous,District General Hospital,500-1000,10,Mixed ICU,,Consultant,More than 10 years,Anaesthesia,120-139/beats per min,Rate control,Amiodarone,,Supplement electrolytes to a high normal level and anti-arrhythmics,>4.5 mmol/l,0.75-1 mmol/l,Pharmacodynamic properties,,I do not regularly anti-coagulate critically ill patients with new-onset fast AF,I do not use stroke risk scores routinely in critically ill patients with new onset AF to assess the need for anticoagulation,I do not regularly anti-coagulate critically ill patients with new onset fast AF,I regularly perform or request transthoracic echocardiography,No,Amiodarone,,No
31/10/2016 19:12,31/10/2016 20:56,IP Address,81.154.16.14,100,6239,TRUE,31/10/2016 20:56,R_ahMOWoVtXaBKUiR,,,,,53.75,-2.483306885,anonymous,District General Hospital,1000-2000,24,Mixed ICU,,Consultant,More than 10 years,Anaesthesia,100-119/beats per min,Rate control,"Other anti-arrhythmics (e. g. Verapamil, sotalol): please specify:",Magnesium,DC cardioversion when anti-arrhythmics and electrolyte replacement fail to achieve rate and/or rhythm control,>4.5 mmol/l,>1.2 mmol/l,"Pharmacokinetic advantages,Pharmacodynamic properties,Adverse effect profile",,I do not regularly anti-coagulate critically ill patients with new-onset fast AF,I do not use stroke risk scores routinely in critically ill patients with new onset AF to assess the need for anticoagulation,Subcutaneous Low Molecular Weight heparin in therapeutic dose,I regularly perform or request transthoracic echocardiography,Yes,"DC cardioversion,ß-blocker",,No
31/10/2016 20:52,31/10/2016 21:00,IP Address,82.13.100.44,100,521,TRUE,31/10/2016 21:00,R_2alR4yXttA5esEZ,,,,,51.51420593,-0.093093872,anonymous,Tertiary Referral Centre or University Hospital,1000-2000,21,Mixed ICU,,SAS,3-5 years,Anaesthesia,120-139/beats per min,Rate control,ß-blocker,,Supplement electrolytes to a high normal level and anti-arrhythmics,>4 mmol/l,I do not aim for a specific serum magnesium level,"Availability from hospital pharmacy,ICU drug policy,Cost,Pharmacokinetic advantages,Pharmacodynamic properties,Adverse effect profile",,New onset AF within 24 hours,"I do not use stroke risk scores routinely in critically ill patients with new onset AF to assess the need for anticoagulation,Stroke risk scores inaccurately reflect the risk of embolic events in critically ill patients with new-onset atrial fibrillation due to prothrombotic changes associated with critical illness",Subcutaneous Low Molecular Weight heparin in therapeutic dose,I do not routinely perform Echocardiography to guide treatment,Yes,"Amiodarone,DC cardioversion,ß-blocker,Other anti-arrhythmics (e. g. verapamil, sotalol): Please specify:",High-dose magnesium,Yes
31/10/2016 20:52,31/10/2016 21:01,IP Address,86.177.83.17,100,532,TRUE,31/10/2016 21:01,R_3lWcLPAwpJ52KYP,,,,,52.13160706,-1.907592773,anonymous,District General Hospital,1000-2000,16,Mixed ICU,,Consultant,More than 10 years,Anaesthesia,120-139/beats per min,Rate control,ß-blocker,,Supplement electrolytes to a high normal level and anti-arrhythmics,>4 mmol/l,1.0-1.2 mmol/l,Pharmacodynamic properties,,I do not regularly anti-coagulate critically ill patients with new-onset fast AF,I do not use stroke risk scores routinely in critically ill patients with new onset AF to assess the need for anticoagulation,I do not regularly anti-coagulate critically ill patients with new onset fast AF,I regularly perform or request transthoracic echocardiography,Yes,Amiodarone,,Yes
31/10/2016 21:01,31/10/2016 21:04,IP Address,78.144.95.143,100,174,TRUE,31/10/2016 21:04,R_NVc8zxVpITi8BSF,,,,,53.16670227,-3.133300781,anonymous,Tertiary Referral Centre or University Hospital,1000-2000,31,Mixed ICU,,Consultant,More than 10 years,Anaesthesia,120-139/beats per min,Rate control,Amiodarone,,Supplement electrolytes to a high normal level and anti-arrhythmics,>4.5 mmol/l,1.0-1.2 mmol/l,"ICU drug policy,Pharmacodynamic properties",,New onset AF within 72 hours,"I do not use stroke risk scores routinely in critically ill patients with new onset AF to assess the need for anticoagulation,Stroke risk scores inaccurately reflect the risk of embolic events in critically ill patients with new-onset atrial fibrillation due to prothrombotic changes associated with critical illness,Stroke risk scores favour anti-coagulation despite a higher risk of bleeding in critical illness,Modified risk scores should be developed for critically ill patients with new-onset atrial fibrillation","Intravenous High Molecular Weight heparin in therapeutic dose,Subcutaneous Low Molecular Weight heparin in therapeutic dose",I only regularly perform Echocardiography in patients with cardiac history,Yes,"Amiodarone,ß-blocker,Diltiazem",,No
31/10/2016 20:59,31/10/2016 21:04,IP Address,146.185.29.210,100,306,TRUE,31/10/2016 21:04,R_Ao21R2veoAFJlKN,,,,,51.49639893,-0.122406006,anonymous,District General Hospital,500-1000,14,Mixed ICU,,Trainee,3-5 years,Emergency Medicine,"Independent of their heart rate I treat all patients who have developed new onset fast AF, even if the blood pressure remains stable",Rhythm control,Amiodarone,,Supplement electrolytes to a high normal level and anti-arrhythmics,>4.5 mmol/l,>1.2 mmol/l,Adverse effect profile,,New onset AF within 48 hours,I do not use stroke risk scores routinely in critically ill patients with new onset AF to assess the need for anticoagulation,I do not regularly anti-coagulate critically ill patients with new onset fast AF,I only regularly perform Echocardiography in patients with cardiac history,Yes,"Amiodarone,DC cardioversion,Other anti-arrhythmics (e. g. verapamil, sotalol): Please specify:",Magnesium,Yes
31/10/2016 21:00,31/10/2016 21:06,IP Address,174.69.5.57,100,382,TRUE,31/10/2016 21:06,R_1pEyTyg7eGmtNtE,,,,,30.39810181,-86.45629883,anonymous,District General Hospital,500-1000,7 ICU flexing to 14 HDU,Mixed ICU,,Consultant,More than 10 years,Anaesthesia,"Independent of their heart rate I treat all patients who have developed new onset fast AF, even if the blood pressure remains stable",Rhythm control,Amiodarone,,Supplement electrolytes to a high normal level and anti-arrhythmics,>5 mmol/l,I do not aim for a specific serum magnesium level,"Availability from hospital pharmacy,Cost,Pharmacodynamic properties",,New onset AF within 48 hours,"I regularly calculate a risk score (e. g. CHAD2, CHA2DS2-VASc) to assess the need for anti-coagulation,Modified risk scores should be developed for critically ill patients with new-onset atrial fibrillation","Intravenous High Molecular Weight heparin in therapeutic dose,Subcutaneous Low Molecular Weight heparin in therapeutic dose",I regularly perform or request transthoracic echocardiography,Yes,"Amiodarone,DC cardioversion,ß-blocker",,Yes
31/10/2016 21:08,31/10/2016 21:15,IP Address,82.6.51.90,100,398,TRUE,31/10/2016 21:15,R_1CkG4qxumkWOtmo,,,,,51.75,-1.25,anonymous,Tertiary Referral Centre or University Hospital,I do not know,24,Mixed ICU,,Trainee,1-3 years,Anaesthesia,140-159/beats per min,Rate control,Amiodarone,,Supplement electrolytes to a high normal level and anti-arrhythmics,>4 mmol/l,1.0-1.2 mmol/l,ICU drug policy,,New onset AF within 24 hours,I do not use stroke risk scores routinely in critically ill patients with new onset AF to assess the need for anticoagulation,Subcutaneous Low Molecular Weight heparin in therapeutic dose,I do not routinely perform Echocardiography to guide treatment,Yes,Amiodarone,,Yes
31/10/2016 21:10,31/10/2016 21:15,IP Address,86.146.182.237,100,301,TRUE,31/10/2016 21:15,R_1ODGRiHiPwMK9xr,,,,,52.96670532,-1.166702271,anonymous,Tertiary Referral Centre or University Hospital,1000-2000,60,Mixed ICU,,Consultant,More than 10 years,Anaesthesia,"Independent of their heart rate I treat all patients who have developed new onset fast AF, even if the blood pressure remains stable",Rhythm control,"Other anti-arrhythmics (e. g. Verapamil, sotalol): please specify:",Amiodarone and Magnesium ,Supplement electrolytes to a high normal level and anti-arrhythmics,>4.5 mmol/l,>1.2 mmol/l,"Availability from hospital pharmacy,ICU drug policy,Pharmacokinetic advantages,Pharmacodynamic properties",,I do not regularly anti-coagulate critically ill patients with new-onset fast AF,I do not use stroke risk scores routinely in critically ill patients with new onset AF to assess the need for anticoagulation,Intravenous High Molecular Weight heparin in therapeutic dose,I do not routinely perform Echocardiography to guide treatment,Yes,"Amiodarone,ß-blocker,Digoxin,Other anti-arrhythmics (e. g. verapamil, sotalol): Please specify:",Magnesium,No
31/10/2016 21:21,31/10/2016 21:25,IP Address,85.189.119.163,100,235,TRUE,31/10/2016 21:25,R_1N3rgUuja6w7YA6,,,,,51.49639893,-0.122406006,anonymous,Tertiary Referral Centre or University Hospital,>2000,44,Specialist ICU (please name specialty):,"Burns, Neuro, Trauma",Trainee,5-10 years,Anaesthesia,140-159/beats per min,I have no primary treatment goal in these patients,Amiodarone,,Supplement electrolytes (magnesium and/or potassium) to a high normal level,>4.5 mmol/l,>1.2 mmol/l,ICU drug policy,,I do not regularly anti-coagulate critically ill patients with new-onset fast AF,"I do not use stroke risk scores routinely in critically ill patients with new onset AF to assess the need for anticoagulation,Modified risk scores should be developed for critically ill patients with new-onset atrial fibrillation",I do not regularly anti-coagulate critically ill patients with new onset fast AF,I regularly perform or request transthoracic echocardiography,No,"Amiodarone,DC cardioversion,ß-blocker",,Yes
31/10/2016 21:23,31/10/2016 21:34,IP Address,51.9.138.130,100,663,TRUE,31/10/2016 21:34,R_29hUoCXqTHF3aV1,,,,,53.45509338,-2.26449585,anonymous,Tertiary Referral Centre or University Hospital,I do not know,19,Mixed ICU,,Trainee,5-10 years,Anaesthesia,"Independent of their heart rate I treat all patients who have developed new onset fast AF, even if the blood pressure remains stable",Rhythm control,Amiodarone,,Supplement electrolytes (magnesium and/or potassium) to a high normal level,>4.5 mmol/l,0.75-1 mmol/l,Pharmacodynamic properties,,I do not regularly anti-coagulate critically ill patients with new-onset fast AF,"I do not use stroke risk scores routinely in critically ill patients with new onset AF to assess the need for anticoagulation,Stroke risk scores inaccurately reflect the risk of embolic events in critically ill patients with new-onset atrial fibrillation due to prothrombotic changes associated with critical illness,Modified risk scores should be developed for critically ill patients with new-onset atrial fibrillation",Subcutaneous Low Molecular Weight heparin in therapeutic dose,I do not routinely perform Echocardiography to guide treatment,Yes,"Amiodarone,DC cardioversion",,No
31/10/2016 21:30,31/10/2016 21:37,IP Address,86.157.145.64,100,381,TRUE,31/10/2016 21:37,R_3isSk2Zxg015AZq,,,,,51.88330078,0.899993896,anonymous,District General Hospital,500-1000,13,Mixed ICU,,Consultant,More than 10 years,Anaesthesia,100-119/beats per min,Rhythm control,Amiodarone,,Supplement electrolytes to a high normal level and anti-arrhythmics,>4.5 mmol/l,1.0-1.2 mmol/l,"Pharmacodynamic properties,Adverse effect profile",,I do not regularly anti-coagulate critically ill patients with new-onset fast AF,"I do not use stroke risk scores routinely in critically ill patients with new onset AF to assess the need for anticoagulation,Modified risk scores should be developed for critically ill patients with new-onset atrial fibrillation","Intravenous High Molecular Weight heparin in therapeutic dose,Subcutaneous Low Molecular Weight heparin in therapeutic dose",I do not routinely perform Echocardiography to guide treatment,Yes,"Amiodarone,DC cardioversion,ß-blocker",,Yes
31/10/2016 21:31,31/10/2016 21:38,IP Address,82.14.96.53,100,432,TRUE,31/10/2016 21:38,R_UyeWj9ojGhqEU93,,,,,51.08329773,-1.350006104,anonymous,District General Hospital,500-1000,16,Mixed ICU,,Consultant,More than 10 years,Anaesthesia,"Independent of their heart rate I treat all patients who have developed new onset fast AF, even if the blood pressure remains stable",Rhythm control,Amiodarone,,Supplement electrolytes to a high normal level and anti-arrhythmics,>4.5 mmol/l,>1.2 mmol/l,"Pharmacokinetic advantages,Pharmacodynamic properties,Adverse effect profile",,New onset AF within 72 hours,Modified risk scores should be developed for critically ill patients with new-onset atrial fibrillation,"Subcutaneous Low Molecular Weight heparin in therapeutic dose,Use of novel oral anti-coagulants (NOACs)","I regularly perform or request transthoracic echocardiography,I do not routinely perform Echocardiography to guide treatment",Yes,"Amiodarone,ß-blocker,Flecainide",,Yes
31/10/2016 21:35,31/10/2016 21:39,IP Address,81.129.231.62,100,265,TRUE,31/10/2016 21:39,R_3nJeF7qMfM53GS2,,,,,53.48330688,-2.333297729,anonymous,District General Hospital,500-1000,18,Mixed ICU,,Consultant,More than 10 years,Anaesthesia,120-139/beats per min,Rate control,Amiodarone,,Supplement electrolytes (magnesium and/or potassium) to a high normal level,>4.5 mmol/l,1.0-1.2 mmol/l,Adverse effect profile,,New onset AF within 72 hours,"I do not use stroke risk scores routinely in critically ill patients with new onset AF to assess the need for anticoagulation,Stroke risk scores inaccurately reflect the risk of embolic events in critically ill patients with new-onset atrial fibrillation due to prothrombotic changes associated with critical illness,Stroke risk scores favour anti-coagulation despite a higher risk of bleeding in critical illness",Subcutaneous Low Molecular Weight heparin in therapeutic dose,I regularly perform or request transthoracic echocardiography,Yes,Amiodarone,,No
31/10/2016 21:38,31/10/2016 21:43,IP Address,77.98.241.185,100,314,TRUE,31/10/2016 21:44,R_ufUuMierWuPEiAx,,,,,55.00320435,-1.633895874,anonymous,Tertiary Referral Centre or University Hospital,I do not know,18,Predominantly surgical,,Trainee,1-3 years,Acute medicine,"Independent of their heart rate I treat all patients who have developed new onset fast AF, even if the blood pressure remains stable",Rate control,Amiodarone,,Supplement electrolytes to a high normal level and anti-arrhythmics,>4.5 mmol/l,1.0-1.2 mmol/l,Adverse effect profile,,I do not regularly anti-coagulate critically ill patients with new-onset fast AF,Modified risk scores should be developed for critically ill patients with new-onset atrial fibrillation,I do not regularly anti-coagulate critically ill patients with new onset fast AF,I regularly perform or request transthoracic echocardiography,Yes,ß-blocker,,Yes
31/10/2016 21:40,31/10/2016 21:47,IP Address,80.6.102.190,100,396,TRUE,31/10/2016 21:47,R_XBSFNSDxG4sNc1H,,,,,51.51420593,-0.093093872,anonymous,Tertiary Referral Centre or University Hospital,>2000,4,Predominantly medical,,Consultant,5-10 years,Acute medicine,"Independent of their heart rate I treat all patients who have developed new onset fast AF, even if the blood pressure remains stable",Rate control,Amiodarone,,Supplement electrolytes to a high normal level and anti-arrhythmics,>4.5 mmol/l,>1.2 mmol/l,Pharmacodynamic properties,,I do not regularly anti-coagulate critically ill patients with new-onset fast AF,"I do not use stroke risk scores routinely in critically ill patients with new onset AF to assess the need for anticoagulation,Modified risk scores should be developed for critically ill patients with new-onset atrial fibrillation",I do not regularly anti-coagulate critically ill patients with new onset fast AF,I regularly perform or request transthoracic echocardiography,Yes,ß-blocker,,Yes
31/10/2016 21:46,31/10/2016 21:57,IP Address,86.20.41.238,100,634,TRUE,31/10/2016 21:57,R_AhNXD9BmEyL1INr,,,,,50.86140442,-0.120407104,anonymous,Teaching Hospital,>2000,43,Mixed ICU,,Consultant,More than 10 years,Anaesthesia,"Independent of their heart rate I treat all patients who have developed new onset fast AF, even if the blood pressure remains stable",Rhythm control,Amiodarone,,Supplement electrolytes (magnesium and/or potassium) to a high normal level,>4.5 mmol/l,1.0-1.2 mmol/l,"Pharmacokinetic advantages,Pharmacodynamic properties,Adverse effect profile",,I do not regularly anti-coagulate critically ill patients with new-onset fast AF,I do not use stroke risk scores routinely in critically ill patients with new onset AF to assess the need for anticoagulation,I do not regularly anti-coagulate critically ill patients with new onset fast AF,"I regularly perform or request transthoracic echocardiography,I do not routinely perform Echocardiography to guide treatment,I only regularly perform Echocardiography in patients with cardiac history",No,Amiodarone,,No
31/10/2016 21:41,31/10/2016 22:00,IP Address,85.115.54.202,100,1118,TRUE,31/10/2016 22:00,R_T5k74cvmXyCl7wZ,,,,,51.49639893,-0.122406006,anonymous,District General Hospital,<500,9,Mixed ICU,,Trainee,3-5 years,Anaesthesia,"Independent of their heart rate I treat all patients who have developed new onset fast AF, even if the blood pressure remains stable",Rate control,Amiodarone,,Supplement electrolytes to a high normal level and anti-arrhythmics,>4 mmol/l,1.0-1.2 mmol/l,Pharmacodynamic properties,,I do not regularly anti-coagulate critically ill patients with new-onset fast AF,"I do not use stroke risk scores routinely in critically ill patients with new onset AF to assess the need for anticoagulation,Stroke risk scores inaccurately reflect the risk of embolic events in critically ill patients with new-onset atrial fibrillation due to prothrombotic changes associated with critical illness",I do not regularly anti-coagulate critically ill patients with new onset fast AF,I only regularly perform Echocardiography in patients with cardiac history,Yes,Digoxin,,Yes
31/10/2016 22:03,31/10/2016 22:07,IP Address,213.205.252.211,100,247,TRUE,31/10/2016 22:07,R_u8oEOZNksWMeShb,,,,,52.6000061,-2,anonymous,District General Hospital,I do not know,28,Mixed ICU,,Trainee,3-5 years,Anaesthesia,>160/beats per min,Rate control,Amiodarone,,DC cardioversion when anti-arrhythmics and electrolyte replacement fail to achieve rate and/or rhythm control,>4 mmol/l,I do not aim for a specific serum magnesium level,Pharmacodynamic properties,,New onset AF within 48 hours,"I regularly calculate a risk score (e. g. CHAD2, CHA2DS2-VASc) to assess the need for anti-coagulation",Subcutaneous Low Molecular Weight heparin in therapeutic dose,I regularly perform or request transthoracic echocardiography,Yes,"Amiodarone,DC cardioversion,ß-blocker,Other anti-arrhythmics (e. g. verapamil, sotalol): Please specify:",Metorolol,No
31/10/2016 21:08,31/10/2016 22:10,IP Address,31.185.238.55,100,3695,TRUE,31/10/2016 22:10,R_1KviNoYAuHsgFGI,,,,,52.46670532,-1.916702271,anonymous,Tertiary Referral Centre or University Hospital,>2000,65,Mixed ICU,,Consultant,5-10 years,Acute medicine,100-119/beats per min,Rate control,Amiodarone,,Supplement electrolytes to a high normal level and anti-arrhythmics,>4 mmol/l,1.0-1.2 mmol/l,ICU drug policy,,I do not regularly anti-coagulate critically ill patients with new-onset fast AF,I do not use stroke risk scores routinely in critically ill patients with new onset AF to assess the need for anticoagulation,I do not regularly anti-coagulate critically ill patients with new onset fast AF,I regularly perform or request transthoracic echocardiography,Yes,ß-blocker,,No
31/10/2016 22:07,31/10/2016 22:10,IP Address,86.140.237.251,100,194,TRUE,31/10/2016 22:10,R_3M047Q6Qbbimch4,,,,,50.63330078,-3.333297729,anonymous,District General Hospital,1000-2000,16,Mixed ICU,,Consultant,More than 10 years,Anaesthesia,140-159/beats per min,Rate control,Amiodarone,,Supplement electrolytes to a high normal level and anti-arrhythmics,>4.5 mmol/l,1.0-1.2 mmol/l,"Other, please specify:",The only one that may work,I do not regularly anti-coagulate critically ill patients with new-onset fast AF,"I do not use stroke risk scores routinely in critically ill patients with new onset AF to assess the need for anticoagulation,Stroke risk scores inaccurately reflect the risk of embolic events in critically ill patients with new-onset atrial fibrillation due to prothrombotic changes associated with critical illness,Modified risk scores should be developed for critically ill patients with new-onset atrial fibrillation",I do not regularly anti-coagulate critically ill patients with new onset fast AF,I regularly perform or request transthoracic echocardiography,Yes,"Amiodarone,ß-blocker,Digoxin",,Yes
31/10/2016 22:07,31/10/2016 22:11,IP Address,86.170.32.142,100,237,TRUE,31/10/2016 22:11,R_9LDMbgDkHffxJMR,,,,,56.08979797,-3.910903931,anonymous,District General Hospital,1000-2000,19,Mixed ICU,,Consultant,More than 10 years,Anaesthesia,140-159/beats per min,Rate control,Amiodarone,,Supplement electrolytes to a high normal level and anti-arrhythmics,>4.5 mmol/l,1.0-1.2 mmol/l,Pharmacodynamic properties,,I do not regularly anti-coagulate critically ill patients with new-onset fast AF,I do not use stroke risk scores routinely in critically ill patients with new onset AF to assess the need for anticoagulation,I do not regularly anti-coagulate critically ill patients with new onset fast AF,I do not routinely perform Echocardiography to guide treatment,No,Amiodarone,,No
31/10/2016 22:08,31/10/2016 22:12,IP Address,86.186.153.22,100,235,TRUE,31/10/2016 22:12,R_3hoJ2uPhkuyVs6K,,,,,51.44410706,-3.186004639,anonymous,District General Hospital,<500,7,Predominantly medical,,Consultant,More than 10 years,Anaesthesia,"Independent of their heart rate I treat all patients who have developed new onset fast AF, even if the blood pressure remains stable",Rhythm control,Amiodarone,,Supplement electrolytes to a high normal level and anti-arrhythmics,>4 mmol/l,0.75-1 mmol/l,"Availability from hospital pharmacy,Adverse effect profile,Other, please specify:",hallowed tradition,I do not regularly anti-coagulate critically ill patients with new-onset fast AF,"I do not use stroke risk scores routinely in critically ill patients with new onset AF to assess the need for anticoagulation,Modified risk scores should be developed for critically ill patients with new-onset atrial fibrillation",Subcutaneous Low Molecular Weight heparin in therapeutic dose,I do not routinely perform Echocardiography to guide treatment,Yes,"Amiodarone,Other anti-arrhythmics (e. g. verapamil, sotalol): Please specify:",fluid boluses,No
31/10/2016 22:07,31/10/2016 22:12,IP Address,213.94.199.81,100,309,TRUE,31/10/2016 22:12,R_3R1q1eGea2r1KZn,,,,,53.34779358,-6.25970459,anonymous,Tertiary Referral Centre or University Hospital,1000-2000,25,Mixed ICU,,Consultant,More than 10 years,Intensive Care Medicine only,120-139/beats per min,I have no primary treatment goal in these patients,Amiodarone,,DC cardioversion when anti-arrhythmics and electrolyte replacement fail to achieve rate and/or rhythm control,>4 mmol/l,1.0-1.2 mmol/l,"Other, please specify:",Clinical assessment ,I do not regularly anti-coagulate critically ill patients with new-onset fast AF,"I do not use stroke risk scores routinely in critically ill patients with new onset AF to assess the need for anticoagulation,Stroke risk scores inaccurately reflect the risk of embolic events in critically ill patients with new-onset atrial fibrillation due to prothrombotic changes associated with critical illness,Stroke risk scores favour anti-coagulation despite a higher risk of bleeding in critical illness,Modified risk scores should be developed for critically ill patients with new-onset atrial fibrillation",I do not regularly anti-coagulate critically ill patients with new onset fast AF,I regularly perform or request transthoracic echocardiography,Yes,"DC cardioversion,ß-blocker",,Yes
31/10/2016 22:12,31/10/2016 22:16,IP Address,151.227.71.172,100,258,TRUE,31/10/2016 22:16,R_3QJGh3MhZEYi81u,,,,,51.58329773,-2.983306885,anonymous,District General Hospital,500-1000,16,Mixed ICU,,Consultant,5-10 years,Anaesthesia,140-159/beats per min,Rhythm control,Amiodarone,,Supplement electrolytes to a high normal level and anti-arrhythmics,>4.5 mmol/l,1.0-1.2 mmol/l,ICU drug policy,,I do not regularly anti-coagulate critically ill patients with new-onset fast AF,I do not use stroke risk scores routinely in critically ill patients with new onset AF to assess the need for anticoagulation,Subcutaneous Low Molecular Weight heparin in therapeutic dose,I regularly perform or request transthoracic echocardiography,Yes,Amiodarone,,Yes
31/10/2016 22:04,31/10/2016 22:23,IP Address,81.141.77.137,100,1155,TRUE,31/10/2016 22:23,R_1mRhXjaZkLHfmSV,,,,,51.61669922,0.416702271,anonymous,District General Hospital,<500,11,Mixed ICU,,Consultant,More than 10 years,Anaesthesia,"Independent of their heart rate I treat all patients who have developed new onset fast AF, even if the blood pressure remains stable",Rate control,Amiodarone,,Supplement electrolytes to a high normal level and anti-arrhythmics,>4.5 mmol/l,1.0-1.2 mmol/l,"Availability from hospital pharmacy,Pharmacokinetic advantages,Adverse effect profile",,I do not regularly anti-coagulate critically ill patients with new-onset fast AF,"I regularly calculate a risk score (e. g. CHAD2, CHA2DS2-VASc) to assess the need for anti-coagulation,Modified risk scores should be developed for critically ill patients with new-onset atrial fibrillation","Subcutaneous Low Molecular Weight heparin in therapeutic dose,Use of warfarin,I do not regularly anti-coagulate critically ill patients with new onset fast AF",I do not routinely perform Echocardiography to guide treatment,Yes,Flecainide,,No
31/10/2016 22:14,31/10/2016 22:26,IP Address,194.168.216.98,100,742,TRUE,31/10/2016 22:26,R_1MXRyFbscbeotUI,,,,,50.79670715,-1.083297729,anonymous,District General Hospital,1000-2000,19,Mixed ICU,,Consultant,More than 10 years,Anaesthesia,"Independent of their heart rate I treat all patients who have developed new onset fast AF, even if the blood pressure remains stable",Rhythm control,Amiodarone,,Supplement electrolytes to a high normal level and anti-arrhythmics,>4.5 mmol/l,I do not aim for a specific serum magnesium level,"Pharmacokinetic advantages,Pharmacodynamic properties,Adverse effect profile",,New onset AF within 72 hours,Modified risk scores should be developed for critically ill patients with new-onset atrial fibrillation,"Intravenous High Molecular Weight heparin in therapeutic dose,Subcutaneous Low Molecular Weight heparin in therapeutic dose",I regularly perform or request transthoracic echocardiography,Yes,"Amiodarone,ß-blocker",,Yes
31/10/2016 22:22,31/10/2016 22:26,IP Address,109.153.172.240,100,262,TRUE,31/10/2016 22:26,R_1oAYcmo4VIWQnER,,,,,52.77160645,-1.550292969,anonymous,District General Hospital,<500,10,Mixed ICU,,Consultant,5-10 years,Anaesthesia,120-139/beats per min,Rhythm control,Amiodarone,,Supplement electrolytes (magnesium and/or potassium) to a high normal level,>4 mmol/l,>1.2 mmol/l,Adverse effect profile,,I do not regularly anti-coagulate critically ill patients with new-onset fast AF,I do not use stroke risk scores routinely in critically ill patients with new onset AF to assess the need for anticoagulation,Subcutaneous Low Molecular Weight heparin in therapeutic dose,I regularly perform or request transthoracic echocardiography,Yes,ß-blocker,,Yes
31/10/2016 22:19,31/10/2016 22:29,IP Address,82.16.196.130,100,572,TRUE,31/10/2016 22:29,R_3mefyavppZrNHlg,,,,,50.79670715,-1.083297729,anonymous,District General Hospital,500-1000,10,Mixed ICU,,Consultant,5-10 years,Anaesthesia,120-139/beats per min,Rhythm control,Amiodarone,,Supplement electrolytes to a high normal level and anti-arrhythmics,>4.5 mmol/l,I do not aim for a specific serum magnesium level,Pharmacodynamic properties,,I do not regularly anti-coagulate critically ill patients with new-onset fast AF,"I do not use stroke risk scores routinely in critically ill patients with new onset AF to assess the need for anticoagulation,Stroke risk scores inaccurately reflect the risk of embolic events in critically ill patients with new-onset atrial fibrillation due to prothrombotic changes associated with critical illness,Stroke risk scores favour anti-coagulation despite a higher risk of bleeding in critical illness,Modified risk scores should be developed for critically ill patients with new-onset atrial fibrillation",I do not regularly anti-coagulate critically ill patients with new onset fast AF,I regularly perform or request transthoracic echocardiography,Yes,"Amiodarone,Flecainide",,Yes
31/10/2016 22:21,31/10/2016 22:30,IP Address,86.26.137.84,100,565,TRUE,31/10/2016 22:30,R_2xPhRerhvawR47V,,,,,51.3999939,0.050003052,anonymous,District General Hospital,500-1000,10,Mixed ICU,,Consultant,3-5 years,Anaesthesia,120-139/beats per min,Rhythm control,Amiodarone,,Supplement electrolytes to a high normal level and anti-arrhythmics,>4.5 mmol/l,1.0-1.2 mmol/l,"Pharmacokinetic advantages,Pharmacodynamic properties,Adverse effect profile",,New onset AF within 48 hours,"I regularly calculate a risk score (e. g. CHAD2, CHA2DS2-VASc) to assess the need for anti-coagulation,Stroke risk scores inaccurately reflect the risk of embolic events in critically ill patients with new-onset atrial fibrillation due to prothrombotic changes associated with critical illness","Intravenous High Molecular Weight heparin in therapeutic dose,Subcutaneous Low Molecular Weight heparin in therapeutic dose",I regularly perform or request transthoracic echocardiography,Yes,ß-blocker,,No
31/10/2016 22:33,31/10/2016 22:36,IP Address,94.174.25.176,100,216,TRUE,31/10/2016 22:36,R_1KlEKjhddxn2phQ,,,,,51.44540405,-0.329696655,anonymous,Tertiary Referral Centre or University Hospital,1000-2000,40,Mixed ICU,,Consultant,More than 10 years,Anaesthesia,"Independent of their heart rate I treat all patients who have developed new onset fast AF, even if the blood pressure remains stable",Rhythm control,Amiodarone,,Supplement electrolytes (magnesium and/or potassium) to a high normal level,>4.5 mmol/l,I do not aim for a specific serum magnesium level,Pharmacodynamic properties,,New onset AF within 24 hours,"I do not use stroke risk scores routinely in critically ill patients with new onset AF to assess the need for anticoagulation,Stroke risk scores favour anti-coagulation despite a higher risk of bleeding in critical illness",Intravenous High Molecular Weight heparin in therapeutic dose,I regularly perform or request transoesophageal echocardiography,Yes,Amiodarone,,No
31/10/2016 22:44,31/10/2016 22:50,IP Address,194.176.105.144,100,354,TRUE,31/10/2016 22:50,R_aa6PWektD5qcWYR,,,,,51.51420593,-0.093093872,anonymous,District General Hospital,<500,12,Mixed ICU,,Consultant,More than 10 years,Anaesthesia,120-139/beats per min,Rate control,Amiodarone,,DC cardioversion when anti-arrhythmics and electrolyte replacement fail to achieve rate and/or rhythm control,>4.5 mmol/l,>1.2 mmol/l,Availability from hospital pharmacy,,I do not regularly anti-coagulate critically ill patients with new-onset fast AF,"I do not use stroke risk scores routinely in critically ill patients with new onset AF to assess the need for anticoagulation,Modified risk scores should be developed for critically ill patients with new-onset atrial fibrillation","Subcutaneous Low Molecular Weight heparin in therapeutic dose,I do not regularly anti-coagulate critically ill patients with new onset fast AF",I regularly perform or request transthoracic echocardiography,Yes,"Amiodarone,DC cardioversion,Other anti-arrhythmics (e. g. verapamil, sotalol): Please specify:",Electrolytes,No
31/10/2016 22:51,31/10/2016 22:57,IP Address,109.158.10.39,100,363,TRUE,31/10/2016 22:57,R_2QSdp8cDXS6tDiW,,,,,54.44030762,-1.396606445,anonymous,Tertiary Referral Centre or University Hospital,1000-2000,16,Mixed ICU,,Consultant,More than 10 years,Anaesthesia,"Independent of their heart rate I treat all patients who have developed new onset fast AF, even if the blood pressure remains stable",Rate control,Amiodarone,,Supplement electrolytes to a high normal level and anti-arrhythmics,>4.5 mmol/l,1.0-1.2 mmol/l,Pharmacodynamic properties,,I do not regularly anti-coagulate critically ill patients with new-onset fast AF,I do not use stroke risk scores routinely in critically ill patients with new onset AF to assess the need for anticoagulation,I do not regularly anti-coagulate critically ill patients with new onset fast AF,I do not routinely perform Echocardiography to guide treatment,Yes,"Amiodarone,Digoxin",,No
31/10/2016 22:59,31/10/2016 23:06,IP Address,1.128.97.62,100,389,TRUE,31/10/2016 23:06,R_10GU7mbtoXa39Qx,,,,,-27.47099304,153.024292,anonymous,District General Hospital,500-1000,12,Mixed ICU,,Trainee,1-3 years,Anaesthesia,120-139/beats per min,Rhythm control,Amiodarone,,Supplement electrolytes to a high normal level and anti-arrhythmics,>4.5 mmol/l,1.0-1.2 mmol/l,"Availability from hospital pharmacy,ICU drug policy,Pharmacodynamic properties,Adverse effect profile",,Before DC cardioversion,"I regularly calculate a risk score (e. g. CHAD2, CHA2DS2-VASc) to assess the need for anti-coagulation,Modified risk scores should be developed for critically ill patients with new-onset atrial fibrillation","Intravenous High Molecular Weight heparin in therapeutic dose,Subcutaneous Low Molecular Weight heparin in therapeutic dose,Use of warfarin",I regularly perform or request transthoracic echocardiography,Yes,"DC cardioversion,ß-blocker,Flecainide",,Yes
31/10/2016 23:03,31/10/2016 23:07,IP Address,82.2.80.199,100,255,TRUE,31/10/2016 23:07,R_1AdE68DG7OIRE8F,,,,,51.44340515,-0.14680481,anonymous,Tertiary Referral Centre or University Hospital,1000-2000,50,Mixed ICU,,Consultant,5-10 years,Emergency Medicine,120-139/beats per min,I have no primary treatment goal in these patients,Amiodarone,,Supplement electrolytes (magnesium and/or potassium) to a high normal level,>4.5 mmol/l,>1.2 mmol/l,Adverse effect profile,,New onset AF within 24 hours,Modified risk scores should be developed for critically ill patients with new-onset atrial fibrillation,Intravenous High Molecular Weight heparin in therapeutic dose,I regularly perform or request transthoracic echocardiography,Yes,Amiodarone,,Yes
31/10/2016 18:31,31/10/2016 23:36,IP Address,82.32.120.76,100,18342,TRUE,31/10/2016 23:36,R_QifR9KdXBwJozgl,,,,,52.58329773,-2.133300781,anonymous,Teaching Hospital,>2000,90,Specialist ICU (please name specialty):,"cardiac, neuro, burns, liver",Trainee,3-5 years,Anaesthesia,"Independent of their heart rate I treat all patients who have developed new onset fast AF, even if the blood pressure remains stable",Rate control,Digoxin,,Supplement electrolytes (magnesium and/or potassium) to a high normal level,>4.5 mmol/l,1.0-1.2 mmol/l,"Availability from hospital pharmacy,Pharmacokinetic advantages,Adverse effect profile",,New onset AF within 48 hours,Modified risk scores should be developed for critically ill patients with new-onset atrial fibrillation,Subcutaneous Low Molecular Weight heparin in therapeutic dose,"I do not routinely perform Echocardiography to guide treatment,I only regularly perform Echocardiography in patients with cardiac history",Yes,ß-blocker,,Yes
31/10/2016 23:52,31/10/2016 23:58,IP Address,87.114.17.66,100,357,TRUE,31/10/2016 23:58,R_YYs4vrrQwttybkJ,,,,,51.49639893,-0.122406006,anonymous,Tertiary Referral Centre or University Hospital,1000-2000,38,Mixed ICU,,Consultant,More than 10 years,Anaesthesia,120-139/beats per min,Rate control,Amiodarone,,Supplement electrolytes to a high normal level and anti-arrhythmics,>4.5 mmol/l,1.0-1.2 mmol/l,"Availability from hospital pharmacy,ICU drug policy,Cost,Pharmacokinetic advantages,Pharmacodynamic properties,Adverse effect profile",,I do not regularly anti-coagulate critically ill patients with new-onset fast AF,Modified risk scores should be developed for critically ill patients with new-onset atrial fibrillation,I do not regularly anti-coagulate critically ill patients with new onset fast AF,I do not routinely perform Echocardiography to guide treatment,Yes,"Amiodarone,DC cardioversion,ß-blocker,Digoxin",,Yes
31/10/2016 23:54,31/10/2016 23:58,IP Address,86.11.185.223,100,291,TRUE,31/10/2016 23:58,R_1InPgXLt973ZPFD,,,,,55.83329773,-4.25,anonymous,Tertiary Referral Centre or University Hospital,500-1000,20,Specialist ICU (please name specialty):,Cardiac,Trainee,5-10 years,Anaesthesia,140-159/beats per min,I have no primary treatment goal in these patients,Amiodarone,,Supplement electrolytes to a high normal level and anti-arrhythmics,>4.5 mmol/l,I do not aim for a specific serum magnesium level,ICU drug policy,,New onset AF within 72 hours,"Stroke risk scores inaccurately reflect the risk of embolic events in critically ill patients with new-onset atrial fibrillation due to prothrombotic changes associated with critical illness,Stroke risk scores favour anti-coagulation despite a higher risk of bleeding in critical illness,Modified risk scores should be developed for critically ill patients with new-onset atrial fibrillation","Subcutaneous Low Molecular Weight heparin in therapeutic dose,Use of novel oral anti-coagulants (NOACs),I do not regularly anti-coagulate critically ill patients with new onset fast AF",I regularly perform or request transthoracic echocardiography,Yes,Amiodarone,,Yes
01/11/2016 00:35,01/11/2016 00:43,IP Address,81.159.6.69,100,476,TRUE,01/11/2016 00:43,R_1n2T7LZTuadcXKZ,,,,,52.24630737,0.711105347,anonymous,District General Hospital,500-1000,9,Predominantly medical,,Consultant,5-10 years,Anaesthesia,"Independent of their heart rate I treat all patients who have developed new onset fast AF, even if the blood pressure remains stable",Rhythm control,"Other anti-arrhythmics (e. g. Verapamil, sotalol): please specify:",Electrolyte correction is the best anti arrhythmic ,Supplement electrolytes to a high normal level and DC cardioversion,>4.5 mmol/l,>1.2 mmol/l,Adverse effect profile,,I do not regularly anti-coagulate critically ill patients with new-onset fast AF,"I do not use stroke risk scores routinely in critically ill patients with new onset AF to assess the need for anticoagulation,Stroke risk scores favour anti-coagulation despite a higher risk of bleeding in critical illness,Modified risk scores should be developed for critically ill patients with new-onset atrial fibrillation",I do not regularly anti-coagulate critically ill patients with new onset fast AF,I do not routinely perform Echocardiography to guide treatment,Yes,Amiodarone,,No
01/11/2016 01:17,01/11/2016 01:25,IP Address,80.1.121.162,100,486,TRUE,01/11/2016 01:25,R_p02CTyXcbeN9Iwp,,,,,53.82449341,-1.509902954,anonymous,Teaching Hospital,I do not know,16,Mixed ICU,,Trainee,1-3 years,Acute medicine,"Independent of their heart rate I treat all patients who have developed new onset fast AF, even if the blood pressure remains stable",Rhythm control,Amiodarone,,DC cardioversion when anti-arrhythmics and electrolyte replacement fail to achieve rate and/or rhythm control,I do not aim for a specific serum potassium level,I do not aim for a specific serum magnesium level,"Other, please specify:",Familiarity ,I do not regularly anti-coagulate critically ill patients with new-onset fast AF,I do not use stroke risk scores routinely in critically ill patients with new onset AF to assess the need for anticoagulation,I do not regularly anti-coagulate critically ill patients with new onset fast AF,I do not routinely perform Echocardiography to guide treatment,Yes,Amiodarone,,Yes
01/11/2016 01:24,01/11/2016 01:28,IP Address,97.76.214.190,100,231,TRUE,01/11/2016 01:28,R_9M0tYqF6MOnIPrH,,,,,27.77879333,-82.68229675,anonymous,Tertiary Referral Centre or University Hospital,>2000,75,Mixed ICU,,Consultant,5-10 years,Anaesthesia,140-159/beats per min,Rhythm control,Amiodarone,,Supplement electrolytes to a high normal level and anti-arrhythmics,>4.5 mmol/l,1.0-1.2 mmol/l,Pharmacokinetic advantages,,New onset AF within 48 hours,I do not use stroke risk scores routinely in critically ill patients with new onset AF to assess the need for anticoagulation,Subcutaneous Low Molecular Weight heparin in therapeutic dose,I regularly perform or request transthoracic echocardiography,Yes,Amiodarone,,Yes
01/11/2016 04:03,01/11/2016 04:06,IP Address,1.152.97.56,100,197,TRUE,01/11/2016 04:06,R_2frG9vq0JHkZXm5,,,,,-37.83329773,145,anonymous,District General Hospital,1000-2000,15,Mixed ICU,,Trainee,5-10 years,Intensive Care Medicine only,120-139/beats per min,Rate control,Amiodarone,,Supplement electrolytes (magnesium and/or potassium) to a high normal level,>4.5 mmol/l,1.0-1.2 mmol/l,"Other, please specify:",Least likely to compromise the acutely unwell patient,New onset AF within 48 hours,I do not use stroke risk scores routinely in critically ill patients with new onset AF to assess the need for anticoagulation,Subcutaneous Low Molecular Weight heparin in therapeutic dose,"I regularly perform or request transthoracic echocardiography,I do not routinely perform Echocardiography to guide treatment",Yes,Diltiazem,,Yes
01/11/2016 04:23,01/11/2016 04:30,IP Address,86.101.126.68,100,422,TRUE,01/11/2016 04:30,R_3pseKTvw8ecNqqU,,,,,47.50669861,19.08360291,anonymous,District General Hospital,500-1000,6,Mixed ICU,,Consultant,More than 10 years,Anaesthesia,120-139/beats per min,Rate control,Amiodarone,,Supplement electrolytes to a high normal level and anti-arrhythmics,>4 mmol/l,>1.2 mmol/l,"Availability from hospital pharmacy,ICU drug policy",,I do not regularly anti-coagulate critically ill patients with new-onset fast AF,I do not use stroke risk scores routinely in critically ill patients with new onset AF to assess the need for anticoagulation,"Subcutaneous Low Molecular Weight heparin in therapeutic dose,I do not regularly anti-coagulate critically ill patients with new onset fast AF",I do not routinely perform Echocardiography to guide treatment,Yes,"Amiodarone,DC cardioversion,ß-blocker,Digoxin",,Yes
01/11/2016 05:46,01/11/2016 05:52,IP Address,86.183.191.142,100,357,TRUE,01/11/2016 05:52,R_t0tKlJyLSHl8WvT,,,,,51.65150452,-0.085006714,anonymous,District General Hospital,500-1000,9,Mixed ICU,,Consultant,5-10 years,Anaesthesia,"Independent of their heart rate I treat all patients who have developed new onset fast AF, even if the blood pressure remains stable",Rate control,Amiodarone,,Supplement electrolytes to a high normal level and anti-arrhythmics,>4.5 mmol/l,1.0-1.2 mmol/l,"Other, please specify:",Habit,I do not regularly anti-coagulate critically ill patients with new-onset fast AF,I do not use stroke risk scores routinely in critically ill patients with new onset AF to assess the need for anticoagulation,I do not regularly anti-coagulate critically ill patients with new onset fast AF,I do not routinely perform Echocardiography to guide treatment,No,"Amiodarone,DC cardioversion,ß-blocker,Digoxin",,No
01/11/2016 06:29,01/11/2016 06:34,IP Address,86.174.109.194,100,346,TRUE,01/11/2016 06:34,R_2ah4KvgKDaAv304,,,,,52.20930481,0.148193359,anonymous,District General Hospital,<500,9,Mixed ICU,,Consultant,More than 10 years,Anaesthesia,"Independent of their heart rate I treat all patients who have developed new onset fast AF, even if the blood pressure remains stable",Rhythm control,Amiodarone,,Supplement electrolytes to a high normal level and anti-arrhythmics,>4.5 mmol/l,0.75-1 mmol/l,Pharmacodynamic properties,,I do not regularly anti-coagulate critically ill patients with new-onset fast AF,"I do not use stroke risk scores routinely in critically ill patients with new onset AF to assess the need for anticoagulation,Modified risk scores should be developed for critically ill patients with new-onset atrial fibrillation",I do not regularly anti-coagulate critically ill patients with new onset fast AF,I do not routinely perform Echocardiography to guide treatment,Yes,Amiodarone,,No
01/11/2016 06:42,01/11/2016 06:48,IP Address,90.202.153.239,100,377,TRUE,01/11/2016 06:48,R_2tKKpVLLKrvcIh3,,,,,53.41670227,-3,anonymous,Tertiary Referral Centre or University Hospital,500-1000,33,Mixed ICU,,Consultant,5-10 years,Surgery,"Independent of their heart rate I treat all patients who have developed new onset fast AF, even if the blood pressure remains stable",Rhythm control,Amiodarone,,Supplement electrolytes (magnesium and/or potassium) to a high normal level,>4.5 mmol/l,1.0-1.2 mmol/l,"Availability from hospital pharmacy,Pharmacokinetic advantages",,I do not regularly anti-coagulate critically ill patients with new-onset fast AF,I do not use stroke risk scores routinely in critically ill patients with new onset AF to assess the need for anticoagulation,"Subcutaneous Low Molecular Weight heparin in therapeutic dose,I do not regularly anti-coagulate critically ill patients with new onset fast AF",I only regularly perform Echocardiography in patients with cardiac history,Yes,"Amiodarone,ß-blocker",,Yes
01/11/2016 06:49,01/11/2016 06:53,IP Address,62.252.201.238,100,231,TRUE,01/11/2016 06:53,R_spNbXUPu6UyWJfH,,,,,51.43330383,-1,anonymous,District General Hospital,I do not know,12,Mixed ICU,,Trainee,1-3 years,Anaesthesia,120-139/beats per min,I have no primary treatment goal in these patients,Amiodarone,,DC cardioversion when anti-arrhythmics and electrolyte replacement fail to achieve rate and/or rhythm control,>4.5 mmol/l,1.0-1.2 mmol/l,"ICU drug policy,Pharmacodynamic properties",,I do not regularly anti-coagulate critically ill patients with new-onset fast AF,I do not use stroke risk scores routinely in critically ill patients with new onset AF to assess the need for anticoagulation,I do not regularly anti-coagulate critically ill patients with new onset fast AF,I only regularly perform Echocardiography in patients with cardiac history,Yes,"Amiodarone,DC cardioversion,Digoxin",,No
01/11/2016 06:57,01/11/2016 07:01,IP Address,86.20.248.161,100,199,TRUE,01/11/2016 07:01,R_sYh4GbpG98NFwMF,,,,,51.39920044,-0.255599976,anonymous,District General Hospital,500-1000,14,Predominantly medical,,Consultant,More than 10 years,Anaesthesia,120-139/beats per min,Rate control,Amiodarone,,Supplement electrolytes to a high normal level and anti-arrhythmics,>4.5 mmol/l,>1.2 mmol/l,ICU drug policy,,I do not regularly anti-coagulate critically ill patients with new-onset fast AF,Stroke risk scores favour anti-coagulation despite a higher risk of bleeding in critical illness,I do not regularly anti-coagulate critically ill patients with new onset fast AF,I do not routinely perform Echocardiography to guide treatment,Yes,Amiodarone,,Yes
01/11/2016 07:18,01/11/2016 07:22,IP Address,101.190.107.144,100,212,TRUE,01/11/2016 07:22,R_2uxE9MSs0MAbq0c,,,,,-33.88330078,151.166687,anonymous,Tertiary Referral Centre or University Hospital,1000-2000,40,Mixed ICU,,Consultant,More than 10 years,Intensive Care Medicine only,"Independent of their heart rate I treat all patients who have developed new onset fast AF, even if the blood pressure remains stable",Rhythm control,Amiodarone,,Supplement electrolytes to a high normal level and anti-arrhythmics,>4.5 mmol/l,1.0-1.2 mmol/l,"Pharmacokinetic advantages,Pharmacodynamic properties",,New onset AF within 24 hours,I do not use stroke risk scores routinely in critically ill patients with new onset AF to assess the need for anticoagulation,Intravenous High Molecular Weight heparin in therapeutic dose,I do not routinely perform Echocardiography to guide treatment,Yes,Amiodarone,,No
01/11/2016 07:28,01/11/2016 07:36,IP Address,5.71.225.188,100,476,TRUE,01/11/2016 07:36,R_1Gvq2Up2UOh0Cwj,,,,,51.60139465,-3.344696045,anonymous,Teaching Hospital,1000-2000,12 level 3,Mixed ICU,,Trainee,5-10 years,Anaesthesia,120-139/beats per min,Rhythm control,Amiodarone,,Supplement electrolytes to a high normal level and anti-arrhythmics,>4.5 mmol/l,1.0-1.2 mmol/l,ICU drug policy,,I do not regularly anti-coagulate critically ill patients with new-onset fast AF,"I do not use stroke risk scores routinely in critically ill patients with new onset AF to assess the need for anticoagulation,Modified risk scores should be developed for critically ill patients with new-onset atrial fibrillation",I do not regularly anti-coagulate critically ill patients with new onset fast AF,I only regularly perform Echocardiography in patients with cardiac history,Yes,"Amiodarone,ß-blocker",,Yes
01/11/2016 07:53,01/11/2016 08:02,IP Address,194.168.216.98,100,508,TRUE,01/11/2016 08:02,R_u8R92hqXEyWUr3b,,,,,50.79670715,-1.083297729,anonymous,District General Hospital,1000-2000,19 level 3 equivalents,Mixed ICU,,Consultant,More than 10 years,Anaesthesia,"Independent of their heart rate I treat all patients who have developed new onset fast AF, even if the blood pressure remains stable",Rhythm control,Amiodarone,,Supplement electrolytes (magnesium and/or potassium) to a high normal level,>4.5 mmol/l,1.0-1.2 mmol/l,"Other, please specify:",It works more than others,I do not regularly anti-coagulate critically ill patients with new-onset fast AF,Stroke risk scores favour anti-coagulation despite a higher risk of bleeding in critical illness,"Use of warfarin,I do not regularly anti-coagulate critically ill patients with new onset fast AF",I regularly perform or request transthoracic echocardiography,Yes,"Amiodarone,ß-blocker",,Yes
01/11/2016 08:08,01/11/2016 08:12,IP Address,86.176.155.30,100,249,TRUE,01/11/2016 08:12,R_3HIjtg8s5Zro1OM,,,,,53.49409485,-2.086593628,anonymous,District General Hospital,500-1000,13,Mixed ICU,,Consultant,5-10 years,Anaesthesia,"Independent of their heart rate I treat all patients who have developed new onset fast AF, even if the blood pressure remains stable",Rate control,ß-blocker,,Supplement electrolytes (magnesium and/or potassium) to a high normal level,>4.5 mmol/l,1.0-1.2 mmol/l,ICU drug policy,,I do not regularly anti-coagulate critically ill patients with new-onset fast AF,I do not use stroke risk scores routinely in critically ill patients with new onset AF to assess the need for anticoagulation,I do not regularly anti-coagulate critically ill patients with new onset fast AF,I regularly perform or request transthoracic echocardiography,Yes,ß-blocker,,Yes
01/11/2016 08:24,01/11/2016 08:29,IP Address,85.115.54.202,100,326,TRUE,01/11/2016 08:29,R_UuvK9xyyJo0q4fL,,,,,51.49639893,-0.122406006,anonymous,Tertiary Referral Centre or University Hospital,500-1000,11,Specialist ICU (please name specialty):,"Cardiology, oncology",Consultant,More than 10 years,Anaesthesia,100-119/beats per min,Rate control,Amiodarone,,Supplement electrolytes to a high normal level and anti-arrhythmics,>4.5 mmol/l,1.0-1.2 mmol/l,"Other, please specify:",Efficacy,I do not regularly anti-coagulate critically ill patients with new-onset fast AF,I do not use stroke risk scores routinely in critically ill patients with new onset AF to assess the need for anticoagulation,I do not regularly anti-coagulate critically ill patients with new onset fast AF,I only regularly perform Echocardiography in patients with cardiac history,Yes,Amiodarone,,No
01/11/2016 08:19,01/11/2016 08:30,IP Address,62.255.13.162,100,630,TRUE,01/11/2016 08:30,R_3MR6eTMSiyAxQcb,,,,,51.44999695,-2.583297729,anonymous,Tertiary Referral Centre or University Hospital,1000-2000,42,Mixed ICU,,Consultant,More than 10 years,Anaesthesia,100-119/beats per min,Rate control,Amiodarone,,Supplement electrolytes to a high normal level and anti-arrhythmics,>4.5 mmol/l,1.0-1.2 mmol/l,ICU drug policy,,I do not regularly anti-coagulate critically ill patients with new-onset fast AF,I do not use stroke risk scores routinely in critically ill patients with new onset AF to assess the need for anticoagulation,I do not regularly anti-coagulate critically ill patients with new onset fast AF,I regularly perform or request transthoracic echocardiography,Yes,Amiodarone,,No
01/11/2016 08:34,01/11/2016 08:47,IP Address,88.98.77.107,100,771,TRUE,01/11/2016 08:47,R_UG6JMB18OHx6MU1,,,,,52.25,0.716705322,anonymous,District General Hospital,500-1000,10,Predominantly medical,,Consultant,More than 10 years,Anaesthesia,100-119/beats per min,Rate control,Amiodarone,,Supplement electrolytes to a high normal level and anti-arrhythmics,>4.5 mmol/l,1.0-1.2 mmol/l,Pharmacodynamic properties,,I do not regularly anti-coagulate critically ill patients with new-onset fast AF,"I do not use stroke risk scores routinely in critically ill patients with new onset AF to assess the need for anticoagulation,Stroke risk scores inaccurately reflect the risk of embolic events in critically ill patients with new-onset atrial fibrillation due to prothrombotic changes associated with critical illness,Stroke risk scores favour anti-coagulation despite a higher risk of bleeding in critical illness,Modified risk scores should be developed for critically ill patients with new-onset atrial fibrillation","Subcutaneous Low Molecular Weight heparin in therapeutic dose,I do not regularly anti-coagulate critically ill patients with new onset fast AF",I regularly perform or request transthoracic echocardiography,Yes,"Amiodarone,DC cardioversion,ß-blocker,Digoxin",,No
01/11/2016 08:43,01/11/2016 08:53,IP Address,90.9.26.239,100,611,TRUE,01/11/2016 08:53,R_2WMPibwPyHbcNVI,,,,,45.70350647,3.168106079,anonymous,District General Hospital,500-1000,30,Mixed ICU,,Consultant,More than 10 years,Anaesthesia,120-139/beats per min,Rate control,ß-blocker,,Supplement electrolytes (magnesium and/or potassium) to a high normal level,>4 mmol/l,>1.2 mmol/l,Pharmacodynamic properties,,Before starting anti-arrhythmic medication,"Stroke risk scores inaccurately reflect the risk of embolic events in critically ill patients with new-onset atrial fibrillation due to prothrombotic changes associated with critical illness,Stroke risk scores favour anti-coagulation despite a higher risk of bleeding in critical illness,Modified risk scores should be developed for critically ill patients with new-onset atrial fibrillation",Intravenous High Molecular Weight heparin in therapeutic dose,I regularly perform or request transthoracic echocardiography,Yes,ß-blocker,,Yes
01/11/2016 08:51,01/11/2016 08:55,IP Address,194.176.105.161,100,218,TRUE,01/11/2016 08:55,R_1laht7NBbleJp5K,,,,,51.51420593,-0.093093872,anonymous,District General Hospital,500-1000,12,Predominantly surgical,,Consultant,More than 10 years,Anaesthesia,"Independent of their heart rate I treat all patients who have developed new onset fast AF, even if the blood pressure remains stable",I have no primary treatment goal in these patients,Amiodarone,,Supplement electrolytes to a high normal level and DC cardioversion,>3.5mmol/l,I do not aim for a specific serum magnesium level,ICU drug policy,,Before starting anti-arrhythmic medication,I do not use stroke risk scores routinely in critically ill patients with new onset AF to assess the need for anticoagulation,Subcutaneous Low Molecular Weight heparin in therapeutic dose,I do not routinely perform Echocardiography to guide treatment,No,Digoxin,,No
01/11/2016 09:03,01/11/2016 09:09,IP Address,194.176.105.152,100,360,TRUE,01/11/2016 09:09,R_1n8zGNBiesk3tN3,,,,,51.51420593,-0.093093872,anonymous,District General Hospital,500-1000,12,Mixed ICU,,Consultant,More than 10 years,Anaesthesia,"Independent of their heart rate I treat all patients who have developed new onset fast AF, even if the blood pressure remains stable",Rhythm control,Amiodarone,,Supplement electrolytes to a high normal level and anti-arrhythmics,>4 mmol/l,0.75-1 mmol/l,Pharmacodynamic properties,,I do not regularly anti-coagulate critically ill patients with new-onset fast AF,"I do not use stroke risk scores routinely in critically ill patients with new onset AF to assess the need for anticoagulation,Modified risk scores should be developed for critically ill patients with new-onset atrial fibrillation","Intravenous High Molecular Weight heparin in therapeutic dose,Subcutaneous Low Molecular Weight heparin in therapeutic dose,Use of novel oral anti-coagulants (NOACs),I do not regularly anti-coagulate critically ill patients with new onset fast AF",I do not routinely perform Echocardiography to guide treatment,Yes,Amiodarone,,Yes
01/11/2016 09:05,01/11/2016 09:10,IP Address,212.250.188.197,100,314,TRUE,01/11/2016 09:10,R_1OjhgoIyFC9DZAG,,,,,52.96670532,-1.166702271,anonymous,Tertiary Referral Centre or University Hospital,>2000,approx 60,Mixed ICU,,Consultant,More than 10 years,Anaesthesia,120-139/beats per min,Rate control,Amiodarone,,Supplement electrolytes to a high normal level and anti-arrhythmics,>4 mmol/l,1.0-1.2 mmol/l,Pharmacokinetic advantages,,I do not regularly anti-coagulate critically ill patients with new-onset fast AF,"I do not use stroke risk scores routinely in critically ill patients with new onset AF to assess the need for anticoagulation,Stroke risk scores favour anti-coagulation despite a higher risk of bleeding in critical illness",I do not regularly anti-coagulate critically ill patients with new onset fast AF,I do not routinely perform Echocardiography to guide treatment,No,ß-blocker,,Yes
01/11/2016 09:07,01/11/2016 09:11,IP Address,92.18.169.233,100,234,TRUE,01/11/2016 09:11,R_1ozgSbjEwtxiqJ4,,,,,54.51669312,-3.516693115,anonymous,District General Hospital,<500,11,Mixed ICU,,Consultant,More than 10 years,Anaesthesia,"Independent of their heart rate I treat all patients who have developed new onset fast AF, even if the blood pressure remains stable",Rhythm control,Amiodarone,,Supplement electrolytes to a high normal level and anti-arrhythmics,>4 mmol/l,1.0-1.2 mmol/l,"ICU drug policy,Pharmacokinetic advantages",,I do not regularly anti-coagulate critically ill patients with new-onset fast AF,I do not use stroke risk scores routinely in critically ill patients with new onset AF to assess the need for anticoagulation,I do not regularly anti-coagulate critically ill patients with new onset fast AF,I regularly perform or request transthoracic echocardiography,Yes,Amiodarone,,No
01/11/2016 09:03,01/11/2016 09:15,IP Address,213.7.1.116,100,765,TRUE,01/11/2016 09:15,R_2SoGUyYSFL5llKS,,,,,35.16670227,33.36669922,anonymous,Teaching Hospital,500-1000,6+9 (but varies according to case-mix),Mixed ICU,,Consultant,More than 10 years,Anaesthesia,"Independent of their heart rate I treat all patients who have developed new onset fast AF, even if the blood pressure remains stable",Rhythm control,Amiodarone,,Supplement electrolytes to a high normal level and anti-arrhythmics,>4.5 mmol/l,>1.2 mmol/l,"ICU drug policy,Other, please specify:",Efficacy,I do not regularly anti-coagulate critically ill patients with new-onset fast AF,"I do not use stroke risk scores routinely in critically ill patients with new onset AF to assess the need for anticoagulation,Stroke risk scores favour anti-coagulation despite a higher risk of bleeding in critical illness,Modified risk scores should be developed for critically ill patients with new-onset atrial fibrillation",I do not regularly anti-coagulate critically ill patients with new onset fast AF,I regularly perform or request transthoracic echocardiography,Yes,"Amiodarone,DC cardioversion",,No
01/11/2016 09:27,01/11/2016 09:33,IP Address,161.17.0.1,100,417,TRUE,01/11/2016 09:33,R_80JkVCYzwoZr0W1,,,,,51.51420593,-0.093093872,anonymous,Tertiary Referral Centre or University Hospital,>2000,68,Mixed ICU,,Consultant,More than 10 years,Anaesthesia,"Independent of their heart rate I treat all patients who have developed new onset fast AF, even if the blood pressure remains stable",Rhythm control,Amiodarone,,DC cardioversion when anti-arrhythmics and electrolyte replacement fail to achieve rate and/or rhythm control,>4.5 mmol/l,>1.2 mmol/l,"Pharmacodynamic properties,Adverse effect profile",,I do not regularly anti-coagulate critically ill patients with new-onset fast AF,"I do not use stroke risk scores routinely in critically ill patients with new onset AF to assess the need for anticoagulation,Stroke risk scores favour anti-coagulation despite a higher risk of bleeding in critical illness,Modified risk scores should be developed for critically ill patients with new-onset atrial fibrillation","Intravenous High Molecular Weight heparin in therapeutic dose,Subcutaneous Low Molecular Weight heparin in therapeutic dose,I do not regularly anti-coagulate critically ill patients with new onset fast AF",I regularly perform or request transthoracic echocardiography,Yes,"Amiodarone,ß-blocker",,No
01/11/2016 09:27,01/11/2016 09:34,IP Address,185.58.164.44,100,411,TRUE,01/11/2016 09:34,R_1P5mksFKRweBV5F,,,,,55.83329773,-4.25,anonymous,Tertiary Referral Centre or University Hospital,>2000,58,Mixed ICU,,Consultant,5-10 years,Anaesthesia,120-139/beats per min,Rate control,Amiodarone,,Supplement electrolytes to a high normal level and anti-arrhythmics,>4.5 mmol/l,1.0-1.2 mmol/l,ICU drug policy,,I do not regularly anti-coagulate critically ill patients with new-onset fast AF,"I do not use stroke risk scores routinely in critically ill patients with new onset AF to assess the need for anticoagulation,Stroke risk scores inaccurately reflect the risk of embolic events in critically ill patients with new-onset atrial fibrillation due to prothrombotic changes associated with critical illness,Modified risk scores should be developed for critically ill patients with new-onset atrial fibrillation",I do not regularly anti-coagulate critically ill patients with new onset fast AF,I only regularly perform Echocardiography in patients with cardiac history,Yes,Amiodarone,,No
01/11/2016 09:05,01/11/2016 09:36,IP Address,159.92.238.13,100,1867,TRUE,01/11/2016 09:36,R_3e02pTqWXsiUv4Z,,,,,51.49789429,-0.066101074,anonymous,Teaching Hospital,>2000,60,Mixed ICU,,Trainee,1-3 years,Intensive Care Medicine only,120-139/beats per min,Rate control,Amiodarone,,Supplement electrolytes (magnesium and/or potassium) to a high normal level,>4 mmol/l,1.0-1.2 mmol/l,Pharmacokinetic advantages,,New onset AF within 72 hours,Stroke risk scores inaccurately reflect the risk of embolic events in critically ill patients with new-onset atrial fibrillation due to prothrombotic changes associated with critical illness,Use of warfarin,I do not routinely perform Echocardiography to guide treatment,No,Flecainide,,Yes
01/11/2016 09:32,01/11/2016 09:37,IP Address,137.222.114.241,100,294,TRUE,01/11/2016 09:37,R_a4ACHt4ryoskB6F,,,,,51.44999695,-2.583297729,anonymous,Tertiary Referral Centre or University Hospital,I do not know,21,Mixed ICU,,Consultant,More than 10 years,Anaesthesia,120-139/beats per min,Rate control,ß-blocker,,DC cardioversion when anti-arrhythmics and electrolyte replacement fail to achieve rate and/or rhythm control,>4.5 mmol/l,1.0-1.2 mmol/l,ICU drug policy,,New onset AF within 24 hours,I do not use stroke risk scores routinely in critically ill patients with new onset AF to assess the need for anticoagulation,Intravenous High Molecular Weight heparin in therapeutic dose,I regularly perform or request transthoracic echocardiography,Yes,ß-blocker,,No
01/11/2016 09:34,01/11/2016 09:49,IP Address,217.65.53.150,100,903,TRUE,01/11/2016 09:49,R_2tG7q0L2tHkj2ct,,,,,36.13330078,-5.350006104,anonymous,District General Hospital,<500,6,Mixed ICU,,Consultant,More than 10 years,Anaesthesia,"Independent of their heart rate I treat all patients who have developed new onset fast AF, even if the blood pressure remains stable",Rate control,Amiodarone,,DC cardioversion when anti-arrhythmics and electrolyte replacement fail to achieve rate and/or rhythm control,>4.5 mmol/l,1.0-1.2 mmol/l,ICU drug policy,,I do not regularly anti-coagulate critically ill patients with new-onset fast AF,"I do not use stroke risk scores routinely in critically ill patients with new onset AF to assess the need for anticoagulation,Modified risk scores should be developed for critically ill patients with new-onset atrial fibrillation",Subcutaneous Low Molecular Weight heparin in therapeutic dose,I regularly perform or request transthoracic echocardiography,No,Amiodarone,,Yes
01/11/2016 09:52,01/11/2016 09:58,IP Address,86.152.85.237,100,356,TRUE,01/11/2016 09:58,R_umnt17fiBCQeMGl,,,,,51.26669312,-1.083297729,anonymous,District General Hospital,500-1000,16,Mixed ICU,,Consultant,More than 10 years,Anaesthesia,"Independent of their heart rate I treat all patients who have developed new onset fast AF, even if the blood pressure remains stable",I have no primary treatment goal in these patients,ß-blocker,,DC cardioversion when anti-arrhythmics and electrolyte replacement fail to achieve rate and/or rhythm control,>4.5 mmol/l,0.75-1 mmol/l,Pharmacodynamic properties,,New onset AF within 24 hours,"I do not use stroke risk scores routinely in critically ill patients with new onset AF to assess the need for anticoagulation,Modified risk scores should be developed for critically ill patients with new-onset atrial fibrillation",Intravenous High Molecular Weight heparin in therapeutic dose,I regularly perform or request transthoracic echocardiography,Yes,DC cardioversion,,No
01/11/2016 09:58,01/11/2016 10:05,IP Address,94.193.4.171,100,411,TRUE,01/11/2016 10:05,R_3ESkn9x7hKABNXt,,,,,53,-2.183303833,anonymous,Tertiary Referral Centre or University Hospital,1000-2000,32,Mixed ICU,,Trainee,5-10 years,Intensive Care Medicine only,"Independent of their heart rate I treat all patients who have developed new onset fast AF, even if the blood pressure remains stable",Rate control,Amiodarone,,Supplement electrolytes to a high normal level and anti-arrhythmics,>4.5 mmol/l,1.0-1.2 mmol/l,"Pharmacokinetic advantages,Pharmacodynamic properties",,New onset AF within 24 hours,"I do not use stroke risk scores routinely in critically ill patients with new onset AF to assess the need for anticoagulation,Stroke risk scores inaccurately reflect the risk of embolic events in critically ill patients with new-onset atrial fibrillation due to prothrombotic changes associated with critical illness,Stroke risk scores favour anti-coagulation despite a higher risk of bleeding in critical illness,Modified risk scores should be developed for critically ill patients with new-onset atrial fibrillation",Subcutaneous Low Molecular Weight heparin in therapeutic dose,"I do not routinely perform Echocardiography to guide treatment,I only regularly perform Echocardiography in patients with cardiac history",Yes,Amiodarone,,No
01/11/2016 08:48,01/11/2016 10:14,IP Address,85.255.235.90,100,5128,TRUE,01/11/2016 10:14,R_3prRdoSeNk6FzKm,,,,,51.49639893,-0.122406006,anonymous,District General Hospital,500-1000,14,Predominantly medical,,Consultant,More than 10 years,Anaesthesia,120-139/beats per min,Rate control,Amiodarone,,Supplement electrolytes (magnesium and/or potassium) to a high normal level,>4.5 mmol/l,1.0-1.2 mmol/l,Pharmacokinetic advantages,,I do not regularly anti-coagulate critically ill patients with new-onset fast AF,"I do not use stroke risk scores routinely in critically ill patients with new onset AF to assess the need for anticoagulation,Stroke risk scores inaccurately reflect the risk of embolic events in critically ill patients with new-onset atrial fibrillation due to prothrombotic changes associated with critical illness,Modified risk scores should be developed for critically ill patients with new-onset atrial fibrillation",Subcutaneous Low Molecular Weight heparin in therapeutic dose,I only regularly perform Echocardiography in patients with cardiac history,Yes,"Amiodarone,Flecainide,Digoxin",,Yes
01/11/2016 10:06,01/11/2016 10:24,IP Address,185.58.164.44,100,1041,TRUE,01/11/2016 10:24,R_1P5Emxcn3iIedO6,,,,,55.83329773,-4.25,anonymous,District General Hospital,<500,8,Mixed ICU,,Trainee,5-10 years,Anaesthesia,120-139/beats per min,Rate control,Amiodarone,,Supplement electrolytes (magnesium and/or potassium) to a high normal level,>4 mmol/l,1.0-1.2 mmol/l,"Pharmacokinetic advantages,Pharmacodynamic properties,Adverse effect profile",,New onset AF within 48 hours,Stroke risk scores inaccurately reflect the risk of embolic events in critically ill patients with new-onset atrial fibrillation due to prothrombotic changes associated with critical illness,"Subcutaneous Low Molecular Weight heparin in therapeutic dose,I do not regularly anti-coagulate critically ill patients with new onset fast AF",I regularly perform or request transthoracic echocardiography,Yes,"Amiodarone,DC cardioversion,ß-blocker,Diltiazem,Other anti-arrhythmics (e. g. verapamil, sotalol): Please specify:",Verapamil,Yes
01/11/2016 10:36,01/11/2016 10:43,IP Address,143.159.103.125,100,416,TRUE,01/11/2016 10:43,R_2PiiH9al05aoJ7c,,,,,53.36669922,-1.5,anonymous,District General Hospital,1000-2000,18,Mixed ICU,,Consultant,More than 10 years,Anaesthesia,120-139/beats per min,Rate control,ß-blocker,,Supplement electrolytes to a high normal level and DC cardioversion,>4.5 mmol/l,1.0-1.2 mmol/l,Adverse effect profile,,New onset AF within 24 hours,"I do not use stroke risk scores routinely in critically ill patients with new onset AF to assess the need for anticoagulation,Stroke risk scores inaccurately reflect the risk of embolic events in critically ill patients with new-onset atrial fibrillation due to prothrombotic changes associated with critical illness","Intravenous High Molecular Weight heparin in therapeutic dose,Subcutaneous Low Molecular Weight heparin in therapeutic dose",I do not routinely perform Echocardiography to guide treatment,Yes,"Amiodarone,DC cardioversion,ß-blocker",,No
01/11/2016 10:54,01/11/2016 10:59,IP Address,188.39.68.2,100,271,TRUE,01/11/2016 10:59,R_3kpiZjwzHcLIaB6,,,,,50.83329773,-0.149993896,anonymous,Teaching Hospital,1000-2000,39,Mixed ICU,,Consultant,More than 10 years,Anaesthesia,120-139/beats per min,Rate control,Amiodarone,,Supplement electrolytes to a high normal level and anti-arrhythmics,>4.5 mmol/l,1.0-1.2 mmol/l,"Pharmacokinetic advantages,Pharmacodynamic properties",,I do not regularly anti-coagulate critically ill patients with new-onset fast AF,I do not use stroke risk scores routinely in critically ill patients with new onset AF to assess the need for anticoagulation,I do not regularly anti-coagulate critically ill patients with new onset fast AF,I do not routinely perform Echocardiography to guide treatment,Yes,"Amiodarone,DC cardioversion,ß-blocker",,No
01/11/2016 10:53,01/11/2016 10:59,IP Address,109.159.110.91,100,363,TRUE,01/11/2016 10:59,R_1JDWJWzSzqUpZQZ,,,,,53.41700745,-2.231506348,anonymous,Teaching Hospital,I do not know,14,Mixed ICU,,Trainee,1-3 years,Anaesthesia,120-139/beats per min,Rate control,ß-blocker,,Supplement electrolytes to a high normal level and anti-arrhythmics,>4 mmol/l,1.0-1.2 mmol/l,"Pharmacodynamic properties,Adverse effect profile",,After starting anti-arrhythmic medication,I do not use stroke risk scores routinely in critically ill patients with new onset AF to assess the need for anticoagulation,Subcutaneous Low Molecular Weight heparin in therapeutic dose,I regularly perform or request transthoracic echocardiography,No,"Amiodarone,ß-blocker,Digoxin",,No
01/11/2016 11:14,01/11/2016 11:20,IP Address,185.58.164.44,100,365,TRUE,01/11/2016 11:20,R_cvhh2e7uWnRdC5L,,,,,55.83329773,-4.25,anonymous,District General Hospital,<500,6.5,Mixed ICU,,Consultant,More than 10 years,Anaesthesia,"Independent of their heart rate I treat all patients who have developed new onset fast AF, even if the blood pressure remains stable",Rate control,Amiodarone,,Supplement electrolytes (magnesium and/or potassium) to a high normal level,>4.5 mmol/l,1.0-1.2 mmol/l,ICU drug policy,,I do not regularly anti-coagulate critically ill patients with new-onset fast AF,Stroke risk scores favour anti-coagulation despite a higher risk of bleeding in critical illness,Subcutaneous Low Molecular Weight heparin in therapeutic dose,I regularly perform or request transthoracic echocardiography,No,"Amiodarone,ß-blocker,Digoxin",,No
01/11/2016 11:21,01/11/2016 11:30,IP Address,194.176.105.141,100,541,TRUE,01/11/2016 11:30,R_bNJkFEOnm1Cx5WJ,,,,,51.51420593,-0.093093872,anonymous,Tertiary Referral Centre or University Hospital,1000-2000,31,Mixed ICU,,Consultant,5-10 years,Anaesthesia,"Independent of their heart rate I treat all patients who have developed new onset fast AF, even if the blood pressure remains stable",Rhythm control,Amiodarone,,Supplement electrolytes to a high normal level and anti-arrhythmics,>4.5 mmol/l,1.0-1.2 mmol/l,"Pharmacokinetic advantages,Pharmacodynamic properties,Adverse effect profile",,New onset AF within 48 hours,"I regularly calculate a risk score (e. g. CHAD2, CHA2DS2-VASc) to assess the need for anti-coagulation,Stroke risk scores inaccurately reflect the risk of embolic events in critically ill patients with new-onset atrial fibrillation due to prothrombotic changes associated with critical illness,Stroke risk scores favour anti-coagulation despite a higher risk of bleeding in critical illness,Modified risk scores should be developed for critically ill patients with new-onset atrial fibrillation",Subcutaneous Low Molecular Weight heparin in therapeutic dose,I only regularly perform Echocardiography in patients with cardiac history,Yes,Amiodarone,,Yes
01/11/2016 11:28,01/11/2016 11:31,IP Address,194.80.45.237,100,203,TRUE,01/11/2016 11:31,R_6xx4tAKViri1Lwt,,,,,55.83329773,-4.25,anonymous,Tertiary Referral Centre or University Hospital,1000-2000,20,Mixed ICU,,Consultant,More than 10 years,Anaesthesia,120-139/beats per min,Rate control,"Other anti-arrhythmics (e. g. Verapamil, sotalol): please specify:",magnesium,Supplement electrolytes (magnesium and/or potassium) to a high normal level,>4 mmol/l,I do not aim for a specific serum magnesium level,"Other, please specify:",trial evidence,I do not regularly anti-coagulate critically ill patients with new-onset fast AF,I do not use stroke risk scores routinely in critically ill patients with new onset AF to assess the need for anticoagulation,I do not regularly anti-coagulate critically ill patients with new onset fast AF,I regularly perform or request transthoracic echocardiography,Yes,"Other anti-arrhythmics (e. g. verapamil, sotalol): Please specify:",magnesium,Yes
01/11/2016 11:40,01/11/2016 11:54,IP Address,188.39.68.2,100,836,TRUE,01/11/2016 11:54,R_3m1B25BXiackLGw,,,,,50.83329773,-0.149993896,anonymous,Tertiary Referral Centre or University Hospital,>2000,39,Mixed ICU,,Consultant,5-10 years,Acute medicine,120-139/beats per min,Rate control,Amiodarone,,Supplement electrolytes to a high normal level and anti-arrhythmics,>4.5 mmol/l,I do not aim for a specific serum magnesium level,"ICU drug policy,Pharmacokinetic advantages,Adverse effect profile",,I do not regularly anti-coagulate critically ill patients with new-onset fast AF,"I do not use stroke risk scores routinely in critically ill patients with new onset AF to assess the need for anticoagulation,Stroke risk scores inaccurately reflect the risk of embolic events in critically ill patients with new-onset atrial fibrillation due to prothrombotic changes associated with critical illness,Stroke risk scores favour anti-coagulation despite a higher risk of bleeding in critical illness","Subcutaneous Low Molecular Weight heparin in therapeutic dose,I do not regularly anti-coagulate critically ill patients with new onset fast AF",I do not routinely perform Echocardiography to guide treatment,Yes,"Amiodarone,ß-blocker",,No
01/11/2016 11:56,01/11/2016 12:01,IP Address,143.159.182.9,100,264,TRUE,01/11/2016 12:01,R_6V9Uqe0S2FdIsxj,,,,,51.41859436,-0.290405273,anonymous,Tertiary Referral Centre or University Hospital,1000-2000,21,Specialist ICU (please name specialty):,Cardiothoracic & Vascular,Consultant,5-10 years,Anaesthesia,100-119/beats per min,Rhythm control,Amiodarone,,Supplement electrolytes to a high normal level and anti-arrhythmics,>4.5 mmol/l,>1.2 mmol/l,ICU drug policy,,New onset AF within 48 hours,"I regularly calculate a risk score (e. g. CHAD2, CHA2DS2-VASc) to assess the need for anti-coagulation,Stroke risk scores inaccurately reflect the risk of embolic events in critically ill patients with new-onset atrial fibrillation due to prothrombotic changes associated with critical illness,Stroke risk scores favour anti-coagulation despite a higher risk of bleeding in critical illness","Intravenous High Molecular Weight heparin in therapeutic dose,Subcutaneous Low Molecular Weight heparin in therapeutic dose",I do not routinely perform Echocardiography to guide treatment,No,"Amiodarone,Digoxin",,No
01/11/2016 12:01,01/11/2016 12:06,IP Address,62.25.77.200,100,283,TRUE,01/11/2016 12:06,R_21GLdpHepcOzcA6,,,,,51.6000061,-0.216705322,anonymous,Tertiary Referral Centre or University Hospital,500-1000,8,Specialist ICU (please name specialty):,Oncology,Consultant,More than 10 years,Anaesthesia,"Independent of their heart rate I treat all patients who have developed new onset fast AF, even if the blood pressure remains stable",Rhythm control,Amiodarone,,Supplement electrolytes to a high normal level and anti-arrhythmics,>4.5 mmol/l,I do not aim for a specific serum magnesium level,"Availability from hospital pharmacy,ICU drug policy,Pharmacodynamic properties",,I do not regularly anti-coagulate critically ill patients with new-onset fast AF,Stroke risk scores favour anti-coagulation despite a higher risk of bleeding in critical illness,Subcutaneous Low Molecular Weight heparin in therapeutic dose,I regularly perform or request transthoracic echocardiography,Yes,"Amiodarone,DC cardioversion,ß-blocker",,No
01/11/2016 11:58,01/11/2016 12:08,IP Address,194.176.105.167,100,624,TRUE,01/11/2016 12:08,R_dd313R4SdwGDtml,,,,,51.51420593,-0.093093872,anonymous,District General Hospital,500-1000,14,Mixed ICU,,Consultant,More than 10 years,Anaesthesia,120-139/beats per min,Rate control,ß-blocker,,Supplement electrolytes (magnesium and/or potassium) to a high normal level,>5 mmol/l,1.0-1.2 mmol/l,"Pharmacodynamic properties,Adverse effect profile",,New onset AF within 72 hours,I do not use stroke risk scores routinely in critically ill patients with new onset AF to assess the need for anticoagulation,"Intravenous High Molecular Weight heparin in therapeutic dose,Subcutaneous Low Molecular Weight heparin in therapeutic dose",I do not routinely perform Echocardiography to guide treatment,Yes,"Amiodarone,ß-blocker,Digoxin",,Yes
01/11/2016 12:18,01/11/2016 12:30,IP Address,109.176.101.163,100,721,TRUE,01/11/2016 12:30,R_2TGgN2QehYQbzKZ,,,,,51.02110291,-3.104705811,anonymous,District General Hospital,500-1000,12,Mixed ICU,,Consultant,More than 10 years,Anaesthesia,120-139/beats per min,Rhythm control,Amiodarone,,DC cardioversion when anti-arrhythmics and electrolyte replacement fail to achieve rate and/or rhythm control,>4.5 mmol/l,1.0-1.2 mmol/l,Pharmacodynamic properties,,I do not regularly anti-coagulate critically ill patients with new-onset fast AF,"I do not use stroke risk scores routinely in critically ill patients with new onset AF to assess the need for anticoagulation,Modified risk scores should be developed for critically ill patients with new-onset atrial fibrillation",I do not regularly anti-coagulate critically ill patients with new onset fast AF,I regularly perform or request transthoracic echocardiography,Yes,"Amiodarone,ß-blocker,Digoxin",,No
01/11/2016 12:38,01/11/2016 12:53,IP Address,194.176.105.132,100,923,TRUE,01/11/2016 12:53,R_T6py0TqPtEVrUZP,,,,,51.44340515,-0.14680481,anonymous,District General Hospital,<500,6,Mixed ICU,,Consultant,More than 10 years,Anaesthesia,"Independent of their heart rate I treat all patients who have developed new onset fast AF, even if the blood pressure remains stable",Rhythm control,Amiodarone,,Supplement electrolytes to a high normal level and anti-arrhythmics,>4.5 mmol/l,1.0-1.2 mmol/l,"Other, please specify:",effectiveness,I do not regularly anti-coagulate critically ill patients with new-onset fast AF,I do not use stroke risk scores routinely in critically ill patients with new onset AF to assess the need for anticoagulation,I do not regularly anti-coagulate critically ill patients with new onset fast AF,I do not routinely perform Echocardiography to guide treatment,No,ß-blocker,,No
01/11/2016 12:55,01/11/2016 13:04,IP Address,194.176.105.166,100,514,TRUE,01/11/2016 13:04,R_1OwbWfcbqHZYYJn,,,,,51.41670227,-0.283294678,anonymous,District General Hospital,500-1000,12,Mixed ICU,,Consultant,More than 10 years,Intensive Care Medicine only,140-159/beats per min,Rate control,Amiodarone,,Supplement electrolytes to a high normal level and anti-arrhythmics,>4.5 mmol/l,1.0-1.2 mmol/l,"Other, please specify:",Chance of cardioversion,New onset AF within 72 hours,"I regularly calculate a risk score (e. g. CHAD2, CHA2DS2-VASc) to assess the need for anti-coagulation,Stroke risk scores inaccurately reflect the risk of embolic events in critically ill patients with new-onset atrial fibrillation due to prothrombotic changes associated with critical illness,Modified risk scores should be developed for critically ill patients with new-onset atrial fibrillation",Subcutaneous Low Molecular Weight heparin in therapeutic dose,I regularly perform or request transthoracic echocardiography,Yes,"Amiodarone,DC cardioversion,ß-blocker,Digoxin",,No
01/11/2016 13:00,01/11/2016 13:05,IP Address,159.86.191.19,100,321,TRUE,01/11/2016 13:05,R_3ICujwsJuCxidaB,,,,,51.60139465,-3.344696045,anonymous,Tertiary Referral Centre or University Hospital,1000-2000,33,Mixed ICU,,Consultant,More than 10 years,Anaesthesia,120-139/beats per min,Rhythm control,Amiodarone,,Supplement electrolytes to a high normal level and anti-arrhythmics,>4.5 mmol/l,>1.2 mmol/l,"ICU drug policy,Pharmacodynamic properties,Adverse effect profile",,I do not regularly anti-coagulate critically ill patients with new-onset fast AF,"I do not use stroke risk scores routinely in critically ill patients with new onset AF to assess the need for anticoagulation,Stroke risk scores inaccurately reflect the risk of embolic events in critically ill patients with new-onset atrial fibrillation due to prothrombotic changes associated with critical illness,Stroke risk scores favour anti-coagulation despite a higher risk of bleeding in critical illness,Modified risk scores should be developed for critically ill patients with new-onset atrial fibrillation",I do not regularly anti-coagulate critically ill patients with new onset fast AF,I do not routinely perform Echocardiography to guide treatment,Yes,"Amiodarone,DC cardioversion,Flecainide,Digoxin",,No
01/11/2016 13:29,01/11/2016 13:36,IP Address,82.132.244.238,100,457,TRUE,01/11/2016 13:36,R_1FEeJxSxjqgHgSu,,,,,51.49639893,-0.122406006,anonymous,District General Hospital,500-1000,9,Mixed ICU,,Consultant,More than 10 years,Anaesthesia,120-139/beats per min,Rate control,Amiodarone,,Supplement electrolytes to a high normal level and anti-arrhythmics,>4 mmol/l,1.0-1.2 mmol/l,Pharmacodynamic properties,,Before DC cardioversion,"I do not use stroke risk scores routinely in critically ill patients with new onset AF to assess the need for anticoagulation,Stroke risk scores favour anti-coagulation despite a higher risk of bleeding in critical illness",Subcutaneous Low Molecular Weight heparin in therapeutic dose,I regularly perform or request transthoracic echocardiography,Yes,"Amiodarone,ß-blocker",,No
01/11/2016 13:47,01/11/2016 13:51,IP Address,137.50.62.74,100,193,TRUE,01/11/2016 13:51,R_3JjUIvZjIBeBKUW,,,,,57.13330078,-2.100006104,anonymous,Tertiary Referral Centre or University Hospital,500-1000,12,Mixed ICU,,Consultant,5-10 years,Intensive Care Medicine only,120-139/beats per min,Rate control,Amiodarone,,Anti-arrhythmics only,>4.5 mmol/l,0.75-1 mmol/l,Adverse effect profile,,I do not regularly anti-coagulate critically ill patients with new-onset fast AF,I do not use stroke risk scores routinely in critically ill patients with new onset AF to assess the need for anticoagulation,I do not regularly anti-coagulate critically ill patients with new onset fast AF,I do not routinely perform Echocardiography to guide treatment,Yes,"Amiodarone,DC cardioversion,ß-blocker,Diltiazem",,Yes
01/11/2016 13:41,01/11/2016 13:56,IP Address,159.86.191.18,100,860,TRUE,01/11/2016 13:56,R_ehXBBzn7voUM8BL,,,,,51.60139465,-3.344696045,anonymous,District General Hospital,500-1000,11,Mixed ICU,,Consultant,More than 10 years,Anaesthesia,"Independent of their heart rate I treat all patients who have developed new onset fast AF, even if the blood pressure remains stable",Rhythm control,Amiodarone,,Supplement electrolytes to a high normal level and anti-arrhythmics,>4.5 mmol/l,1.0-1.2 mmol/l,"Availability from hospital pharmacy,Pharmacodynamic properties",,New onset AF within 48 hours,"I regularly calculate a risk score (e. g. CHAD2, CHA2DS2-VASc) to assess the need for anti-coagulation,Modified risk scores should be developed for critically ill patients with new-onset atrial fibrillation",Subcutaneous Low Molecular Weight heparin in therapeutic dose,I regularly perform or request transthoracic echocardiography,No,"Amiodarone,ß-blocker,Digoxin",,No
01/11/2016 14:02,01/11/2016 14:07,IP Address,194.176.105.168,100,285,TRUE,01/11/2016 14:07,R_1pm8BYtBAnJONSf,,,,,51.44999695,-0.416702271,anonymous,Tertiary Referral Centre or University Hospital,>2000,41,Mixed ICU,,Consultant,More than 10 years,Anaesthesia,140-159/beats per min,Rhythm control,"Other anti-arrhythmics (e. g. Verapamil, sotalol): please specify:",magnesium first then amiodarone,Supplement electrolytes (magnesium and/or potassium) to a high normal level,>4.5 mmol/l,>1.2 mmol/l,Pharmacodynamic properties,,New onset AF within 72 hours,I do not use stroke risk scores routinely in critically ill patients with new onset AF to assess the need for anticoagulation,"Intravenous High Molecular Weight heparin in therapeutic dose,Subcutaneous Low Molecular Weight heparin in therapeutic dose",I do not routinely perform Echocardiography to guide treatment,Yes,"Amiodarone,ß-blocker",,Yes
01/11/2016 14:01,01/11/2016 14:08,IP Address,194.176.105.167,100,398,TRUE,01/11/2016 14:08,R_3QRkKg5EfbdPkKe,,,,,51.41670227,-0.283294678,anonymous,District General Hospital,1000-2000,16,Mixed ICU,,Consultant,More than 10 years,Anaesthesia,100-119/beats per min,Rhythm control,Amiodarone,,DC cardioversion when anti-arrhythmics and electrolyte replacement fail to achieve rate and/or rhythm control,>4.5 mmol/l,0.75-1 mmol/l,"Availability from hospital pharmacy,ICU drug policy,Pharmacokinetic advantages,Pharmacodynamic properties,Adverse effect profile",,I do not regularly anti-coagulate critically ill patients with new-onset fast AF,Modified risk scores should be developed for critically ill patients with new-onset atrial fibrillation,I do not regularly anti-coagulate critically ill patients with new onset fast AF,I only regularly perform Echocardiography in patients with cardiac history,Yes,"Amiodarone,DC cardioversion,ß-blocker,Flecainide,Diltiazem,Digoxin",,No
01/11/2016 14:06,01/11/2016 14:11,IP Address,194.176.105.138,100,279,TRUE,01/11/2016 14:11,R_WCegz7HfFbxu5fr,,,,,51.51420593,-0.093093872,anonymous,District General Hospital,I do not know,15,Mixed ICU,,Trainee,1-3 years,Anaesthesia,140-159/beats per min,Rate control,ß-blocker,,Supplement electrolytes (magnesium and/or potassium) to a high normal level,>4.5 mmol/l,1.0-1.2 mmol/l,Pharmacokinetic advantages,,I do not regularly anti-coagulate critically ill patients with new-onset fast AF,"I do not use stroke risk scores routinely in critically ill patients with new onset AF to assess the need for anticoagulation,Modified risk scores should be developed for critically ill patients with new-onset atrial fibrillation",I do not regularly anti-coagulate critically ill patients with new onset fast AF,I do not routinely perform Echocardiography to guide treatment,Yes,"Amiodarone,DC cardioversion,ß-blocker",,Yes
01/11/2016 14:07,01/11/2016 14:11,IP Address,194.176.105.165,100,253,TRUE,01/11/2016 14:11,R_9GEVAbubIxrOFSp,,,,,51.51420593,-0.093093872,anonymous,District General Hospital,<500,10,Mixed ICU,,Consultant,More than 10 years,Anaesthesia,120-139/beats per min,Rhythm control,Amiodarone,,Supplement electrolytes to a high normal level and anti-arrhythmics,>4 mmol/l,0.75-1 mmol/l,Adverse effect profile,,I do not regularly anti-coagulate critically ill patients with new-onset fast AF,"I do not use stroke risk scores routinely in critically ill patients with new onset AF to assess the need for anticoagulation,Modified risk scores should be developed for critically ill patients with new-onset atrial fibrillation",I do not regularly anti-coagulate critically ill patients with new onset fast AF,I do not routinely perform Echocardiography to guide treatment,Yes,Amiodarone,,Yes
01/11/2016 14:25,01/11/2016 14:30,IP Address,194.176.105.152,100,289,TRUE,01/11/2016 14:30,R_8H6xrfDB1FAIgDv,,,,,51.51420593,-0.093093872,anonymous,Teaching Hospital,1000-2000,16,Mixed ICU,,Consultant,More than 10 years,Anaesthesia,120-139/beats per min,Rhythm control,ß-blocker,,Supplement electrolytes to a high normal level and anti-arrhythmics,>4 mmol/l,>1.2 mmol/l,Pharmacodynamic properties,,I do not regularly anti-coagulate critically ill patients with new-onset fast AF,Modified risk scores should be developed for critically ill patients with new-onset atrial fibrillation,"Intravenous High Molecular Weight heparin in therapeutic dose,Subcutaneous Low Molecular Weight heparin in therapeutic dose,I do not regularly anti-coagulate critically ill patients with new onset fast AF",I regularly perform or request transthoracic echocardiography,Yes,"Amiodarone,ß-blocker",,No
01/11/2016 14:38,01/11/2016 14:44,IP Address,106.51.241.121,100,359,TRUE,01/11/2016 14:44,R_23435JD1sDYMwCy,,,,,12.98330688,77.58331299,anonymous,Tertiary Referral Centre or University Hospital,1000-2000,24,Mixed ICU,,Consultant,1-3 years,Anaesthesia,"Independent of their heart rate I treat all patients who have developed new onset fast AF, even if the blood pressure remains stable",Rhythm control,Amiodarone,,Supplement electrolytes to a high normal level and DC cardioversion,>4.5 mmol/l,1.0-1.2 mmol/l,ICU drug policy,,New onset AF within 72 hours,"I regularly calculate a risk score (e. g. CHAD2, CHA2DS2-VASc) to assess the need for anti-coagulation",Subcutaneous Low Molecular Weight heparin in therapeutic dose,I do not routinely perform Echocardiography to guide treatment,Yes,"Amiodarone,DC cardioversion,ß-blocker",,No
01/11/2016 12:05,01/11/2016 14:49,IP Address,185.58.166.44,100,9816,TRUE,01/11/2016 14:49,R_23ddkJxcepBsLbC,,,,,55.88330078,-3.533294678,anonymous,District General Hospital,<500,6,Mixed ICU,,Consultant,More than 10 years,Anaesthesia,120-139/beats per min,Rate control,Amiodarone,,Supplement electrolytes to a high normal level and anti-arrhythmics,>4 mmol/l,1.0-1.2 mmol/l,"Pharmacodynamic properties,Adverse effect profile,Other, please specify:",Anecdotal experience,I do not regularly anti-coagulate critically ill patients with new-onset fast AF,I do not use stroke risk scores routinely in critically ill patients with new onset AF to assess the need for anticoagulation,I do not regularly anti-coagulate critically ill patients with new onset fast AF,I do not routinely perform Echocardiography to guide treatment,Yes,Amiodarone,,Yes
01/11/2016 14:45,01/11/2016 14:54,IP Address,213.120.144.161,100,532,TRUE,01/11/2016 14:54,R_3lPPWfQ1jX6gT5u,,,,,51.56669617,-0.333297729,anonymous,District General Hospital,500-1000,20,Mixed ICU,,Consultant,More than 10 years,Anaesthesia,120-139/beats per min,Rate control,Amiodarone,,DC cardioversion when anti-arrhythmics and electrolyte replacement fail to achieve rate and/or rhythm control,>4.5 mmol/l,1.0-1.2 mmol/l,Pharmacodynamic properties,,New onset AF within 24 hours,I do not use stroke risk scores routinely in critically ill patients with new onset AF to assess the need for anticoagulation,Subcutaneous Low Molecular Weight heparin in therapeutic dose,I regularly perform or request transthoracic echocardiography,Yes,Amiodarone,,Yes
01/11/2016 15:05,01/11/2016 15:10,IP Address,109.152.201.241,100,282,TRUE,01/11/2016 15:10,R_31KlHE6Dl6LFPa0,,,,,51.8999939,-2.083297729,anonymous,District General Hospital,500-1000,13,Mixed ICU,,Consultant,More than 10 years,Anaesthesia,120-139/beats per min,Rate control,Amiodarone,,Supplement electrolytes to a high normal level and anti-arrhythmics,>4 mmol/l,I do not aim for a specific serum magnesium level,"Availability from hospital pharmacy,ICU drug policy,Pharmacokinetic advantages,Pharmacodynamic properties,Adverse effect profile",,Before DC cardioversion,I do not use stroke risk scores routinely in critically ill patients with new onset AF to assess the need for anticoagulation,Intravenous High Molecular Weight heparin in therapeutic dose,I do not routinely perform Echocardiography to guide treatment,No,Amiodarone,,No
01/11/2016 15:35,01/11/2016 15:42,IP Address,86.184.138.185,100,420,TRUE,01/11/2016 15:42,R_3shUwgCe48fih1D,,,,,50.26170349,-5.043304443,anonymous,Tertiary Referral Centre or University Hospital,1000-2000,23,Mixed ICU,,Consultant,More than 10 years,Anaesthesia,"Independent of their heart rate I treat all patients who have developed new onset fast AF, even if the blood pressure remains stable",Rhythm control,Amiodarone,,Supplement electrolytes to a high normal level and anti-arrhythmics,>4.5 mmol/l,1.0-1.2 mmol/l,Pharmacokinetic advantages,,New onset AF within 72 hours,"Stroke risk scores inaccurately reflect the risk of embolic events in critically ill patients with new-onset atrial fibrillation due to prothrombotic changes associated with critical illness,Stroke risk scores favour anti-coagulation despite a higher risk of bleeding in critical illness,Modified risk scores should be developed for critically ill patients with new-onset atrial fibrillation",I do not regularly anti-coagulate critically ill patients with new onset fast AF,I do not routinely perform Echocardiography to guide treatment,Yes,Digoxin,,No
01/11/2016 15:53,01/11/2016 15:59,IP Address,165.225.80.136,100,357,TRUE,01/11/2016 15:59,R_5hjLyzP4i73A3s1,,,,,51.51420593,-0.093093872,anonymous,District General Hospital,500-1000,9,Mixed ICU,,Trainee,3-5 years,Anaesthesia,120-139/beats per min,Rate control,Amiodarone,,Supplement electrolytes (magnesium and/or potassium) to a high normal level,>4.5 mmol/l,1.0-1.2 mmol/l,ICU drug policy,,I do not regularly anti-coagulate critically ill patients with new-onset fast AF,I do not use stroke risk scores routinely in critically ill patients with new onset AF to assess the need for anticoagulation,Subcutaneous Low Molecular Weight heparin in therapeutic dose,I regularly perform or request transthoracic echocardiography,Yes,Amiodarone,,No
01/11/2016 16:03,01/11/2016 16:07,IP Address,193.63.75.68,100,270,TRUE,01/11/2016 16:07,R_3siyWheZvttAYTR,,,,,51.52070618,-0.196502686,anonymous,Teaching Hospital,500-1000,16,Mixed ICU,,Consultant,More than 10 years,Anaesthesia,"Independent of their heart rate I treat all patients who have developed new onset fast AF, even if the blood pressure remains stable",Rate control,Amiodarone,,Supplement electrolytes to a high normal level and anti-arrhythmics,>4 mmol/l,>1.2 mmol/l,ICU drug policy,,New onset AF within 48 hours,"I do not use stroke risk scores routinely in critically ill patients with new onset AF to assess the need for anticoagulation,Stroke risk scores inaccurately reflect the risk of embolic events in critically ill patients with new-onset atrial fibrillation due to prothrombotic changes associated with critical illness,Stroke risk scores favour anti-coagulation despite a higher risk of bleeding in critical illness,Modified risk scores should be developed for critically ill patients with new-onset atrial fibrillation","Intravenous High Molecular Weight heparin in therapeutic dose,Subcutaneous Low Molecular Weight heparin in therapeutic dose",I regularly perform or request transthoracic echocardiography,Yes,Amiodarone,,Yes
01/11/2016 16:09,01/11/2016 16:14,IP Address,81.132.110.215,100,267,TRUE,01/11/2016 16:14,R_1mmjLja2BjFQxmn,,,,,51.05470276,-2.733901978,anonymous,District General Hospital,500-1000,12,Mixed ICU,,Consultant,More than 10 years,Anaesthesia,100-119/beats per min,Rate control,ß-blocker,,Supplement electrolytes to a high normal level and anti-arrhythmics,>4.5 mmol/l,0.75-1 mmol/l,"Pharmacokinetic advantages,Pharmacodynamic properties,Adverse effect profile",,New onset AF within 48 hours,"I do not use stroke risk scores routinely in critically ill patients with new onset AF to assess the need for anticoagulation,I regularly calculate a risk score (e. g. CHAD2, CHA2DS2-VASc) to assess the need for anti-coagulation,Stroke risk scores inaccurately reflect the risk of embolic events in critically ill patients with new-onset atrial fibrillation due to prothrombotic changes associated with critical illness,Stroke risk scores favour anti-coagulation despite a higher risk of bleeding in critical illness,Modified risk scores should be developed for critically ill patients with new-onset atrial fibrillation",Subcutaneous Low Molecular Weight heparin in therapeutic dose,I regularly perform or request transthoracic echocardiography,Yes,ß-blocker,,No
01/11/2016 16:44,01/11/2016 16:52,IP Address,148.252.128.180,100,457,TRUE,01/11/2016 16:52,R_3lreR5Y7A726x9O,,,,,51.55000305,-0.050003052,anonymous,Teaching Hospital,1000-2000,18,Mixed ICU,,Consultant,More than 10 years,Anaesthesia,120-139/beats per min,Rate control,ß-blocker,,Supplement electrolytes to a high normal level and DC cardioversion,>4.5 mmol/l,0.75-1 mmol/l,ICU drug policy,,New onset AF within 48 hours,"Stroke risk scores inaccurately reflect the risk of embolic events in critically ill patients with new-onset atrial fibrillation due to prothrombotic changes associated with critical illness,Modified risk scores should be developed for critically ill patients with new-onset atrial fibrillation",Subcutaneous Low Molecular Weight heparin in therapeutic dose,I do not routinely perform Echocardiography to guide treatment,No,Amiodarone,,Yes
01/11/2016 16:49,01/11/2016 16:52,IP Address,159.86.191.19,100,191,TRUE,01/11/2016 16:52,R_bqDfItgRYM4gC65,,,,,51.60139465,-3.344696045,anonymous,Tertiary Referral Centre or University Hospital,500-1000,9,Specialist ICU (please name specialty):,Cardiac,Consultant,More than 10 years,Anaesthesia,100-119/beats per min,Rate control,Amiodarone,,Supplement electrolytes to a high normal level and anti-arrhythmics,>4.5 mmol/l,1.0-1.2 mmol/l,Pharmacodynamic properties,,New onset AF within 48 hours,I do not use stroke risk scores routinely in critically ill patients with new onset AF to assess the need for anticoagulation,Subcutaneous Low Molecular Weight heparin in therapeutic dose,I do not routinely perform Echocardiography to guide treatment,No,Amiodarone,,No
01/11/2016 16:54,01/11/2016 16:58,IP Address,82.132.186.96,100,254,TRUE,01/11/2016 16:58,R_qJgReF87tHsX1x7,,,,,51.49639893,-0.122406006,anonymous,District General Hospital,500-1000,12,Mixed ICU,,Consultant,More than 10 years,Anaesthesia,120-139/beats per min,Rate control,ß-blocker,,Supplement electrolytes to a high normal level and anti-arrhythmics,>4.5 mmol/l,1.0-1.2 mmol/l,"Pharmacodynamic properties,Adverse effect profile",,New onset AF within 48 hours,I do not use stroke risk scores routinely in critically ill patients with new onset AF to assess the need for anticoagulation,Subcutaneous Low Molecular Weight heparin in therapeutic dose,I do not routinely perform Echocardiography to guide treatment,Yes,ß-blocker,,Yes
01/11/2016 16:58,01/11/2016 17:03,IP Address,80.194.246.130,100,263,TRUE,01/11/2016 17:03,R_re8j6mUblicd7qh,,,,,51.73330688,0.483306885,anonymous,District General Hospital,<500,6,Specialist ICU (please name specialty):,Burns,Consultant,3-5 years,Anaesthesia,120-139/beats per min,Rhythm control,Amiodarone,,Supplement electrolytes to a high normal level and anti-arrhythmics,>4.5 mmol/l,1.0-1.2 mmol/l,"Availability from hospital pharmacy,ICU drug policy,Pharmacokinetic advantages,Adverse effect profile",,New onset AF within 48 hours,"I do not use stroke risk scores routinely in critically ill patients with new onset AF to assess the need for anticoagulation,Modified risk scores should be developed for critically ill patients with new-onset atrial fibrillation",Subcutaneous Low Molecular Weight heparin in therapeutic dose,I only regularly perform Echocardiography in patients with cardiac history,Yes,"Amiodarone,DC cardioversion,ß-blocker,Diltiazem",,No
01/11/2016 17:45,01/11/2016 17:55,IP Address,79.67.148.245,100,570,TRUE,01/11/2016 17:55,R_2t4h5C7E9CtD6MN,,,,,53.13330078,-1.199996948,anonymous,Tertiary Referral Centre or University Hospital,1000-2000,22,Mixed ICU,,Consultant,5-10 years,Anaesthesia,"Independent of their heart rate I treat all patients who have developed new onset fast AF, even if the blood pressure remains stable",Rhythm control,Amiodarone,,Supplement electrolytes to a high normal level and anti-arrhythmics,>4.5 mmol/l,>1.2 mmol/l,"Availability from hospital pharmacy,ICU drug policy,Cost",,I do not regularly anti-coagulate critically ill patients with new-onset fast AF,Stroke risk scores inaccurately reflect the risk of embolic events in critically ill patients with new-onset atrial fibrillation due to prothrombotic changes associated with critical illness,I do not regularly anti-coagulate critically ill patients with new onset fast AF,I do not routinely perform Echocardiography to guide treatment,Yes,"Amiodarone,DC cardioversion,ß-blocker",,Yes
01/11/2016 17:53,01/11/2016 17:58,IP Address,86.158.47.30,100,349,TRUE,01/11/2016 17:58,R_6EyNx1M06TbhOUN,,,,,52.13330078,-0.449996948,anonymous,District General Hospital,500-1000,10,Mixed ICU,,Consultant,More than 10 years,Anaesthesia,140-159/beats per min,Rate control,Amiodarone,,Supplement electrolytes to a high normal level and anti-arrhythmics,>4 mmol/l,0.75-1 mmol/l,"Availability from hospital pharmacy,Pharmacokinetic advantages,Pharmacodynamic properties,Adverse effect profile",,I do not regularly anti-coagulate critically ill patients with new-onset fast AF,"I do not use stroke risk scores routinely in critically ill patients with new onset AF to assess the need for anticoagulation,Stroke risk scores inaccurately reflect the risk of embolic events in critically ill patients with new-onset atrial fibrillation due to prothrombotic changes associated with critical illness,Stroke risk scores favour anti-coagulation despite a higher risk of bleeding in critical illness,Modified risk scores should be developed for critically ill patients with new-onset atrial fibrillation","Intravenous High Molecular Weight heparin in therapeutic dose,Subcutaneous Low Molecular Weight heparin in therapeutic dose",I do not routinely perform Echocardiography to guide treatment,Yes,"Amiodarone,DC cardioversion,Digoxin",,Yes
01/11/2016 18:34,01/11/2016 18:38,IP Address,86.63.24.71,100,270,TRUE,01/11/2016 18:38,R_C4aqrl2SMgGvr57,,,,,50.7631073,-1.297698975,anonymous,Tertiary Referral Centre or University Hospital,500-1000,13,Specialist ICU (please name specialty):,Neuro critical care,Trainee,3-5 years,Intensive Care Medicine only,120-139/beats per min,I have no primary treatment goal in these patients,ß-blocker,,Supplement electrolytes (magnesium and/or potassium) to a high normal level,>4.5 mmol/l,1.0-1.2 mmol/l,ICU drug policy,,Before starting anti-arrhythmic medication,"I regularly calculate a risk score (e. g. CHAD2, CHA2DS2-VASc) to assess the need for anti-coagulation","Intravenous High Molecular Weight heparin in therapeutic dose,Subcutaneous Low Molecular Weight heparin in therapeutic dose",I regularly perform or request transthoracic echocardiography,Yes,Flecainide,,Yes
01/11/2016 18:47,01/11/2016 18:52,IP Address,90.254.102.36,100,339,TRUE,01/11/2016 18:52,R_2tzfOjsvTJBM28l,,,,,53.5,-2.216705322,anonymous,Teaching Hospital,I do not know,40,Mixed ICU,,Trainee,1-3 years,Acute medicine,"Independent of their heart rate I treat all patients who have developed new onset fast AF, even if the blood pressure remains stable",Rhythm control,Amiodarone,,Supplement electrolytes to a high normal level and anti-arrhythmics,>4.5 mmol/l,1.0-1.2 mmol/l,ICU drug policy,,New onset AF within 24 hours,"I regularly calculate a risk score (e. g. CHAD2, CHA2DS2-VASc) to assess the need for anti-coagulation",Subcutaneous Low Molecular Weight heparin in therapeutic dose,I regularly perform or request transthoracic echocardiography,Yes,Diltiazem,,No
01/11/2016 18:56,01/11/2016 19:00,IP Address,82.132.228.169,100,188,TRUE,01/11/2016 19:00,R_puTFO5CLqWO0usN,,,,,51.49639893,-0.122406006,anonymous,District General Hospital,500-1000,9,Predominantly medical,,Consultant,More than 10 years,Anaesthesia,100-119/beats per min,Rate control,Amiodarone,,Supplement electrolytes to a high normal level and anti-arrhythmics,>4.5 mmol/l,1.0-1.2 mmol/l,"Other, please specify:",Efficacy ,I do not regularly anti-coagulate critically ill patients with new-onset fast AF,I do not use stroke risk scores routinely in critically ill patients with new onset AF to assess the need for anticoagulation,Intravenous High Molecular Weight heparin in therapeutic dose,I do not routinely perform Echocardiography to guide treatment,Yes,Flecainide,,No
01/11/2016 19:00,01/11/2016 19:11,IP Address,194.176.105.166,100,670,TRUE,01/11/2016 19:11,R_BsRENG7UhA4Q6Ax,,,,,51.41670227,-0.283294678,anonymous,District General Hospital,500-1000,19,Predominantly medical,,Consultant,5-10 years,Anaesthesia,"Independent of their heart rate I treat all patients who have developed new onset fast AF, even if the blood pressure remains stable",Rhythm control,Amiodarone,,Supplement electrolytes to a high normal level and anti-arrhythmics,>4 mmol/l,1.0-1.2 mmol/l,Pharmacodynamic properties,,New onset AF within 72 hours,"I regularly calculate a risk score (e. g. CHAD2, CHA2DS2-VASc) to assess the need for anti-coagulation",Subcutaneous Low Molecular Weight heparin in therapeutic dose,I regularly perform or request transthoracic echocardiography,Yes,"DC cardioversion,Flecainide,Diltiazem,Other anti-arrhythmics (e. g. verapamil, sotalol): Please specify:",Verapamil,No
01/11/2016 19:19,01/11/2016 19:33,IP Address,143.159.0.151,100,883,TRUE,01/11/2016 19:33,R_3KObcEop4xLcseR,,,,,53.43330383,-1.350006104,anonymous,District General Hospital,1000-2000,17,Mixed ICU,,Consultant,3-5 years,Anaesthesia,120-139/beats per min,Rhythm control,Amiodarone,,Supplement electrolytes (magnesium and/or potassium) to a high normal level,>4 mmol/l,1.0-1.2 mmol/l,"Pharmacokinetic advantages,Adverse effect profile",,I do not regularly anti-coagulate critically ill patients with new-onset fast AF,"I do not use stroke risk scores routinely in critically ill patients with new onset AF to assess the need for anticoagulation,Modified risk scores should be developed for critically ill patients with new-onset atrial fibrillation","Intravenous High Molecular Weight heparin in therapeutic dose,Subcutaneous Low Molecular Weight heparin in therapeutic dose,I do not regularly anti-coagulate critically ill patients with new onset fast AF",I do not routinely perform Echocardiography to guide treatment,Yes,DC cardioversion,,Yes
01/11/2016 19:54,01/11/2016 20:02,IP Address,82.42.65.242,100,489,TRUE,01/11/2016 20:02,R_prtEMlXpRhqODkJ,,,,,55.00469971,-1.472793579,anonymous,District General Hospital,500-1000,9,Mixed ICU,,Consultant,5-10 years,Anaesthesia,120-139/beats per min,Rate control,"Other anti-arrhythmics (e. g. Verapamil, sotalol): please specify:",Magnesium,Supplement electrolytes to a high normal level and anti-arrhythmics,>4.5 mmol/l,1.0-1.2 mmol/l,"Pharmacodynamic properties,Adverse effect profile",,New onset AF within 48 hours,"I regularly calculate a risk score (e. g. CHAD2, CHA2DS2-VASc) to assess the need for anti-coagulation,Modified risk scores should be developed for critically ill patients with new-onset atrial fibrillation",Subcutaneous Low Molecular Weight heparin in therapeutic dose,I regularly perform or request transthoracic echocardiography,Yes,"Amiodarone,Other anti-arrhythmics (e. g. verapamil, sotalol): Please specify:",Magnesium,Yes
01/11/2016 20:12,01/11/2016 20:15,IP Address,62.103.185.74,100,181,TRUE,01/11/2016 20:15,R_3fxVjokMhxeZ592,,,,,37.98330688,23.73330688,anonymous,District General Hospital,1000-2000,13,Mixed ICU,,Consultant,More than 10 years,Anaesthesia,120-139/beats per min,Rate control,Amiodarone,,Supplement electrolytes to a high normal level and anti-arrhythmics,>4.5 mmol/l,1.0-1.2 mmol/l,"Other, please specify:",Experience ,I do not regularly anti-coagulate critically ill patients with new-onset fast AF,I do not use stroke risk scores routinely in critically ill patients with new onset AF to assess the need for anticoagulation,I do not regularly anti-coagulate critically ill patients with new onset fast AF,I do not routinely perform Echocardiography to guide treatment,Yes,"Flecainide,Diltiazem",,Yes
01/11/2016 20:39,01/11/2016 20:42,IP Address,86.171.245.242,100,197,TRUE,01/11/2016 20:42,R_XQSQi91QFyHCsTf,,,,,51.57629395,0.421707153,anonymous,Teaching Hospital,<500,11,Mixed ICU,,Consultant,More than 10 years,Anaesthesia,120-139/beats per min,Rhythm control,Amiodarone,,DC cardioversion when anti-arrhythmics and electrolyte replacement fail to achieve rate and/or rhythm control,>4.5 mmol/l,I do not aim for a specific serum magnesium level,Adverse effect profile,,New onset AF within 72 hours,Modified risk scores should be developed for critically ill patients with new-onset atrial fibrillation,Subcutaneous Low Molecular Weight heparin in therapeutic dose,I only regularly perform Echocardiography in patients with cardiac history,Yes,Amiodarone,,No
01/11/2016 19:33,01/11/2016 20:47,IP Address,81.141.14.122,100,4395,TRUE,01/11/2016 20:47,R_1gdoHqScTs8rNVI,,,,,51.5,-0.083297729,anonymous,Tertiary Referral Centre or University Hospital,>2000,79,Specialist ICU (please name specialty):,Mixed & specialist ,Consultant,More than 10 years,Anaesthesia,100-119/beats per min,Rhythm control,Amiodarone,,Supplement electrolytes to a high normal level and anti-arrhythmics,>4.5 mmol/l,>1.2 mmol/l,"Other, please specify:",Efficacy & short term 'unwanted' effect profile,I do not regularly anti-coagulate critically ill patients with new-onset fast AF,"Stroke risk scores inaccurately reflect the risk of embolic events in critically ill patients with new-onset atrial fibrillation due to prothrombotic changes associated with critical illness,Modified risk scores should be developed for critically ill patients with new-onset atrial fibrillation","Intravenous High Molecular Weight heparin in therapeutic dose,Subcutaneous Low Molecular Weight heparin in therapeutic dose,I do not regularly anti-coagulate critically ill patients with new onset fast AF",I regularly perform or request transthoracic echocardiography,Yes,Digoxin,,No
01/11/2016 21:04,01/11/2016 21:14,IP Address,82.8.204.170,100,627,TRUE,01/11/2016 21:15,R_2wbrwd5zO8JRB1M,,,,,52.19999695,0.116699219,anonymous,District General Hospital,500-1000,12,Mixed ICU,,Trainee,1-3 years,Anaesthesia,120-139/beats per min,Rate control,Digoxin,,Supplement electrolytes to a high normal level and anti-arrhythmics,>4.5 mmol/l,1.0-1.2 mmol/l,"Pharmacodynamic properties,Adverse effect profile",,I do not regularly anti-coagulate critically ill patients with new-onset fast AF,"I do not use stroke risk scores routinely in critically ill patients with new onset AF to assess the need for anticoagulation,Stroke risk scores inaccurately reflect the risk of embolic events in critically ill patients with new-onset atrial fibrillation due to prothrombotic changes associated with critical illness,Modified risk scores should be developed for critically ill patients with new-onset atrial fibrillation","Intravenous High Molecular Weight heparin in therapeutic dose,Subcutaneous Low Molecular Weight heparin in therapeutic dose,Use of novel oral anti-coagulants (NOACs)",I do not routinely perform Echocardiography to guide treatment,Yes,Digoxin,,Yes
01/11/2016 21:57,01/11/2016 22:04,IP Address,94.5.3.241,100,389,TRUE,01/11/2016 22:04,R_2Pd6tZAtpUHTaef,,,,,51.51420593,-0.093093872,anonymous,Tertiary Referral Centre or University Hospital,500-1000,20,Specialist ICU (please name specialty):,Cardiac,Trainee,1-3 years,Intensive Care Medicine only,120-139/beats per min,Rhythm control,Amiodarone,,Supplement electrolytes (magnesium and/or potassium) to a high normal level,>4.5 mmol/l,1.0-1.2 mmol/l,Adverse effect profile,,New onset AF within 48 hours,"Stroke risk scores inaccurately reflect the risk of embolic events in critically ill patients with new-onset atrial fibrillation due to prothrombotic changes associated with critical illness,Modified risk scores should be developed for critically ill patients with new-onset atrial fibrillation","Intravenous High Molecular Weight heparin in therapeutic dose,Subcutaneous Low Molecular Weight heparin in therapeutic dose",I regularly perform or request transthoracic echocardiography,Yes,ß-blocker,,Yes
01/11/2016 22:26,01/11/2016 22:32,IP Address,2.123.83.52,100,370,TRUE,01/11/2016 22:32,R_2bPEebmsv2ry3PE,,,,,51.3999939,0.050003052,anonymous,District General Hospital,500-1000,18,Predominantly medical,,Consultant,More than 10 years,Anaesthesia,100-119/beats per min,Rhythm control,Amiodarone,,Supplement electrolytes (magnesium and/or potassium) to a high normal level,>4.5 mmol/l,I do not aim for a specific serum magnesium level,Pharmacodynamic properties,,I do not regularly anti-coagulate critically ill patients with new-onset fast AF,I do not use stroke risk scores routinely in critically ill patients with new onset AF to assess the need for anticoagulation,I do not regularly anti-coagulate critically ill patients with new onset fast AF,I do not routinely perform Echocardiography to guide treatment,No,Amiodarone,,No
01/11/2016 23:15,01/11/2016 23:22,IP Address,86.159.54.227,100,401,TRUE,01/11/2016 23:22,R_2e2atxRveAlfo6D,,,,,51.33050537,-0.270095825,anonymous,Tertiary Referral Centre or University Hospital,1000-2000,18,Specialist ICU (please name specialty):,Neuro-ITU,Consultant,More than 10 years,Anaesthesia,"Independent of their heart rate I treat all patients who have developed new onset fast AF, even if the blood pressure remains stable",Rate control,ß-blocker,,Supplement electrolytes to a high normal level and DC cardioversion,>4.5 mmol/l,1.0-1.2 mmol/l,Pharmacokinetic advantages,,I do not regularly anti-coagulate critically ill patients with new-onset fast AF,I do not use stroke risk scores routinely in critically ill patients with new onset AF to assess the need for anticoagulation,Subcutaneous Low Molecular Weight heparin in therapeutic dose,I regularly perform or request transthoracic echocardiography,Yes,ß-blocker,,Yes
02/11/2016 00:18,02/11/2016 00:23,IP Address,81.97.25.32,100,281,TRUE,02/11/2016 00:23,R_ONnifR5bbLfOYM1,,,,,52.58329773,-0.25,anonymous,District General Hospital,<500,14,Mixed ICU,,Consultant,More than 10 years,Anaesthesia,"Independent of their heart rate I treat all patients who have developed new onset fast AF, even if the blood pressure remains stable",Rhythm control,Amiodarone,,Supplement electrolytes to a high normal level and anti-arrhythmics,>4.5 mmol/l,1.0-1.2 mmol/l,"Pharmacokinetic advantages,Pharmacodynamic properties",,I do not regularly anti-coagulate critically ill patients with new-onset fast AF,"I do not use stroke risk scores routinely in critically ill patients with new onset AF to assess the need for anticoagulation,Modified risk scores should be developed for critically ill patients with new-onset atrial fibrillation","Intravenous High Molecular Weight heparin in therapeutic dose,I do not regularly anti-coagulate critically ill patients with new onset fast AF",I do not routinely perform Echocardiography to guide treatment,Yes,"Amiodarone,DC cardioversion,ß-blocker,Digoxin",,Yes
01/11/2016 12:11,02/11/2016 05:50,IP Address,213.205.251.179,100,63539,TRUE,02/11/2016 05:50,R_6nBPg3cKvxFdW6J,,,,,51.51420593,-0.093093872,anonymous,Teaching Hospital,<500,4 and 6 ,Mixed ICU,,Consultant,More than 10 years,Anaesthesia,"Independent of their heart rate I treat all patients who have developed new onset fast AF, even if the blood pressure remains stable",I have no primary treatment goal in these patients,Amiodarone,,Supplement electrolytes to a high normal level and anti-arrhythmics,>4.5 mmol/l,1.0-1.2 mmol/l,"Pharmacokinetic advantages,Pharmacodynamic properties",,I do not regularly anti-coagulate critically ill patients with new-onset fast AF,I do not use stroke risk scores routinely in critically ill patients with new onset AF to assess the need for anticoagulation,I do not regularly anti-coagulate critically ill patients with new onset fast AF,I do not routinely perform Echocardiography to guide treatment,Yes,DC cardioversion,,No
02/11/2016 06:14,02/11/2016 06:20,IP Address,213.205.252.178,100,320,TRUE,02/11/2016 06:20,R_AArXVXISvpqMhCp,,,,,52.6000061,-2,anonymous,Tertiary Referral Centre or University Hospital,>2000,78,Specialist ICU (please name specialty):,Burns / Trauma / Neuro,Consultant,5-10 years,Anaesthesia,140-159/beats per min,Rhythm control,"Other anti-arrhythmics (e. g. Verapamil, sotalol): please specify:",Magnesium,Supplement electrolytes (magnesium and/or potassium) to a high normal level,>4.5 mmol/l,>1.2 mmol/l,"Other, please specify:",Literature,I do not regularly anti-coagulate critically ill patients with new-onset fast AF,I do not use stroke risk scores routinely in critically ill patients with new onset AF to assess the need for anticoagulation,I do not regularly anti-coagulate critically ill patients with new onset fast AF,I regularly perform or request transthoracic echocardiography,Yes,"Other anti-arrhythmics (e. g. verapamil, sotalol): Please specify:",Magnesium,Yes
02/11/2016 07:15,02/11/2016 07:18,IP Address,90.214.118.253,100,157,TRUE,02/11/2016 07:18,R_2dWT2wMfgoomgKI,,,,,52.19999695,0.116699219,anonymous,Teaching Hospital,1000-2000,20,Mixed ICU,,Trainee,5-10 years,Anaesthesia,140-159/beats per min,Rate control,Amiodarone,,Supplement electrolytes (magnesium and/or potassium) to a high normal level,>4.5 mmol/l,0.75-1 mmol/l,"ICU drug policy,Adverse effect profile",,I do not regularly anti-coagulate critically ill patients with new-onset fast AF,"I do not use stroke risk scores routinely in critically ill patients with new onset AF to assess the need for anticoagulation,Modified risk scores should be developed for critically ill patients with new-onset atrial fibrillation","Subcutaneous Low Molecular Weight heparin in therapeutic dose,I do not regularly anti-coagulate critically ill patients with new onset fast AF",I do not routinely perform Echocardiography to guide treatment,Yes,"Amiodarone,ß-blocker,Digoxin",,Yes
02/11/2016 08:06,02/11/2016 08:09,IP Address,86.178.149.203,100,171,TRUE,02/11/2016 08:09,R_3kChZNR7rGYOQ8h,,,,,53.36669922,-1.5,anonymous,District General Hospital,1000-2000,15,Mixed ICU,,Consultant,More than 10 years,Anaesthesia,120-139/beats per min,Rate control,Amiodarone,,Supplement electrolytes to a high normal level and anti-arrhythmics,>4.5 mmol/l,0.75-1 mmol/l,Adverse effect profile,,I do not regularly anti-coagulate critically ill patients with new-onset fast AF,I do not use stroke risk scores routinely in critically ill patients with new onset AF to assess the need for anticoagulation,I do not regularly anti-coagulate critically ill patients with new onset fast AF,I regularly perform or request transthoracic echocardiography,Yes,ß-blocker,,Yes
02/11/2016 08:41,02/11/2016 08:47,IP Address,188.39.68.2,100,338,TRUE,02/11/2016 08:47,R_1pEX1Y0DyJ1Lovv,,,,,50.83329773,-0.149993896,anonymous,Tertiary Referral Centre or University Hospital,>2000,34,Mixed ICU,,Consultant,More than 10 years,Anaesthesia,100-119/beats per min,Rate control,Amiodarone,,Supplement electrolytes to a high normal level and anti-arrhythmics,>4 mmol/l,1.0-1.2 mmol/l,"Availability from hospital pharmacy,Pharmacodynamic properties",,I do not regularly anti-coagulate critically ill patients with new-onset fast AF,I do not use stroke risk scores routinely in critically ill patients with new onset AF to assess the need for anticoagulation,"Intravenous High Molecular Weight heparin in therapeutic dose,Subcutaneous Low Molecular Weight heparin in therapeutic dose,I do not regularly anti-coagulate critically ill patients with new onset fast AF",I regularly perform or request transthoracic echocardiography,Yes,"Amiodarone,DC cardioversion,ß-blocker,Digoxin",,Yes
02/11/2016 08:49,02/11/2016 08:55,IP Address,2.125.146.0,100,382,TRUE,02/11/2016 08:55,R_1hQNLNn1bKmuXWp,,,,,53.48330688,-1.266693115,anonymous,District General Hospital,500-1000,16,Mixed ICU,,Consultant,5-10 years,Anaesthesia,140-159/beats per min,Rhythm control,Amiodarone,,Supplement electrolytes to a high normal level and anti-arrhythmics,>4.5 mmol/l,1.0-1.2 mmol/l,"ICU drug policy,Pharmacokinetic advantages,Pharmacodynamic properties,Adverse effect profile",,I do not regularly anti-coagulate critically ill patients with new-onset fast AF,"I do not use stroke risk scores routinely in critically ill patients with new onset AF to assess the need for anticoagulation,Stroke risk scores inaccurately reflect the risk of embolic events in critically ill patients with new-onset atrial fibrillation due to prothrombotic changes associated with critical illness,Modified risk scores should be developed for critically ill patients with new-onset atrial fibrillation","Intravenous High Molecular Weight heparin in therapeutic dose,Subcutaneous Low Molecular Weight heparin in therapeutic dose",I do not routinely perform Echocardiography to guide treatment,Yes,"Amiodarone,ß-blocker,Digoxin",,Yes
02/11/2016 08:49,02/11/2016 08:56,IP Address,90.207.99.68,100,401,TRUE,02/11/2016 08:56,R_3PKNnCqXbMk9ER8,,,,,51.83329773,-2.25,anonymous,District General Hospital,1000-2000,14,Mixed ICU,,SAS,More than 10 years,Anaesthesia,120-139/beats per min,Rate control,Digoxin,,Supplement electrolytes to a high normal level and anti-arrhythmics,>4.5 mmol/l,0.75-1 mmol/l,"Availability from hospital pharmacy,ICU drug policy,Pharmacokinetic advantages,Pharmacodynamic properties",,I do not regularly anti-coagulate critically ill patients with new-onset fast AF,Modified risk scores should be developed for critically ill patients with new-onset atrial fibrillation,I do not regularly anti-coagulate critically ill patients with new onset fast AF,"I do not routinely perform Echocardiography to guide treatment,I only regularly perform Echocardiography in patients with cardiac history",Yes,"Amiodarone,ß-blocker,Digoxin",,No
02/11/2016 09:13,02/11/2016 09:16,IP Address,164.39.215.34,100,187,TRUE,02/11/2016 09:16,R_6J31DtejZ4PYY8l,,,,,53.5,-2.216705322,anonymous,Tertiary Referral Centre or University Hospital,1000-2000,17,Mixed ICU,,Consultant,More than 10 years,Anaesthesia,120-139/beats per min,Rate control,Amiodarone,,Supplement electrolytes to a high normal level and anti-arrhythmics,>4.5 mmol/l,1.0-1.2 mmol/l,Pharmacokinetic advantages,,I do not regularly anti-coagulate critically ill patients with new-onset fast AF,I do not use stroke risk scores routinely in critically ill patients with new onset AF to assess the need for anticoagulation,I do not regularly anti-coagulate critically ill patients with new onset fast AF,I do not routinely perform Echocardiography to guide treatment,No,Amiodarone,,No
02/11/2016 09:22,02/11/2016 09:26,IP Address,143.159.213.234,100,259,TRUE,02/11/2016 09:26,R_dhxcx7Hb7BtUEcp,,,,,53.34049988,-1.478103638,anonymous,District General Hospital,I do not know,21,Mixed ICU,,Trainee,3-5 years,Anaesthesia,140-159/beats per min,Rate control,Amiodarone,,Supplement electrolytes (magnesium and/or potassium) to a high normal level,>4.5 mmol/l,1.0-1.2 mmol/l,"Availability from hospital pharmacy,Pharmacodynamic properties,Adverse effect profile",,New onset AF within 48 hours,Modified risk scores should be developed for critically ill patients with new-onset atrial fibrillation,"Intravenous High Molecular Weight heparin in therapeutic dose,Subcutaneous Low Molecular Weight heparin in therapeutic dose",I regularly perform or request transthoracic echocardiography,Yes,Amiodarone,,Yes
02/11/2016 10:53,02/11/2016 10:59,IP Address,194.176.105.171,100,349,TRUE,02/11/2016 10:59,R_CeOtOPzoKfolTwZ,,,,,52.36669922,-1.25,anonymous,Tertiary Referral Centre or University Hospital,500-1000,23,Mixed ICU,,Trainee,3-5 years,Emergency Medicine,100-119/beats per min,Rhythm control,Amiodarone,,Supplement electrolytes to a high normal level and anti-arrhythmics,>4.5 mmol/l,1.0-1.2 mmol/l,"Pharmacodynamic properties,Adverse effect profile",,I do not regularly anti-coagulate critically ill patients with new-onset fast AF,Modified risk scores should be developed for critically ill patients with new-onset atrial fibrillation,Subcutaneous Low Molecular Weight heparin in therapeutic dose,I regularly perform or request transthoracic echocardiography,Yes,"Amiodarone,ß-blocker,Flecainide",,Yes
02/11/2016 11:16,02/11/2016 11:26,IP Address,87.127.117.192,100,575,TRUE,02/11/2016 11:26,R_2fDQ2dutQr6NigY,,,,,51.49639893,-0.122406006,anonymous,District General Hospital,500-1000,16 to 18,Mixed ICU,,SAS,More than 10 years,Anaesthesia,120-139/beats per min,Rate control,Amiodarone,,Supplement electrolytes (magnesium and/or potassium) to a high normal level,>4 mmol/l,0.75-1 mmol/l,Pharmacokinetic advantages,,New onset AF within 48 hours,I do not use stroke risk scores routinely in critically ill patients with new onset AF to assess the need for anticoagulation,Subcutaneous Low Molecular Weight heparin in therapeutic dose,I do not routinely perform Echocardiography to guide treatment,No,Amiodarone,,Yes
02/11/2016 11:41,02/11/2016 11:49,IP Address,194.176.105.138,100,490,TRUE,02/11/2016 11:49,R_0ktrdz6xUefEw6x,,,,,51.51420593,-0.093093872,anonymous,District General Hospital,500-1000,13,Mixed ICU,,Consultant,More than 10 years,Anaesthesia,100-119/beats per min,Rhythm control,Amiodarone,,Supplement electrolytes to a high normal level and anti-arrhythmics,>4.5 mmol/l,>1.2 mmol/l,"Adverse effect profile,Other, please specify:",Perceived efficacy,I do not regularly anti-coagulate critically ill patients with new-onset fast AF,"I do not use stroke risk scores routinely in critically ill patients with new onset AF to assess the need for anticoagulation,Stroke risk scores inaccurately reflect the risk of embolic events in critically ill patients with new-onset atrial fibrillation due to prothrombotic changes associated with critical illness,Stroke risk scores favour anti-coagulation despite a higher risk of bleeding in critical illness,Modified risk scores should be developed for critically ill patients with new-onset atrial fibrillation",I do not regularly anti-coagulate critically ill patients with new onset fast AF,I regularly perform or request transthoracic echocardiography,No,"Amiodarone,ß-blocker",,No
31/10/2016 16:08,02/11/2016 11:50,IP Address,163.1.192.21,100,157352,TRUE,02/11/2016 11:50,R_1kT5Z6EZodQsTed,,,,,51.75,-1.25,anonymous,Tertiary Referral Centre or University Hospital,1000-2000,19,Mixed ICU,,Consultant,More than 10 years,Acute medicine,120-139/beats per min,Rate control,Amiodarone,,Supplement electrolytes (magnesium and/or potassium) to a high normal level,>4 mmol/l,1.0-1.2 mmol/l,"Other, please specify:",evidenceless belief it works better,New onset AF within 24 hours,Modified risk scores should be developed for critically ill patients with new-onset atrial fibrillation,Subcutaneous Low Molecular Weight heparin in therapeutic dose,I do not routinely perform Echocardiography to guide treatment,Yes,"Amiodarone,ß-blocker,Digoxin",,Yes
02/11/2016 13:44,02/11/2016 13:49,IP Address,159.86.191.19,100,348,TRUE,02/11/2016 13:49,R_2En1SCgLzpuHAhe,,,,,51.60139465,-3.344696045,anonymous,Tertiary Referral Centre or University Hospital,I do not know,40,Mixed ICU,,Trainee,1-3 years,Acute medicine,140-159/beats per min,Rate control,Amiodarone,,Supplement electrolytes to a high normal level and anti-arrhythmics,>4 mmol/l,I do not aim for a specific serum magnesium level,ICU drug policy,,New onset AF within 72 hours,"I regularly calculate a risk score (e. g. CHAD2, CHA2DS2-VASc) to assess the need for anti-coagulation","Intravenous High Molecular Weight heparin in therapeutic dose,Use of novel oral anti-coagulants (NOACs),Use of warfarin",I regularly perform or request transthoracic echocardiography,Yes,"Amiodarone,DC cardioversion,ß-blocker,Diltiazem",,Yes
02/11/2016 15:16,02/11/2016 15:19,IP Address,85.255.237.241,100,204,TRUE,02/11/2016 15:19,R_w76gx2vjQ6GWnqp,,,,,51.49639893,-0.122406006,anonymous,Tertiary Referral Centre or University Hospital,1000-2000,41,Mixed ICU,,Consultant,3-5 years,Anaesthesia,100-119/beats per min,Rate control,Amiodarone,,Supplement electrolytes to a high normal level and anti-arrhythmics,>4.5 mmol/l,>1.2 mmol/l,ICU drug policy,,I do not regularly anti-coagulate critically ill patients with new-onset fast AF,"I regularly calculate a risk score (e. g. CHAD2, CHA2DS2-VASc) to assess the need for anti-coagulation","Subcutaneous Low Molecular Weight heparin in therapeutic dose,Use of warfarin",I regularly perform or request transthoracic echocardiography,Yes,ß-blocker,,Yes
02/11/2016 15:56,02/11/2016 16:07,IP Address,194.176.105.139,100,687,TRUE,02/11/2016 16:07,R_3PvgpPKqgvHswXC,,,,,51.51420593,-0.093093872,anonymous,District General Hospital,<500,10,Mixed ICU,,Consultant,3-5 years,Anaesthesia,"Independent of their heart rate I treat all patients who have developed new onset fast AF, even if the blood pressure remains stable",Rhythm control,Amiodarone,,Supplement electrolytes to a high normal level and anti-arrhythmics,>5 mmol/l,1.0-1.2 mmol/l,"Other, please specify:",Efficacy,I do not regularly anti-coagulate critically ill patients with new-onset fast AF,"I do not use stroke risk scores routinely in critically ill patients with new onset AF to assess the need for anticoagulation,Stroke risk scores favour anti-coagulation despite a higher risk of bleeding in critical illness,Modified risk scores should be developed for critically ill patients with new-onset atrial fibrillation",I do not regularly anti-coagulate critically ill patients with new onset fast AF,I only regularly perform Echocardiography in patients with cardiac history,Yes,"Amiodarone,ß-blocker",,Yes
02/11/2016 16:03,02/11/2016 16:08,IP Address,194.176.105.154,100,262,TRUE,02/11/2016 16:08,R_4YMqD4e1Up9b2ER,,,,,51.51420593,-0.093093872,anonymous,Tertiary Referral Centre or University Hospital,1000-2000,19,Mixed ICU,,Consultant,More than 10 years,Anaesthesia,100-119/beats per min,Rate control,Amiodarone,,Supplement electrolytes (magnesium and/or potassium) to a high normal level,>4.5 mmol/l,1.0-1.2 mmol/l,Pharmacodynamic properties,,I do not regularly anti-coagulate critically ill patients with new-onset fast AF,Stroke risk scores favour anti-coagulation despite a higher risk of bleeding in critical illness,I do not regularly anti-coagulate critically ill patients with new onset fast AF,I regularly perform or request transthoracic echocardiography,Yes,"Amiodarone,Flecainide,Digoxin",,Yes
02/11/2016 16:03,02/11/2016 16:08,IP Address,188.39.68.2,100,348,TRUE,02/11/2016 16:08,R_1DqIqg95UjfgXsV,,,,,50.83329773,-0.149993896,anonymous,Teaching Hospital,>2000,39,Mixed ICU,,Consultant,5-10 years,Anaesthesia,140-159/beats per min,Rate control,"Other anti-arrhythmics (e. g. Verapamil, sotalol): please specify:","magnesium,then amiodarone",Supplement electrolytes to a high normal level and anti-arrhythmics,>4.5 mmol/l,I do not aim for a specific serum magnesium level,Pharmacokinetic advantages,,I do not regularly anti-coagulate critically ill patients with new-onset fast AF,"I do not use stroke risk scores routinely in critically ill patients with new onset AF to assess the need for anticoagulation,Stroke risk scores inaccurately reflect the risk of embolic events in critically ill patients with new-onset atrial fibrillation due to prothrombotic changes associated with critical illness,Modified risk scores should be developed for critically ill patients with new-onset atrial fibrillation",Intravenous High Molecular Weight heparin in therapeutic dose,I do not routinely perform Echocardiography to guide treatment,Yes,"Amiodarone,ß-blocker,Digoxin",,No
02/11/2016 16:50,02/11/2016 16:55,IP Address,85.115.54.202,100,279,TRUE,02/11/2016 16:55,R_4JDdjzLJuDh0lx3,,,,,51.49639893,-0.122406006,anonymous,Tertiary Referral Centre or University Hospital,>2000,44,Mixed ICU,,Consultant,5-10 years,Anaesthesia,140-159/beats per min,Rate control,Amiodarone,,Supplement electrolytes to a high normal level and anti-arrhythmics,>4.5 mmol/l,>1.2 mmol/l,"Pharmacodynamic properties,Adverse effect profile",,New onset AF within 24 hours,"I regularly calculate a risk score (e. g. CHAD2, CHA2DS2-VASc) to assess the need for anti-coagulation,Stroke risk scores inaccurately reflect the risk of embolic events in critically ill patients with new-onset atrial fibrillation due to prothrombotic changes associated with critical illness,Modified risk scores should be developed for critically ill patients with new-onset atrial fibrillation",Intravenous High Molecular Weight heparin in therapeutic dose,I regularly perform or request transthoracic echocardiography,Yes,ß-blocker,,Yes
02/11/2016 17:11,02/11/2016 17:17,IP Address,109.149.217.152,100,327,TRUE,02/11/2016 17:17,R_6nyNDLRYlYspU7X,,,,,51.75,-1.25,anonymous,Tertiary Referral Centre or University Hospital,<500,16,Specialist ICU (please name specialty):,Neuro,Trainee,5-10 years,Anaesthesia,"Independent of their heart rate I treat all patients who have developed new onset fast AF, even if the blood pressure remains stable",Rhythm control,Amiodarone,,Supplement electrolytes to a high normal level and anti-arrhythmics,>4 mmol/l,1.0-1.2 mmol/l,"ICU drug policy,Other, please specify:",Familiarity! ,New onset AF within 24 hours,"I do not use stroke risk scores routinely in critically ill patients with new onset AF to assess the need for anticoagulation,Stroke risk scores inaccurately reflect the risk of embolic events in critically ill patients with new-onset atrial fibrillation due to prothrombotic changes associated with critical illness,Modified risk scores should be developed for critically ill patients with new-onset atrial fibrillation","Intravenous High Molecular Weight heparin in therapeutic dose,Subcutaneous Low Molecular Weight heparin in therapeutic dose,I do not regularly anti-coagulate critically ill patients with new onset fast AF","I regularly perform or request transthoracic echocardiography,I regularly perform or request transoesophageal echocardiography",Yes,"Amiodarone,DC cardioversion,ß-blocker,Flecainide,Digoxin",,No
02/11/2016 17:59,02/11/2016 18:03,IP Address,82.1.9.127,100,201,TRUE,02/11/2016 18:03,R_1N8pFF7XW4YeP61,,,,,53.75,-2.483306885,anonymous,District General Hospital,1000-2000,20,Mixed ICU,,Consultant,5-10 years,Intensive Care Medicine only,140-159/beats per min,Rate control,ß-blocker,,Supplement electrolytes (magnesium and/or potassium) to a high normal level,>4 mmol/l,I do not aim for a specific serum magnesium level,"Availability from hospital pharmacy,Pharmacodynamic properties,Adverse effect profile",,I do not regularly anti-coagulate critically ill patients with new-onset fast AF,I do not use stroke risk scores routinely in critically ill patients with new onset AF to assess the need for anticoagulation,I do not regularly anti-coagulate critically ill patients with new onset fast AF,I do not routinely perform Echocardiography to guide treatment,Yes,"Amiodarone,ß-blocker",,Yes
02/11/2016 18:20,02/11/2016 18:27,IP Address,86.177.88.95,100,417,TRUE,02/11/2016 18:27,R_2393IpH9osgDTzR,,,,,52.58529663,-1.98399353,anonymous,Teaching Hospital,500-1000,14,Mixed ICU,,Consultant,5-10 years,Anaesthesia,140-159/beats per min,Rate control,Amiodarone,,Supplement electrolytes to a high normal level and anti-arrhythmics,>4.5 mmol/l,>1.2 mmol/l,"Availability from hospital pharmacy,Pharmacokinetic advantages,Pharmacodynamic properties",,I do not regularly anti-coagulate critically ill patients with new-onset fast AF,"I do not use stroke risk scores routinely in critically ill patients with new onset AF to assess the need for anticoagulation,Stroke risk scores inaccurately reflect the risk of embolic events in critically ill patients with new-onset atrial fibrillation due to prothrombotic changes associated with critical illness,Stroke risk scores favour anti-coagulation despite a higher risk of bleeding in critical illness,Modified risk scores should be developed for critically ill patients with new-onset atrial fibrillation","Subcutaneous Low Molecular Weight heparin in therapeutic dose,I do not regularly anti-coagulate critically ill patients with new onset fast AF",I regularly perform or request transthoracic echocardiography,No,"Amiodarone,ß-blocker,Digoxin",,No
02/11/2016 19:12,02/11/2016 19:17,IP Address,31.48.84.137,100,313,TRUE,02/11/2016 19:17,R_29uzfEZPSw65n5L,,,,,50.8999939,-1.399993896,anonymous,Tertiary Referral Centre or University Hospital,1000-2000,15,Specialist ICU (please name specialty):,Cardiac,Consultant,More than 10 years,Anaesthesia,100-119/beats per min,Rhythm control,Amiodarone,,Supplement electrolytes (magnesium and/or potassium) to a high normal level,>4.5 mmol/l,>1.2 mmol/l,Pharmacodynamic properties,,New onset AF within 48 hours,I do not use stroke risk scores routinely in critically ill patients with new onset AF to assess the need for anticoagulation,Intravenous High Molecular Weight heparin in therapeutic dose,I regularly perform or request transthoracic echocardiography,Yes,Amiodarone,,No
02/11/2016 19:15,02/11/2016 19:18,IP Address,109.176.101.162,100,183,TRUE,02/11/2016 19:18,R_8J6FVhJwwANrPVP,,,,,51.02110291,-3.104705811,anonymous,District General Hospital,500-1000,12,Mixed ICU,,Consultant,More than 10 years,Anaesthesia,120-139/beats per min,Rate control,Digoxin,,Supplement electrolytes (magnesium and/or potassium) to a high normal level,>4.5 mmol/l,1.0-1.2 mmol/l,Adverse effect profile,,I do not regularly anti-coagulate critically ill patients with new-onset fast AF,Modified risk scores should be developed for critically ill patients with new-onset atrial fibrillation,I do not regularly anti-coagulate critically ill patients with new onset fast AF,I do not routinely perform Echocardiography to guide treatment,Yes,ß-blocker,,Yes
02/11/2016 20:23,02/11/2016 20:27,IP Address,86.18.32.239,100,221,TRUE,02/11/2016 20:27,R_10OgqPbm5oYaFyu,,,,,53.69999695,-1.699996948,anonymous,Tertiary Referral Centre or University Hospital,1000-2000,56,Mixed ICU,,Consultant,More than 10 years,Anaesthesia,140-159/beats per min,Rate control,Amiodarone,,Supplement electrolytes (magnesium and/or potassium) to a high normal level,>4.5 mmol/l,>1.2 mmol/l,Availability from hospital pharmacy,,New onset AF within 24 hours,"I regularly calculate a risk score (e. g. CHAD2, CHA2DS2-VASc) to assess the need for anti-coagulation",Subcutaneous Low Molecular Weight heparin in therapeutic dose,I regularly perform or request transoesophageal echocardiography,Yes,Amiodarone,,Yes
02/11/2016 21:54,02/11/2016 22:00,IP Address,90.210.208.208,100,404,TRUE,02/11/2016 22:00,R_3CC7AUjqoHTFfYi,,,,,52.96670532,-1.166702271,anonymous,Tertiary Referral Centre or University Hospital,>2000,41,Mixed ICU,,Consultant,5-10 years,Anaesthesia,120-139/beats per min,Rhythm control,Amiodarone,,Supplement electrolytes to a high normal level and anti-arrhythmics,>4.5 mmol/l,1.0-1.2 mmol/l,ICU drug policy,,I do not regularly anti-coagulate critically ill patients with new-onset fast AF,I do not use stroke risk scores routinely in critically ill patients with new onset AF to assess the need for anticoagulation,I do not regularly anti-coagulate critically ill patients with new onset fast AF,I regularly perform or request transthoracic echocardiography,Yes,"DC cardioversion,ß-blocker",,No
02/11/2016 22:10,02/11/2016 22:28,IP Address,92.40.249.78,100,1097,TRUE,02/11/2016 22:28,R_2Se77wLoECicuKY,,,,,51.49639893,-0.122406006,anonymous,District General Hospital,<500,9,Mixed ICU,,Consultant,More than 10 years,Anaesthesia,100-119/beats per min,Rate control,Amiodarone,,Supplement electrolytes to a high normal level and anti-arrhythmics,>4.5 mmol/l,1.0-1.2 mmol/l,Pharmacodynamic properties,,I do not regularly anti-coagulate critically ill patients with new-onset fast AF,I do not use stroke risk scores routinely in critically ill patients with new onset AF to assess the need for anticoagulation,I do not regularly anti-coagulate critically ill patients with new onset fast AF,I regularly perform or request transthoracic echocardiography,Yes,"Amiodarone,ß-blocker,Digoxin",,No
03/11/2016 08:16,03/11/2016 08:21,IP Address,86.134.46.216,100,299,TRUE,03/11/2016 08:21,R_2Sozg9E6OHZLstY,,,,,51.40859985,-0.042007446,anonymous,District General Hospital,500-1000,18,Mixed ICU,,Consultant,5-10 years,Anaesthesia,"Independent of their heart rate I treat all patients who have developed new onset fast AF, even if the blood pressure remains stable",Rhythm control,Amiodarone,,DC cardioversion when anti-arrhythmics and electrolyte replacement fail to achieve rate and/or rhythm control,>4.5 mmol/l,>1.2 mmol/l,"Pharmacodynamic properties,Adverse effect profile",,New onset AF within 72 hours,"I do not use stroke risk scores routinely in critically ill patients with new onset AF to assess the need for anticoagulation,Stroke risk scores inaccurately reflect the risk of embolic events in critically ill patients with new-onset atrial fibrillation due to prothrombotic changes associated with critical illness,Modified risk scores should be developed for critically ill patients with new-onset atrial fibrillation","Intravenous High Molecular Weight heparin in therapeutic dose,Subcutaneous Low Molecular Weight heparin in therapeutic dose",I regularly perform or request transthoracic echocardiography,Yes,"Amiodarone,ß-blocker",,No
03/11/2016 09:26,03/11/2016 09:46,IP Address,92.20.185.135,100,1176,TRUE,03/11/2016 09:46,R_2CVQRMD6BwOFC8U,,,,,50.8999939,-1.399993896,anonymous,Tertiary Referral Centre or University Hospital,>2000,> 100,Predominantly medical,,SAS,5-10 years,Intensive Care Medicine only,140-159/beats per min,Rate control,ß-blocker,,Supplement electrolytes (magnesium and/or potassium) to a high normal level,>4 mmol/l,>1.2 mmol/l,Pharmacodynamic properties,,I do not regularly anti-coagulate critically ill patients with new-onset fast AF,I do not use stroke risk scores routinely in critically ill patients with new onset AF to assess the need for anticoagulation,I do not regularly anti-coagulate critically ill patients with new onset fast AF,I regularly perform or request transthoracic echocardiography,No,"DC cardioversion,ß-blocker",,Yes
03/11/2016 10:05,03/11/2016 10:12,IP Address,94.175.248.5,100,420,TRUE,03/11/2016 10:12,R_80TtsmL2HAAmbzf,,,,,52.67550659,-2.76159668,anonymous,District General Hospital,500-1000,14,Mixed ICU,,Consultant,5-10 years,Anaesthesia,100-119/beats per min,Rate control,Amiodarone,,Supplement electrolytes to a high normal level and anti-arrhythmics,>4 mmol/l,1.0-1.2 mmol/l,Adverse effect profile,,I do not regularly anti-coagulate critically ill patients with new-onset fast AF,"I do not use stroke risk scores routinely in critically ill patients with new onset AF to assess the need for anticoagulation,Modified risk scores should be developed for critically ill patients with new-onset atrial fibrillation",I do not regularly anti-coagulate critically ill patients with new onset fast AF,I regularly perform or request transthoracic echocardiography,Yes,"Amiodarone,ß-blocker",,No
03/11/2016 12:14,03/11/2016 12:22,IP Address,194.176.105.167,100,491,TRUE,03/11/2016 12:22,R_1N3Ui3hEnCjqkBp,,,,,51.41670227,-0.283294678,anonymous,District General Hospital,500-1000,15,Mixed ICU,,Consultant,More than 10 years,Anaesthesia,100-119/beats per min,Rate control,Amiodarone,,DC cardioversion when anti-arrhythmics and electrolyte replacement fail to achieve rate and/or rhythm control,>4 mmol/l,I do not aim for a specific serum magnesium level,Pharmacodynamic properties,,I do not regularly anti-coagulate critically ill patients with new-onset fast AF,"Stroke risk scores inaccurately reflect the risk of embolic events in critically ill patients with new-onset atrial fibrillation due to prothrombotic changes associated with critical illness,Modified risk scores should be developed for critically ill patients with new-onset atrial fibrillation",Subcutaneous Low Molecular Weight heparin in therapeutic dose,I do not routinely perform Echocardiography to guide treatment,Yes,"Amiodarone,DC cardioversion,ß-blocker",,No
03/11/2016 19:04,03/11/2016 19:08,IP Address,87.254.64.109,100,215,TRUE,03/11/2016 19:08,R_1FJsSf8oIwXqk02,,,,,54.1499939,-4.483306885,anonymous,District General Hospital,<500,6,Mixed ICU,,Consultant,More than 10 years,Anaesthesia,120-139/beats per min,Rate control,Amiodarone,,Supplement electrolytes to a high normal level and DC cardioversion,>4.5 mmol/l,1.0-1.2 mmol/l,Adverse effect profile,,I do not regularly anti-coagulate critically ill patients with new-onset fast AF,I do not use stroke risk scores routinely in critically ill patients with new onset AF to assess the need for anticoagulation,Subcutaneous Low Molecular Weight heparin in therapeutic dose,I regularly perform or request transthoracic echocardiography,No,"DC cardioversion,ß-blocker,Digoxin",,No
03/11/2016 19:26,03/11/2016 19:29,IP Address,82.132.235.243,100,229,TRUE,03/11/2016 19:29,R_2rAEkLDD6I014TT,,,,,51.49639893,-0.122406006,anonymous,Teaching Hospital,1000-2000,24,Mixed ICU,,Consultant,More than 10 years,Anaesthesia,120-139/beats per min,Rate control,Amiodarone,,Supplement electrolytes (magnesium and/or potassium) to a high normal level,>4.5 mmol/l,>1.2 mmol/l,Pharmacodynamic properties,,I do not regularly anti-coagulate critically ill patients with new-onset fast AF,"I do not use stroke risk scores routinely in critically ill patients with new onset AF to assess the need for anticoagulation,Stroke risk scores inaccurately reflect the risk of embolic events in critically ill patients with new-onset atrial fibrillation due to prothrombotic changes associated with critical illness",I do not regularly anti-coagulate critically ill patients with new onset fast AF,I regularly perform or request transthoracic echocardiography,Yes,"Amiodarone,DC cardioversion,Digoxin",,Yes
03/11/2016 22:03,03/11/2016 22:08,IP Address,81.98.84.22,100,334,TRUE,03/11/2016 22:08,R_2uOnZFvilHzsWCw,,,,,54.98809814,-1.619400024,anonymous,Tertiary Referral Centre or University Hospital,1000-2000,22,Mixed ICU,,Consultant,5-10 years,Anaesthesia,"Independent of their heart rate I treat all patients who have developed new onset fast AF, even if the blood pressure remains stable",Rhythm control,Amiodarone,,Supplement electrolytes to a high normal level and anti-arrhythmics,>4 mmol/l,1.0-1.2 mmol/l,Pharmacokinetic advantages,,New onset AF within 72 hours,"I do not use stroke risk scores routinely in critically ill patients with new onset AF to assess the need for anticoagulation,Stroke risk scores inaccurately reflect the risk of embolic events in critically ill patients with new-onset atrial fibrillation due to prothrombotic changes associated with critical illness,Stroke risk scores favour anti-coagulation despite a higher risk of bleeding in critical illness,Modified risk scores should be developed for critically ill patients with new-onset atrial fibrillation",Subcutaneous Low Molecular Weight heparin in therapeutic dose,I regularly perform or request transthoracic echocardiography,Yes,Amiodarone,,No
03/11/2016 23:39,03/11/2016 23:44,IP Address,86.8.242.10,100,314,TRUE,03/11/2016 23:44,R_10Iu4Urdhbh3Ybn,,,,,51.36999512,0.023300171,anonymous,District General Hospital,500-1000,10,Mixed ICU,,Consultant,More than 10 years,Anaesthesia,120-139/beats per min,Rhythm control,Amiodarone,,Supplement electrolytes to a high normal level and anti-arrhythmics,>4 mmol/l,1.0-1.2 mmol/l,Pharmacokinetic advantages,,I do not regularly anti-coagulate critically ill patients with new-onset fast AF,"I do not use stroke risk scores routinely in critically ill patients with new onset AF to assess the need for anticoagulation,Stroke risk scores inaccurately reflect the risk of embolic events in critically ill patients with new-onset atrial fibrillation due to prothrombotic changes associated with critical illness,Modified risk scores should be developed for critically ill patients with new-onset atrial fibrillation",I do not regularly anti-coagulate critically ill patients with new onset fast AF,"I do not routinely perform Echocardiography to guide treatment,I only regularly perform Echocardiography in patients with cardiac history",No,DC cardioversion,,No
04/11/2016 14:43,04/11/2016 14:53,IP Address,81.109.6.245,100,560,TRUE,04/11/2016 14:53,R_2P0e6X7AOb7jtUC,,,,,55.77990723,-4.277099609,anonymous,District General Hospital,<500,Flexible but up to 10 Level 3,Mixed ICU,,Consultant,More than 10 years,Anaesthesia,120-139/beats per min,Rate control,Amiodarone,,Supplement electrolytes (magnesium and/or potassium) to a high normal level,>4 mmol/l,I do not aim for a specific serum magnesium level,ICU drug policy,,I do not regularly anti-coagulate critically ill patients with new-onset fast AF,I do not use stroke risk scores routinely in critically ill patients with new onset AF to assess the need for anticoagulation,"Intravenous High Molecular Weight heparin in therapeutic dose,Subcutaneous Low Molecular Weight heparin in therapeutic dose,Use of warfarin,I do not regularly anti-coagulate critically ill patients with new onset fast AF",I regularly perform or request transthoracic echocardiography,Yes,Amiodarone,,No
04/11/2016 15:22,04/11/2016 15:27,IP Address,82.34.84.216,100,310,TRUE,04/11/2016 15:27,R_yjwBmY3HsctgzqF,,,,,53.36669922,-1.5,anonymous,Teaching Hospital,I do not know,30,Mixed ICU,,Trainee,3-5 years,Anaesthesia,140-159/beats per min,Rate control,Digoxin,,Supplement electrolytes to a high normal level and anti-arrhythmics,>4.5 mmol/l,1.0-1.2 mmol/l,"Pharmacokinetic advantages,Pharmacodynamic properties,Adverse effect profile",,I do not regularly anti-coagulate critically ill patients with new-onset fast AF,"I do not use stroke risk scores routinely in critically ill patients with new onset AF to assess the need for anticoagulation,Stroke risk scores inaccurately reflect the risk of embolic events in critically ill patients with new-onset atrial fibrillation due to prothrombotic changes associated with critical illness,Stroke risk scores favour anti-coagulation despite a higher risk of bleeding in critical illness,Modified risk scores should be developed for critically ill patients with new-onset atrial fibrillation","Intravenous High Molecular Weight heparin in therapeutic dose,Subcutaneous Low Molecular Weight heparin in therapeutic dose",I do not routinely perform Echocardiography to guide treatment,Yes,Digoxin,,Yes
04/11/2016 21:59,04/11/2016 22:04,IP Address,51.7.123.229,100,306,TRUE,04/11/2016 22:04,R_21nViowzYgiOtjc,,,,,53.50520325,-1.616104126,anonymous,District General Hospital,I do not know,13,Mixed ICU,,Consultant,More than 10 years,Anaesthesia,120-139/beats per min,Rate control,Amiodarone,,Supplement electrolytes (magnesium and/or potassium) to a high normal level,>4.5 mmol/l,1.0-1.2 mmol/l,ICU drug policy,,I do not regularly anti-coagulate critically ill patients with new-onset fast AF,Modified risk scores should be developed for critically ill patients with new-onset atrial fibrillation,"Intravenous High Molecular Weight heparin in therapeutic dose,Subcutaneous Low Molecular Weight heparin in therapeutic dose",I do not routinely perform Echocardiography to guide treatment,Yes,Amiodarone,,No
05/11/2016 18:00,05/11/2016 18:06,IP Address,77.99.157.93,100,385,TRUE,05/11/2016 18:06,R_1MKzQhjMLYM9etd,,,,,55.94290161,-3.285003662,anonymous,Tertiary Referral Centre or University Hospital,500-1000,16,Specialist ICU (please name specialty):,and specialist Regional Neuro/ID/Haematologyand Oncology,Consultant,More than 10 years,Acute medicine,"Independent of their heart rate I treat all patients who have developed new onset fast AF, even if the blood pressure remains stable",Rhythm control,"Other anti-arrhythmics (e. g. Verapamil, sotalol): please specify:",this answer is for the next question: optimise oxygenation/CO2 and volume resuscitate plus electrolytes/drugs,Supplement electrolytes to a high normal level and anti-arrhythmics,>4.5 mmol/l,0.75-1 mmol/l,"Other, please specify:",efficacy and limited hypotensive effect,I do not regularly anti-coagulate critically ill patients with new-onset fast AF,I do not use stroke risk scores routinely in critically ill patients with new onset AF to assess the need for anticoagulation,I do not regularly anti-coagulate critically ill patients with new onset fast AF,I regularly perform or request transthoracic echocardiography,Yes,Amiodarone,,No
06/11/2016 12:23,06/11/2016 12:45,IP Address,194.176.105.168,100,1285,TRUE,06/11/2016 12:45,R_0JaXPfwlyEJletv,,,,,52.6000061,-2,anonymous,Tertiary Referral Centre or University Hospital,>2000,75,Mixed ICU,,Consultant,More than 10 years,Anaesthesia,"Independent of their heart rate I treat all patients who have developed new onset fast AF, even if the blood pressure remains stable",Rate control,Amiodarone,,Supplement electrolytes to a high normal level and anti-arrhythmics,>4.5 mmol/l,1.0-1.2 mmol/l,"Availability from hospital pharmacy,Pharmacokinetic advantages,Adverse effect profile",,I do not regularly anti-coagulate critically ill patients with new-onset fast AF,I do not use stroke risk scores routinely in critically ill patients with new onset AF to assess the need for anticoagulation,"Intravenous High Molecular Weight heparin in therapeutic dose,Subcutaneous Low Molecular Weight heparin in therapeutic dose",I do not routinely perform Echocardiography to guide treatment,Yes,"Amiodarone,DC cardioversion,ß-blocker,Digoxin",,Yes
06/11/2016 12:48,06/11/2016 12:53,IP Address,194.176.105.138,100,295,TRUE,06/11/2016 12:53,R_cOogEkTMbAns4f3,,,,,52.6000061,-2,anonymous,District General Hospital,500-1000,07-Jul,Mixed ICU,,Consultant,More than 10 years,Anaesthesia,120-139/beats per min,Rate control,Amiodarone,,Supplement electrolytes to a high normal level and anti-arrhythmics,>4.5 mmol/l,1.0-1.2 mmol/l,ICU drug policy,,I do not regularly anti-coagulate critically ill patients with new-onset fast AF,"I do not use stroke risk scores routinely in critically ill patients with new onset AF to assess the need for anticoagulation,Stroke risk scores inaccurately reflect the risk of embolic events in critically ill patients with new-onset atrial fibrillation due to prothrombotic changes associated with critical illness,Modified risk scores should be developed for critically ill patients with new-onset atrial fibrillation",Intravenous High Molecular Weight heparin in therapeutic dose,I regularly perform or request transthoracic echocardiography,No,"Amiodarone,DC cardioversion,ß-blocker",,No
06/11/2016 15:20,06/11/2016 15:25,IP Address,86.160.153.39,100,289,TRUE,06/11/2016 15:25,R_2VIKwNBccKIcD5b,,,,,51.45019531,-2.650299072,anonymous,Teaching Hospital,1000-2000,24,Mixed ICU,,Trainee,1-3 years,Anaesthesia,"Independent of their heart rate I treat all patients who have developed new onset fast AF, even if the blood pressure remains stable",Rate control,Amiodarone,,Supplement electrolytes to a high normal level and DC cardioversion,>4.5 mmol/l,1.0-1.2 mmol/l,ICU drug policy,,I do not regularly anti-coagulate critically ill patients with new-onset fast AF,"Stroke risk scores inaccurately reflect the risk of embolic events in critically ill patients with new-onset atrial fibrillation due to prothrombotic changes associated with critical illness,Stroke risk scores favour anti-coagulation despite a higher risk of bleeding in critical illness,Modified risk scores should be developed for critically ill patients with new-onset atrial fibrillation","Intravenous High Molecular Weight heparin in therapeutic dose,Subcutaneous Low Molecular Weight heparin in therapeutic dose,Use of novel oral anti-coagulants (NOACs)",I regularly perform or request transthoracic echocardiography,Yes,Amiodarone,,Yes
06/11/2016 17:05,06/11/2016 17:10,IP Address,51.9.70.245,100,318,TRUE,06/11/2016 17:10,R_2905cs3F4k3ugkB,,,,,52.19999695,0.116699219,anonymous,District General Hospital,I do not know,10,Mixed ICU,,Trainee,1-3 years,Anaesthesia,"Independent of their heart rate I treat all patients who have developed new onset fast AF, even if the blood pressure remains stable",Rate control,Amiodarone,,DC cardioversion when anti-arrhythmics and electrolyte replacement fail to achieve rate and/or rhythm control,>4 mmol/l,0.75-1 mmol/l,"Pharmacokinetic advantages,Pharmacodynamic properties",,New onset AF within 72 hours,"Stroke risk scores inaccurately reflect the risk of embolic events in critically ill patients with new-onset atrial fibrillation due to prothrombotic changes associated with critical illness,Stroke risk scores favour anti-coagulation despite a higher risk of bleeding in critical illness,Modified risk scores should be developed for critically ill patients with new-onset atrial fibrillation",Intravenous High Molecular Weight heparin in therapeutic dose,I regularly perform or request transthoracic echocardiography,Yes,"Amiodarone,DC cardioversion,ß-blocker,Digoxin",,No
06/11/2016 20:32,06/11/2016 20:38,IP Address,92.8.159.43,100,346,TRUE,06/11/2016 20:38,R_wRdPmzx7dFoOdmV,,,,,51.47360229,-0.091598511,anonymous,District General Hospital,500-1000,11,Predominantly surgical,,Trainee,5-10 years,Acute medicine,120-139/beats per min,Rhythm control,Amiodarone,,DC cardioversion when anti-arrhythmics and electrolyte replacement fail to achieve rate and/or rhythm control,>4.5 mmol/l,1.0-1.2 mmol/l,"Pharmacokinetic advantages,Pharmacodynamic properties",,New onset AF within 24 hours,"I do not use stroke risk scores routinely in critically ill patients with new onset AF to assess the need for anticoagulation,Stroke risk scores inaccurately reflect the risk of embolic events in critically ill patients with new-onset atrial fibrillation due to prothrombotic changes associated with critical illness,Stroke risk scores favour anti-coagulation despite a higher risk of bleeding in critical illness",Subcutaneous Low Molecular Weight heparin in therapeutic dose,I regularly perform or request transthoracic echocardiography,Yes,"Amiodarone,DC cardioversion,ß-blocker,Flecainide,Diltiazem",,No
07/11/2016 12:07,07/11/2016 12:16,IP Address,194.176.105.161,100,556,TRUE,07/11/2016 12:16,R_5tMwsYGMYDt6QF7,,,,,51.46670532,-0.350006104,anonymous,Tertiary Referral Centre or University Hospital,500-1000,13,Specialist ICU (please name specialty):,Neuro,Consultant,More than 10 years,Anaesthesia,"Independent of their heart rate I treat all patients who have developed new onset fast AF, even if the blood pressure remains stable",Rhythm control,Amiodarone,,Supplement electrolytes to a high normal level and DC cardioversion,>4.5 mmol/l,1.0-1.2 mmol/l,"Availability from hospital pharmacy,Other, please specify:",Familiarity,I do not regularly anti-coagulate critically ill patients with new-onset fast AF,Stroke risk scores inaccurately reflect the risk of embolic events in critically ill patients with new-onset atrial fibrillation due to prothrombotic changes associated with critical illness,"Subcutaneous Low Molecular Weight heparin in therapeutic dose,I do not regularly anti-coagulate critically ill patients with new onset fast AF",I do not routinely perform Echocardiography to guide treatment,No,"Amiodarone,DC cardioversion,ß-blocker",,No
07/11/2016 12:19,07/11/2016 12:24,IP Address,77.100.98.30,100,326,TRUE,07/11/2016 12:24,R_24OD9RYQcn1h43I,,,,,51.48599243,-2.511001587,anonymous,District General Hospital,500-1000,13,Mixed ICU,,Trainee,<1 year,Anaesthesia,120-139/beats per min,Rhythm control,Amiodarone,,Supplement electrolytes to a high normal level and anti-arrhythmics,>4 mmol/l,1.0-1.2 mmol/l,"ICU drug policy,Pharmacodynamic properties",,I do not regularly anti-coagulate critically ill patients with new-onset fast AF,"I do not use stroke risk scores routinely in critically ill patients with new onset AF to assess the need for anticoagulation,Stroke risk scores favour anti-coagulation despite a higher risk of bleeding in critical illness,Modified risk scores should be developed for critically ill patients with new-onset atrial fibrillation","Intravenous High Molecular Weight heparin in therapeutic dose,Subcutaneous Low Molecular Weight heparin in therapeutic dose,I do not regularly anti-coagulate critically ill patients with new onset fast AF",I regularly perform or request transthoracic echocardiography,Yes,Amiodarone,,Yes
07/11/2016 12:58,07/11/2016 13:13,IP Address,194.176.105.132,100,855,TRUE,07/11/2016 13:13,R_2sd9SD5Sk0IPSGU,,,,,51.49639893,-0.122406006,anonymous,Tertiary Referral Centre or University Hospital,1000-2000,28,Mixed ICU,,SAS,3-5 years,Anaesthesia,100-119/beats per min,Rate control,ß-blocker,,DC cardioversion when anti-arrhythmics and electrolyte replacement fail to achieve rate and/or rhythm control,>4.5 mmol/l,I do not aim for a specific serum magnesium level,"Pharmacokinetic advantages,Pharmacodynamic properties,Adverse effect profile",,I do not regularly anti-coagulate critically ill patients with new-onset fast AF,I do not use stroke risk scores routinely in critically ill patients with new onset AF to assess the need for anticoagulation,I do not regularly anti-coagulate critically ill patients with new onset fast AF,I regularly perform or request transthoracic echocardiography,Yes,ß-blocker,,No
07/11/2016 13:08,07/11/2016 13:13,IP Address,213.219.49.160,100,279,TRUE,07/11/2016 13:13,R_3G9WCWlwEn0TxeA,,,,,52.28359985,-1.58140564,anonymous,District General Hospital,500-1000,12,Mixed ICU,,Consultant,More than 10 years,Anaesthesia,120-139/beats per min,Rate control,ß-blocker,,Supplement electrolytes (magnesium and/or potassium) to a high normal level,>4 mmol/l,1.0-1.2 mmol/l,"Availability from hospital pharmacy,Pharmacokinetic advantages,Pharmacodynamic properties,Adverse effect profile",,I do not regularly anti-coagulate critically ill patients with new-onset fast AF,"I do not use stroke risk scores routinely in critically ill patients with new onset AF to assess the need for anticoagulation,Modified risk scores should be developed for critically ill patients with new-onset atrial fibrillation",I do not regularly anti-coagulate critically ill patients with new onset fast AF,I regularly perform or request transthoracic echocardiography,Yes,"Amiodarone,ß-blocker,Diltiazem,Digoxin",,No
31/10/2016 15:57,31/10/2016 15:58,IP Address,82.132.246.134,40,72,FALSE,07/11/2016 15:59,R_3ZY8R9ZydSBPvaN,,,,,,,anonymous,Tertiary Referral Centre or University Hospital,>2000,80,Mixed ICU,,Trainee,3-5 years,Intensive Care Medicine only,,,,,,,,,,,,,,,,,
31/10/2016 15:58,31/10/2016 15:58,IP Address,159.86.191.18,12,20,FALSE,07/11/2016 15:59,R_3lt9FR0bEJ10sNd,,,,,,,anonymous,,,,,,,,,,,,,,,,,,,,,,,,,
31/10/2016 15:57,31/10/2016 16:00,IP Address,151.226.74.14,40,147,FALSE,07/11/2016 16:00,R_55PQFdsNpg8DXP3,,,,,,,anonymous,District General Hospital,<500,20,Mixed ICU,,SAS,More than 10 years,Anaesthesia,,,,,,,,,,,,,,,,,
31/10/2016 16:01,31/10/2016 16:02,IP Address,31.185.208.70,12,47,FALSE,07/11/2016 16:02,R_OAIBYQsj73KWRTX,,,,,,,anonymous,,,,,,,,,,,,,,,,,,,,,,,,,
31/10/2016 16:05,31/10/2016 16:06,IP Address,103.233.122.50,40,95,FALSE,07/11/2016 16:07,R_2rUT320DL7s72NP,,,,,,,anonymous,Teaching Hospital,500-1000,18,Mixed ICU,,Trainee,3-5 years,Anaesthesia,,,,,,,,,,,,,,,,,
31/10/2016 16:06,31/10/2016 16:07,IP Address,37.210.32.109,12,12,FALSE,07/11/2016 16:07,R_3ly82weVebM0wfm,,,,,,,anonymous,,,,,,,,,,,,,,,,,,,,,,,,,
31/10/2016 16:07,31/10/2016 16:08,IP Address,212.250.119.203,40,69,FALSE,07/11/2016 16:08,R_2dLXkwTcmxZgXYL,,,,,,,anonymous,District General Hospital,500-1000,6,Mixed ICU,,Trainee,3-5 years,Acute medicine,,,,,,,,,,,,,,,,,
31/10/2016 15:59,31/10/2016 16:10,IP Address,82.0.143.23,40,654,FALSE,07/11/2016 16:10,R_DjjSRUWLOFz1BUB,,,,,,,anonymous,Teaching Hospital,500-1000,9,Mixed ICU,,SAS,More than 10 years,Intensive Care Medicine only,,,,,,,,,,,,,,,,,
31/10/2016 16:09,31/10/2016 16:10,IP Address,2.223.184.58,12,75,FALSE,07/11/2016 16:11,R_2v1Er8bkLOvaqjF,,,,,,,anonymous,,,,,,,,,,,,,,,,,,,,,,,,,
31/10/2016 16:11,31/10/2016 16:13,IP Address,163.160.107.179,40,103,FALSE,07/11/2016 16:13,R_1Hc6rWOyn3hotS3,,,,,,,anonymous,Teaching Hospital,1000-2000,15,Mixed ICU,,Consultant,More than 10 years,Intensive Care Medicine only,,,,,,,,,,,,,,,,,
31/10/2016 16:25,31/10/2016 16:25,IP Address,185.69.145.171,12,12,FALSE,07/11/2016 16:26,R_1n9kxQJAV1fhu0q,,,,,,,anonymous,,,,,,,,,,,,,,,,,,,,,,,,,
31/10/2016 16:25,31/10/2016 16:26,IP Address,2.223.5.113,12,44,FALSE,07/11/2016 16:26,R_dpaF1b4ttTMa9zz,,,,,,,anonymous,,,,,,,,,,,,,,,,,,,,,,,,,
31/10/2016 16:38,31/10/2016 16:39,IP Address,31.87.108.155,40,38,FALSE,07/11/2016 16:39,R_2OZtfTwy0Nk6AxU,,,,,,,anonymous,District General Hospital,<500,9,Mixed ICU,,Consultant,More than 10 years,Anaesthesia,,,,,,,,,,,,,,,,,
31/10/2016 16:40,31/10/2016 16:43,IP Address,62.254.75.96,40,140,FALSE,07/11/2016 16:43,R_TcJx3zbUJukxdmh,,,,,,,anonymous,Teaching Hospital,1000-2000,18,Predominantly surgical,,SAS,3-5 years,Surgery,,,,,,,,,,,,,,,,,
31/10/2016 16:42,31/10/2016 16:43,IP Address,194.176.105.150,12,106,FALSE,07/11/2016 16:43,R_30oBP00L6SPxoou,,,,,,,anonymous,,,,,,,,,,,,,,,,,,,,,,,,,
31/10/2016 16:48,31/10/2016 16:50,IP Address,85.255.235.184,40,111,FALSE,07/11/2016 16:51,R_3p9yOLO2yKkiUka,,,,,,,anonymous,District General Hospital,1000-2000,21,Predominantly surgical,,Trainee,1-3 years,Anaesthesia,,,,,,,,,,,,,,,,,
31/10/2016 16:43,31/10/2016 16:54,IP Address,86.173.143.193,12,636,FALSE,07/11/2016 16:55,R_27xIOZH5DDnXSn2,,,,,,,anonymous,,,,,,,,,,,,,,,,,,,,,,,,,
31/10/2016 16:54,31/10/2016 16:56,IP Address,92.236.209.29,40,134,FALSE,07/11/2016 16:57,R_1eG0Q5mc6jDN6ay,,,,,,,anonymous,Teaching Hospital,500-1000,12,Mixed ICU,,Consultant,1-3 years,Anaesthesia,,,,,,,,,,,,,,,,,
31/10/2016 17:03,31/10/2016 17:05,IP Address,87.202.7.126,40,113,FALSE,07/11/2016 17:05,R_bJgMHDTQPTmPOg1,,,,,,,anonymous,District General Hospital,500-1000,12,Mixed ICU,,Consultant,More than 10 years,Anaesthesia,,,,,,,,,,,,,,,,,
31/10/2016 17:12,31/10/2016 17:12,IP Address,151.228.161.126,12,8,FALSE,07/11/2016 17:12,R_1AqAeCYA1Nhds0p,,,,,,,anonymous,,,,,,,,,,,,,,,,,,,,,,,,,
31/10/2016 17:14,31/10/2016 17:15,IP Address,82.132.219.54,40,42,FALSE,07/11/2016 17:15,R_4IM11lWlbdBv1OV,,,,,,,anonymous,District General Hospital,500-1000,19,Mixed ICU,,Trainee,1-3 years,Anaesthesia,,,,,,,,,,,,,,,,,
31/10/2016 17:18,31/10/2016 17:19,IP Address,86.31.43.167,12,15,FALSE,07/11/2016 17:19,R_3LZLnmzVziqnwRC,,,,,,,anonymous,,,,,,,,,,,,,,,,,,,,,,,,,
07/11/2016 17:27,07/11/2016 17:32,IP Address,185.58.164.44,100,294,TRUE,07/11/2016 17:32,R_9SRkLzj1OyRyCZD,,,,,55.83009338,-4.25289917,anonymous,Tertiary Referral Centre or University Hospital,1000-2000,20,Mixed ICU,,Consultant,More than 10 years,Anaesthesia,120-139/beats per min,Rate control,Amiodarone,,Supplement electrolytes to a high normal level and anti-arrhythmics,>4 mmol/l,0.75-1 mmol/l,Adverse effect profile,,After starting anti-arrhythmic medication,"I do not use stroke risk scores routinely in critically ill patients with new onset AF to assess the need for anticoagulation,Stroke risk scores inaccurately reflect the risk of embolic events in critically ill patients with new-onset atrial fibrillation due to prothrombotic changes associated with critical illness",Subcutaneous Low Molecular Weight heparin in therapeutic dose,I only regularly perform Echocardiography in patients with cardiac history,Yes,"Amiodarone,DC cardioversion,ß-blocker",,No
31/10/2016 17:38,31/10/2016 17:38,IP Address,90.201.107.202,12,42,FALSE,07/11/2016 17:39,R_3q7goe4ouhKgnv8,,,,,,,anonymous,,,,,,,,,,,,,,,,,,,,,,,,,
31/10/2016 17:50,31/10/2016 17:51,IP Address,83.111.108.132,12,19,FALSE,07/11/2016 17:51,R_OxrbWzKszYEQrIt,,,,,,,anonymous,,,,,,,,,,,,,,,,,,,,,,,,,
31/10/2016 17:59,31/10/2016 17:59,IP Address,90.207.162.121,12,9,FALSE,07/11/2016 17:59,R_Au1OPEQ2j3SimnT,,,,,,,anonymous,,,,,,,,,,,,,,,,,,,,,,,,,
31/10/2016 18:09,31/10/2016 18:10,IP Address,85.255.237.204,40,63,FALSE,07/11/2016 18:10,R_3O1ynjphGWxZS6n,,,,,,,anonymous,Tertiary Referral Centre or University Hospital,<500,4,Specialist ICU (please name specialty):,Burns,Consultant,5-10 years,Anaesthesia,,,,,,,,,,,,,,,,,
31/10/2016 18:12,31/10/2016 18:13,IP Address,90.199.216.57,40,86,FALSE,07/11/2016 18:14,R_qw6hXw3wkwlo4ff,,,,,,,anonymous,District General Hospital,<500,17,Mixed ICU,,Trainee,1-3 years,Anaesthesia,,,,,,,,,,,,,,,,,
31/10/2016 16:40,31/10/2016 18:17,IP Address,109.156.212.149,40,5812,FALSE,07/11/2016 18:17,R_2rZrwjRYWvvUt5b,,,,,,,anonymous,District General Hospital,<500,6,Mixed ICU,,Consultant,More than 10 years,Anaesthesia,,,,,,,,,,,,,,,,,
31/10/2016 18:33,31/10/2016 18:33,IP Address,82.35.171.192,12,8,FALSE,07/11/2016 18:33,R_ROesEhunzj2FT7b,,,,,,,anonymous,,,,,,,,,,,,,,,,,,,,,,,,,
31/10/2016 18:36,31/10/2016 18:37,IP Address,86.154.34.36,12,14,FALSE,07/11/2016 18:37,R_3MhEwC0vDcFTJRp,,,,,,,anonymous,,,,,,,,,,,,,,,,,,,,,,,,,
31/10/2016 18:32,31/10/2016 18:38,IP Address,31.115.177.190,40,327,FALSE,07/11/2016 18:38,R_5dn7IXzXlCMcCtj,,,,,,,anonymous,Tertiary Referral Centre or University Hospital,1000-2000,44,Specialist ICU (please name specialty):,neuro trauma,SAS,More than 10 years,Intensive Care Medicine only,,,,,,,,,,,,,,,,,
31/10/2016 18:50,31/10/2016 18:52,IP Address,86.184.56.88,40,110,FALSE,07/11/2016 18:53,R_YQwiLqLfZDk1tIt,,,,,,,anonymous,Tertiary Referral Centre or University Hospital,1000-2000,16,Specialist ICU (please name specialty):,Cardiology/CT/cancer,Consultant,More than 10 years,Anaesthesia,,,,,,,,,,,,,,,,,
31/10/2016 18:58,31/10/2016 18:59,IP Address,86.177.4.149,12,52,FALSE,07/11/2016 18:59,R_2y15z7Ib7x9Sga2,,,,,,,anonymous,,,,,,,,,,,,,,,,,,,,,,,,,
31/10/2016 19:00,31/10/2016 19:02,IP Address,86.148.108.51,40,106,FALSE,07/11/2016 19:02,R_3JKNwpt7kno6uVS,,,,,,,anonymous,Tertiary Referral Centre or University Hospital,500-1000,16,Mixed ICU,,Consultant,More than 10 years,Anaesthesia,,,,,,,,,,,,,,,,,
31/10/2016 19:05,31/10/2016 19:06,IP Address,217.158.121.130,40,0,FALSE,07/11/2016 19:06,R_2SpELHCUDxAt1ct,,,,,,,anonymous,Tertiary Referral Centre or University Hospital,I do not know,20,Specialist ICU (please name specialty):,Cardiac,Trainee,3-5 years,Anaesthesia,,,,,,,,,,,,,,,,,
31/10/2016 19:20,31/10/2016 19:20,IP Address,176.27.172.95,12,35,FALSE,07/11/2016 19:20,R_1DC5vgQLYbB9DSV,,,,,,,anonymous,,,,,,,,,,,,,,,,,,,,,,,,,
07/11/2016 20:09,07/11/2016 20:14,IP Address,80.193.227.30,100,321,TRUE,07/11/2016 20:14,R_2wNfeRIn7IQy7hW,,,,,52.46409607,-2.15020752,anonymous,Tertiary Referral Centre or University Hospital,1000-2000,34,Mixed ICU,,SAS,More than 10 years,Anaesthesia,140-159/beats per min,Rate control,Amiodarone,,Supplement electrolytes to a high normal level and anti-arrhythmics,>4.5 mmol/l,1.0-1.2 mmol/l,ICU drug policy,,I do not regularly anti-coagulate critically ill patients with new-onset fast AF,Modified risk scores should be developed for critically ill patients with new-onset atrial fibrillation,I do not regularly anti-coagulate critically ill patients with new onset fast AF,I do not routinely perform Echocardiography to guide treatment,Yes,"Amiodarone,DC cardioversion,ß-blocker",,Yes
31/10/2016 20:51,31/10/2016 20:51,IP Address,82.132.227.109,12,19,FALSE,07/11/2016 20:51,R_2SIbHVo3STzn3Vj,,,,,,,anonymous,,,,,,,,,,,,,,,,,,,,,,,,,
31/10/2016 21:16,31/10/2016 21:18,IP Address,90.200.152.154,40,117,FALSE,07/11/2016 21:18,R_2fa3tyrFDhIm9LO,,,,,,,anonymous,District General Hospital,1000-2000,21,Mixed ICU,,Consultant,5-10 years,Surgery,,,,,,,,,,,,,,,,,
31/10/2016 16:08,31/10/2016 21:42,IP Address,86.147.19.59,40,20053,FALSE,07/11/2016 21:42,R_3NxIZG48puSkde8,,,,,,,anonymous,District General Hospital,<500,7,Mixed ICU,,Consultant,5-10 years,Anaesthesia,,,,,,,,,,,,,,,,,
31/10/2016 21:50,31/10/2016 21:51,IP Address,143.159.241.20,40,51,FALSE,07/11/2016 21:51,R_3P6JqiZkFTUhTH8,,,,,,,anonymous,Tertiary Referral Centre or University Hospital,>2000,35,Mixed ICU,,Trainee,1-3 years,Anaesthesia,,,,,,,,,,,,,,,,,
31/10/2016 22:52,31/10/2016 22:53,IP Address,84.92.125.246,12,26,FALSE,07/11/2016 22:53,R_1cXJj42jvhJ6u6I,,,,,,,anonymous,,,,,,,,,,,,,,,,,,,,,,,,,
31/10/2016 23:39,31/10/2016 23:51,IP Address,101.166.213.63,40,703,FALSE,07/11/2016 23:51,R_3j8MOivZc8lR2Nc,,,,,,,anonymous,Tertiary Referral Centre or University Hospital,I do not know,23,Mixed ICU,,Trainee,1-3 years,Emergency Medicine,,,,,,,,,,,,,,,,,
01/11/2016 00:19,01/11/2016 00:20,IP Address,195.99.42.9,40,56,FALSE,08/11/2016 00:20,R_2sQQEDBhlVZ70Fl,,,,,,,anonymous,Teaching Hospital,500-1000,30,Mixed ICU,,Consultant,5-10 years,Anaesthesia,,,,,,,,,,,,,,,,,
01/11/2016 06:27,01/11/2016 06:28,IP Address,90.220.64.136,40,96,FALSE,08/11/2016 06:29,R_1f32uY8MFVry8ao,,,,,,,anonymous,Tertiary Referral Centre or University Hospital,I do not know,38,Mixed ICU,,Trainee,3-5 years,Anaesthesia,,,,,,,,,,,,,,,,,
01/11/2016 09:52,01/11/2016 09:59,IP Address,160.152.24.77,12,419,FALSE,08/11/2016 09:59,R_1DBAy5L2pNavUzN,,,,,,,anonymous,,,,,,,,,,,,,,,,,,,,,,,,,
01/11/2016 10:50,01/11/2016 10:51,IP Address,88.97.76.130,40,78,FALSE,08/11/2016 10:51,R_2zT7LWzK1JtbiLm,,,,,,,anonymous,District General Hospital,1000-2000,25,Mixed ICU,,Consultant,More than 10 years,Intensive Care Medicine only,,,,,,,,,,,,,,,,,
01/11/2016 11:01,01/11/2016 11:01,IP Address,164.39.215.34,40,39,FALSE,08/11/2016 12:01,R_9HPKq0J0wxqkLop,,,,,,,anonymous,Tertiary Referral Centre or University Hospital,1000-2000,32,Mixed ICU,,Consultant,More than 10 years,Anaesthesia,,,,,,,,,,,,,,,,,
01/11/2016 12:01,01/11/2016 12:03,IP Address,159.86.186.99,40,125,FALSE,08/11/2016 12:03,R_2WBSbNdlo4K7a4w,,,,,,,anonymous,District General Hospital,<500,13,Mixed ICU,,Consultant,More than 10 years,Anaesthesia,,,,,,,,,,,,,,,,,
08/11/2016 12:17,08/11/2016 12:23,IP Address,85.255.233.36,100,319,TRUE,08/11/2016 12:23,R_1l4dLNq0D21LegI,,,,,51.49639893,-0.122406006,anonymous,District General Hospital,500-1000,11,Mixed ICU,,Trainee,3-5 years,Anaesthesia,"Independent of their heart rate I treat all patients who have developed new onset fast AF, even if the blood pressure remains stable",Rhythm control,Amiodarone,,Supplement electrolytes to a high normal level and anti-arrhythmics,>4.5 mmol/l,1.0-1.2 mmol/l,"ICU drug policy,Pharmacokinetic advantages,Adverse effect profile",,New onset AF within 48 hours,"Stroke risk scores favour anti-coagulation despite a higher risk of bleeding in critical illness,Modified risk scores should be developed for critically ill patients with new-onset atrial fibrillation","Intravenous High Molecular Weight heparin in therapeutic dose,Subcutaneous Low Molecular Weight heparin in therapeutic dose",I only regularly perform Echocardiography in patients with cardiac history,Yes,"Amiodarone,ß-blocker,Diltiazem",,Yes
08/11/2016 13:09,08/11/2016 13:14,IP Address,62.255.248.2,100,300,TRUE,08/11/2016 13:14,R_3im0XzlY7iHcGrw,,,,,53.46629333,-2.13420105,anonymous,Teaching Hospital,1000-2000,16,Mixed ICU,,Consultant,More than 10 years,Anaesthesia,140-159/beats per min,I have no primary treatment goal in these patients,Amiodarone,,Supplement electrolytes to a high normal level and anti-arrhythmics,>4.5 mmol/l,1.0-1.2 mmol/l,Pharmacodynamic properties,,I do not regularly anti-coagulate critically ill patients with new-onset fast AF,"I do not use stroke risk scores routinely in critically ill patients with new onset AF to assess the need for anticoagulation,Stroke risk scores inaccurately reflect the risk of embolic events in critically ill patients with new-onset atrial fibrillation due to prothrombotic changes associated with critical illness,Modified risk scores should be developed for critically ill patients with new-onset atrial fibrillation",I do not regularly anti-coagulate critically ill patients with new onset fast AF,I regularly perform or request transthoracic echocardiography,Yes,Amiodarone,,Yes
01/11/2016 12:52,01/11/2016 13:30,IP Address,188.39.68.2,40,2291,FALSE,08/11/2016 13:30,R_3ikewLtfMDdnunu,,,,,,,anonymous,Tertiary Referral Centre or University Hospital,1000-2000,39,Mixed ICU,,Consultant,More than 10 years,Anaesthesia,,,,,,,,,,,,,,,,,
01/11/2016 16:04,01/11/2016 16:06,IP Address,143.179.8.39,40,90,FALSE,08/11/2016 16:06,R_3wskWXeFfrGMZKV,,,,,,,anonymous,Tertiary Referral Centre or University Hospital,>2000,30,Mixed ICU,,Consultant,More than 10 years,Anaesthesia,,,,,,,,,,,,,,,,,
01/11/2016 16:56,01/11/2016 16:57,IP Address,194.176.105.154,40,65,FALSE,08/11/2016 16:58,R_21HZ48K4ohnvJi4,,,,,,,anonymous,District General Hospital,500-1000,11,Predominantly surgical,,Trainee,5-10 years,Acute medicine,,,,,,,,,,,,,,,,,
01/11/2016 15:26,01/11/2016 16:01,IP Address,194.176.105.138,40,2078,FALSE,08/11/2016 17:01,R_5aNcyH0K3vDOMVT,,,,,,,anonymous,District General Hospital,1000-2000,10,Mixed ICU,,Consultant,5-10 years,Anaesthesia,,,,,,,,,,,,,,,,,
08/11/2016 18:57,08/11/2016 19:02,IP Address,88.105.125.221,100,319,TRUE,08/11/2016 19:02,R_2wj02KBeOyLUTIK,,,,,53.38330078,-2.600006104,anonymous,District General Hospital,<500,11,Mixed ICU,,Consultant,More than 10 years,Anaesthesia,"Independent of their heart rate I treat all patients who have developed new onset fast AF, even if the blood pressure remains stable",Rhythm control,Amiodarone,,Supplement electrolytes to a high normal level and anti-arrhythmics,>4.5 mmol/l,0.75-1 mmol/l,"Pharmacokinetic advantages,Pharmacodynamic properties",,I do not regularly anti-coagulate critically ill patients with new-onset fast AF,I do not use stroke risk scores routinely in critically ill patients with new onset AF to assess the need for anticoagulation,I do not regularly anti-coagulate critically ill patients with new onset fast AF,I regularly perform or request transthoracic echocardiography,Yes,Amiodarone,,No
01/11/2016 21:10,01/11/2016 21:10,IP Address,86.169.27.169,12,39,FALSE,08/11/2016 21:11,R_R1URFUgDW8AdOI9,,,,,,,anonymous,,,,,,,,,,,,,,,,,,,,,,,,,
01/11/2016 22:44,01/11/2016 22:45,IP Address,1.129.96.47,12,14,FALSE,08/11/2016 22:45,R_27BDCER7WuX2GVu,,,,,,,anonymous,,,,,,,,,,,,,,,,,,,,,,,,,
01/11/2016 20:56,01/11/2016 23:47,IP Address,199.172.197.188,40,10271,FALSE,08/11/2016 23:47,R_2V8VLgzyO7iM9eo,,,,,,,anonymous,District General Hospital,<500,8,Mixed ICU,,Consultant,More than 10 years,Anaesthesia,,,,,,,,,,,,,,,,,
02/11/2016 11:06,02/11/2016 11:08,IP Address,152.78.59.128,12,78,FALSE,09/11/2016 11:08,R_2Y5015DMrOMqYHw,,,,,,,anonymous,,,,,,,,,,,,,,,,,,,,,,,,,
09/11/2016 14:44,09/11/2016 14:49,IP Address,143.117.173.23,100,282,TRUE,09/11/2016 14:49,R_2uDMvQC9llFnj4M,,,,,54.58329773,-5.933303833,anonymous,Tertiary Referral Centre or University Hospital,500-1000,25,Mixed ICU,,Consultant,3-5 years,Intensive Care Medicine only,120-139/beats per min,Rhythm control,Amiodarone,,Supplement electrolytes to a high normal level and anti-arrhythmics,>3.5mmol/l,0.75-1 mmol/l,Pharmacodynamic properties,,New onset AF within 48 hours,"Stroke risk scores inaccurately reflect the risk of embolic events in critically ill patients with new-onset atrial fibrillation due to prothrombotic changes associated with critical illness,Stroke risk scores favour anti-coagulation despite a higher risk of bleeding in critical illness,Modified risk scores should be developed for critically ill patients with new-onset atrial fibrillation",Subcutaneous Low Molecular Weight heparin in therapeutic dose,I do not routinely perform Echocardiography to guide treatment,Yes,Amiodarone,,No
09/11/2016 11:54,09/11/2016 15:04,IP Address,194.176.105.148,100,11454,TRUE,09/11/2016 15:05,R_2b44qzKWPlH8RHy,,,,,52.25,-0.883300781,anonymous,District General Hospital,I do not know,11,Mixed ICU,,Consultant,More than 10 years,Anaesthesia,"Independent of their heart rate I treat all patients who have developed new onset fast AF, even if the blood pressure remains stable",Rate control,Amiodarone,,Supplement electrolytes (magnesium and/or potassium) to a high normal level,>4.5 mmol/l,1.0-1.2 mmol/l,Pharmacodynamic properties,,I do not regularly anti-coagulate critically ill patients with new-onset fast AF,"I do not use stroke risk scores routinely in critically ill patients with new onset AF to assess the need for anticoagulation,Modified risk scores should be developed for critically ill patients with new-onset atrial fibrillation","Subcutaneous Low Molecular Weight heparin in therapeutic dose,I do not regularly anti-coagulate critically ill patients with new onset fast AF",I do not routinely perform Echocardiography to guide treatment,Yes,ß-blocker,,Yes
02/11/2016 16:06,02/11/2016 16:08,IP Address,149.154.199.17,12,108,FALSE,09/11/2016 16:08,R_2TCeLvKbN9S6V2b,,,,,,,anonymous,,,,,,,,,,,,,,,,,,,,,,,,,
09/11/2016 22:33,09/11/2016 22:42,IP Address,77.102.2.180,100,559,TRUE,09/11/2016 22:42,R_2Skr2aSWr8QIcZF,,,,,52.5,-2.083297729,anonymous,District General Hospital,<500,6,Mixed ICU,,Consultant,5-10 years,Anaesthesia,120-139/beats per min,Rate control,Amiodarone,,Supplement electrolytes to a high normal level and anti-arrhythmics,>4.5 mmol/l,1.0-1.2 mmol/l,Adverse effect profile,,I do not regularly anti-coagulate critically ill patients with new-onset fast AF,"I do not use stroke risk scores routinely in critically ill patients with new onset AF to assess the need for anticoagulation,Modified risk scores should be developed for critically ill patients with new-onset atrial fibrillation",I do not regularly anti-coagulate critically ill patients with new onset fast AF,I regularly perform or request transthoracic echocardiography,Yes,DC cardioversion,,No
03/11/2016 05:27,03/11/2016 05:33,IP Address,194.176.105.170,40,408,FALSE,10/11/2016 05:33,R_1guP8oQl3Pd9vbg,,,,,,,anonymous,District General Hospital,500-1000,flex accordingly 12 level 3 max,Mixed ICU,,SAS,More than 10 years,Intensive Care Medicine only,,,,,,,,,,,,,,,,,
03/11/2016 07:57,03/11/2016 07:59,IP Address,86.131.204.241,12,94,FALSE,10/11/2016 07:59,R_2AQLA6yYhWkHfWr,,,,,,,anonymous,,,,,,,,,,,,,,,,,,,,,,,,,
10/11/2016 13:53,10/11/2016 13:57,IP Address,194.176.105.154,100,217,TRUE,10/11/2016 13:57,R_3l24uoex3WEXASV,,,,,51.49639893,-0.122406006,anonymous,Tertiary Referral Centre or University Hospital,1000-2000,31,Predominantly surgical,,Consultant,More than 10 years,Anaesthesia,100-119/beats per min,Rate control,ß-blocker,,Supplement electrolytes to a high normal level and anti-arrhythmics,>4 mmol/l,1.0-1.2 mmol/l,"Availability from hospital pharmacy,ICU drug policy",,New onset AF within 48 hours,I do not use stroke risk scores routinely in critically ill patients with new onset AF to assess the need for anticoagulation,Subcutaneous Low Molecular Weight heparin in therapeutic dose,I do not routinely perform Echocardiography to guide treatment,No,"Amiodarone,DC cardioversion,ß-blocker",,No
10/11/2016 17:14,10/11/2016 17:26,IP Address,86.10.232.151,100,740,TRUE,10/11/2016 17:26,R_tPrt4Ny6L9v0GgV,,,,,51.45779419,-3.343597412,anonymous,Tertiary Referral Centre or University Hospital,1000-2000,28,Mixed ICU,,Consultant,More than 10 years,Anaesthesia,100-119/beats per min,Rate control,Amiodarone,,Supplement electrolytes (magnesium and/or potassium) to a high normal level,>4 mmol/l,I do not aim for a specific serum magnesium level,"Pharmacokinetic advantages,Pharmacodynamic properties",,I do not regularly anti-coagulate critically ill patients with new-onset fast AF,"Stroke risk scores favour anti-coagulation despite a higher risk of bleeding in critical illness,Modified risk scores should be developed for critically ill patients with new-onset atrial fibrillation",I do not regularly anti-coagulate critically ill patients with new onset fast AF,I only regularly perform Echocardiography in patients with cardiac history,No,"DC cardioversion,ß-blocker",,Yes
06/11/2016 11:52,06/11/2016 11:52,IP Address,86.146.6.73,12,17,FALSE,13/11/2016 11:52,R_3MMZk5IfRN2b0pf,,,,,,,anonymous,,,,,,,,,,,,,,,,,,,,,,,,,
13/11/2016 20:25,13/11/2016 20:29,IP Address,109.145.101.169,100,258,TRUE,13/11/2016 20:29,R_3PdAr0uXBoZ26bG,,,,,51.58329773,-0.383300781,anonymous,District General Hospital,500-1000,12,Predominantly surgical,,Consultant,More than 10 years,Anaesthesia,120-139/beats per min,Rate control,Amiodarone,,Supplement electrolytes (magnesium and/or potassium) to a high normal level,>4.5 mmol/l,1.0-1.2 mmol/l,ICU drug policy,,I do not regularly anti-coagulate critically ill patients with new-onset fast AF,I do not use stroke risk scores routinely in critically ill patients with new onset AF to assess the need for anticoagulation,"Subcutaneous Low Molecular Weight heparin in therapeutic dose,Use of novel oral anti-coagulants (NOACs)",I do not routinely perform Echocardiography to guide treatment,No,Amiodarone,,No
13/11/2016 21:28,13/11/2016 21:33,IP Address,86.146.81.54,100,328,TRUE,13/11/2016 21:33,R_uePgVBUtoyKQ6fn,,,,,55.00320435,-1.633895874,anonymous,Tertiary Referral Centre or University Hospital,1000-2000,22,Predominantly surgical,,Consultant,5-10 years,Anaesthesia,"Independent of their heart rate I treat all patients who have developed new onset fast AF, even if the blood pressure remains stable",Rate control,Amiodarone,,DC cardioversion when anti-arrhythmics and electrolyte replacement fail to achieve rate and/or rhythm control,>4.5 mmol/l,1.0-1.2 mmol/l,Pharmacodynamic properties,,I do not regularly anti-coagulate critically ill patients with new-onset fast AF,I do not use stroke risk scores routinely in critically ill patients with new onset AF to assess the need for anticoagulation,"Subcutaneous Low Molecular Weight heparin in therapeutic dose,I do not regularly anti-coagulate critically ill patients with new onset fast AF",I do not routinely perform Echocardiography to guide treatment,Yes,Amiodarone,,Yes
14/11/2016 08:11,14/11/2016 08:15,IP Address,194.176.105.157,100,281,TRUE,14/11/2016 08:15,R_5AehCCkutXIQrJP,,,,,51.32640076,-0.101104736,anonymous,District General Hospital,500-1000,16,Mixed ICU,,Consultant,More than 10 years,Anaesthesia,120-139/beats per min,Rhythm control,Amiodarone,,Supplement electrolytes (magnesium and/or potassium) to a high normal level,>4.5 mmol/l,1.0-1.2 mmol/l,"Availability from hospital pharmacy,ICU drug policy,Pharmacokinetic advantages,Pharmacodynamic properties",,I do not regularly anti-coagulate critically ill patients with new-onset fast AF,"I regularly calculate a risk score (e. g. CHAD2, CHA2DS2-VASc) to assess the need for anti-coagulation,Stroke risk scores inaccurately reflect the risk of embolic events in critically ill patients with new-onset atrial fibrillation due to prothrombotic changes associated with critical illness,Modified risk scores should be developed for critically ill patients with new-onset atrial fibrillation",I do not regularly anti-coagulate critically ill patients with new onset fast AF,I regularly perform or request transthoracic echocardiography,Yes,Amiodarone,,Yes
07/11/2016 15:35,07/11/2016 15:35,IP Address,213.205.198.107,12,10,FALSE,14/11/2016 15:35,R_3nUilGa6EzrsMci,,,,,,,anonymous,,,,,,,,,,,,,,,,,,,,,,,,,
08/11/2016 10:19,08/11/2016 10:21,IP Address,194.176.105.152,40,150,FALSE,15/11/2016 10:21,R_2R1ApXjmdkjCTvk,,,,,,,anonymous,Tertiary Referral Centre or University Hospital,500-1000,12,Specialist ICU (please name specialty):,Cardiothoracic,Consultant,More than 10 years,Anaesthesia,,,,,,,,,,,,,,,,,
15/11/2016 20:38,15/11/2016 20:46,IP Address,2.30.245.216,100,506,TRUE,15/11/2016 20:46,R_3JCHA9sEOUjCMFz,,,,,54.98809814,-1.619400024,anonymous,Tertiary Referral Centre or University Hospital,500-1000,20,Mixed ICU,,Consultant,5-10 years,Anaesthesia,140-159/beats per min,Rate control,Amiodarone,,DC cardioversion when anti-arrhythmics and electrolyte replacement fail to achieve rate and/or rhythm control,>4.5 mmol/l,>1.2 mmol/l,"Availability from hospital pharmacy,ICU drug policy,Cost,Pharmacokinetic advantages,Pharmacodynamic properties,Adverse effect profile,Other, please specify:",Simplicity of administration,I do not regularly anti-coagulate critically ill patients with new-onset fast AF,"I do not use stroke risk scores routinely in critically ill patients with new onset AF to assess the need for anticoagulation,Stroke risk scores inaccurately reflect the risk of embolic events in critically ill patients with new-onset atrial fibrillation due to prothrombotic changes associated with critical illness,Stroke risk scores favour anti-coagulation despite a higher risk of bleeding in critical illness","Intravenous High Molecular Weight heparin in therapeutic dose,Subcutaneous Low Molecular Weight heparin in therapeutic dose,Use of novel oral anti-coagulants (NOACs),I do not regularly anti-coagulate critically ill patients with new onset fast AF",I regularly perform or request transthoracic echocardiography,Yes,"Amiodarone,DC cardioversion,ß-blocker,Digoxin,Other anti-arrhythmics (e. g. verapamil, sotalol): Please specify:",Magnesium,Yes
16/11/2016 15:23,16/11/2016 15:33,IP Address,194.176.105.161,100,558,TRUE,16/11/2016 15:33,R_1OqcdI3Kv2w6V07,,,,,51.53329468,-0.100006104,anonymous,Teaching Hospital,1000-2000,25,Mixed ICU,,Consultant,More than 10 years,Anaesthesia,100-119/beats per min,Rate control,Amiodarone,,Supplement electrolytes to a high normal level and anti-arrhythmics,>4.5 mmol/l,1.0-1.2 mmol/l,"ICU drug policy,Pharmacodynamic properties,Adverse effect profile",,I do not regularly anti-coagulate critically ill patients with new-onset fast AF,I do not use stroke risk scores routinely in critically ill patients with new onset AF to assess the need for anticoagulation,I do not regularly anti-coagulate critically ill patients with new onset fast AF,I regularly perform or request transthoracic echocardiography,Yes,ß-blocker,,No
24/11/2016 00:26,24/11/2016 00:30,IP Address,185.69.144.40,100,252,TRUE,24/11/2016 00:30,R_d3WsEMxtCQdXVcd,,,,,51.49639893,-0.122406006,anonymous,District General Hospital,1000-2000,11,Mixed ICU,,SAS,More than 10 years,Intensive Care Medicine only,120-139/beats per min,Rate control,Amiodarone,,Supplement electrolytes (magnesium and/or potassium) to a high normal level,>4.5 mmol/l,>1.2 mmol/l,Pharmacokinetic advantages,,New onset AF within 24 hours,Modified risk scores should be developed for critically ill patients with new-onset atrial fibrillation,Subcutaneous Low Molecular Weight heparin in therapeutic dose,I do not routinely perform Echocardiography to guide treatment,No,Amiodarone,,No
24/11/2016 17:26,24/11/2016 17:31,IP Address,194.176.105.144,100,264,TRUE,24/11/2016 17:31,R_1LA93hheryypzvY,,,,,51.49639893,-0.122406006,anonymous,District General Hospital,500-1000,11,Mixed ICU,,Consultant,5-10 years,Anaesthesia,140-159/beats per min,Rate control,Amiodarone,,Supplement electrolytes to a high normal level and anti-arrhythmics,>4.5 mmol/l,1.0-1.2 mmol/l,ICU drug policy,,I do not regularly anti-coagulate critically ill patients with new-onset fast AF,"I do not use stroke risk scores routinely in critically ill patients with new onset AF to assess the need for anticoagulation,Stroke risk scores inaccurately reflect the risk of embolic events in critically ill patients with new-onset atrial fibrillation due to prothrombotic changes associated with critical illness",I do not regularly anti-coagulate critically ill patients with new onset fast AF,I do not routinely perform Echocardiography to guide treatment,Yes,ß-blocker,,Yes
26/11/2016 15:38,26/11/2016 15:46,IP Address,176.26.156.251,100,506,TRUE,26/11/2016 15:46,R_eX8Mov4bcy3Ceo9,,,,,52.19999695,-2.199996948,anonymous,Tertiary Referral Centre or University Hospital,500-1000,26,Mixed ICU,,Consultant,5-10 years,Anaesthesia,140-159/beats per min,Rate control,Amiodarone,,Supplement electrolytes to a high normal level and anti-arrhythmics,>4 mmol/l,1.0-1.2 mmol/l,Pharmacodynamic properties,,I do not regularly anti-coagulate critically ill patients with new-onset fast AF,"I do not use stroke risk scores routinely in critically ill patients with new onset AF to assess the need for anticoagulation,Stroke risk scores favour anti-coagulation despite a higher risk of bleeding in critical illness,Modified risk scores should be developed for critically ill patients with new-onset atrial fibrillation","Subcutaneous Low Molecular Weight heparin in therapeutic dose,I do not regularly anti-coagulate critically ill patients with new onset fast AF",I do not routinely perform Echocardiography to guide treatment,Yes,ß-blocker,,Yes
21/11/2016 11:13,21/11/2016 12:50,IP Address,89.197.125.47,12,5804,FALSE,28/11/2016 12:50,R_qUgV5HEdZ8PSxvb,,,,,,,anonymous,,,,,,,,,,,,,,,,,,,,,,,,,
07/12/2016 16:06,07/12/2016 16:10,IP Address,62.254.108.117,100,257,TRUE,07/12/2016 16:11,R_2pXzY9CuuxVyFuV,,,,,52.6000061,-2,anonymous,District General Hospital,<500,13,Mixed ICU,,Consultant,More than 10 years,Anaesthesia,120-139/beats per min,Rhythm control,Amiodarone,,Supplement electrolytes to a high normal level and anti-arrhythmics,>4.5 mmol/l,1.0-1.2 mmol/l,"Other, please specify:",rhytm rather than rate control,I do not regularly anti-coagulate critically ill patients with new-onset fast AF,"I do not use stroke risk scores routinely in critically ill patients with new onset AF to assess the need for anticoagulation,Modified risk scores should be developed for critically ill patients with new-onset atrial fibrillation","Intravenous High Molecular Weight heparin in therapeutic dose,Subcutaneous Low Molecular Weight heparin in therapeutic dose,I do not regularly anti-coagulate critically ill patients with new onset fast AF",I regularly perform or request transthoracic echocardiography,Yes,Amiodarone,,No
15/12/2016 07:44,15/12/2016 07:49,IP Address,82.132.241.14,100,256,TRUE,15/12/2016 07:49,R_DqMMY62y7HFWJ69,,,,,51.49639893,-0.122406006,anonymous,Teaching Hospital,500-1000,18,Mixed ICU,,Consultant,More than 10 years,Anaesthesia,120-139/beats per min,Rhythm control,Amiodarone,,Supplement electrolytes to a high normal level and anti-arrhythmics,>4.5 mmol/l,1.0-1.2 mmol/l,Pharmacodynamic properties,,New onset AF within 48 hours,I do not use stroke risk scores routinely in critically ill patients with new onset AF to assess the need for anticoagulation,"Intravenous High Molecular Weight heparin in therapeutic dose,Subcutaneous Low Molecular Weight heparin in therapeutic dose",I do not routinely perform Echocardiography to guide treatment,Yes,"Amiodarone,ß-blocker",,No